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ALZHEIMER’S DISEASE 
1. History 
In 1907 Alois Alzheimer (1863-1915) described the case of a 51 year-old woman 
who showed rapidly deteriorating memory along with psychiatric disturbances and died 
four years later. At that time, a variety of progressive and fatal neurological conditions 
were known, including senile dementia, but two factors made this case unique: the early 
age at onset and the neurofibrillary tangles (NFT), a new pathological finding. 
Alzheimer’s disease (AD) is a progressive neurologic deterioration accompanied by 
hallmark pathology. 
Over time, AD was split into two clinical conditions depending upon the age of 
onset. “Alzheimer disease” was used to indicate a type of “presenile” dementia, since its 
initial description in a relatively young woman, affecting individuals younger than 65 
years of age, whereas a similar dementia in the elderly, in individuals over 65 years of 
age, was referred to as “senile dementia of the Alzheimer-type” after the pioneering 
studies of Tomlinson, Roth and Blessed (Roth et al., 1966). Although these age-related 
classifications are still sometimes used, ad has never been shown to have a bi-modal age 
of onset, AD was absolutely recognized as a distinct entity from “dementia senilis”. AD 
is now generally recognized as a single entity with a prevalence that increases sharply 
after age of 65 (Castellani et al., 2010). 
 
2. Epidemiology 
AD constitutes approximately 70% of all dementia cases (Fratiglioni et al., 1999; 
Small et al., 1997) . Incidence of AD increases with age, doubling every five to ten 
years. For people between ages 65-69, 70-74, 75-79, 80-84, and 85 and older the 
incidence of AD has been estimated at 0.6%, 1.0%, 2.0%, 3.3% and 8.4%, respectively 
(Hebert et al., 1995). Prevalence also increases exponentially with age, rising from 3% 
among those 65-74, to almost 50% among those 85 or older. AD affects 25 million 
people worldwide. In the US, prevalence was estimated at 5 million in 2007 and, by 
2050, is projected to increase to 13 million in the US alone (Zhu et al., 2006). Aside 
from age, other risk factors include family history of dementia, head trauma, genetic 
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factors (apolipoprotein E [ApoE] ε4 allele), being female, low education level, vascular 
disease and environmental factors. 
The estimated data about incidence are in keeping with the projected demographic 
changes resulting from the “baby boomer” generation reaching old age, and the 
continued increase in life expectancy. The combination of a declining birth rate and an 
increased average life span is expected to increase the proportion of the population aged 
65 years and older in the US from 12.4% in 2000 to 19.6% in 2030. The number of 
people aged 80 years old and older is also expected to double, from 9.3 million in 2000 
to 19.5 million in 2030. The number of people aged 65 years and older is expected to 
increase from 35 million in 2000 to 71 million in 2030. The number of people aged 80 
years and older is also expected to double, from 9.3 million in 2000 to 19.5 in 2030.  
Globally, the number of older adults (aged 65 years and older) is projected to increase 
even more dramatically: more than doubling from 420 million in 2000 to 973 million in 
2030. Considering the fact that advanced age is the most significant risk factor for AD, 
one cannot underestimate the problem this disease poses in terms of its financial and 
human cost. 
Since the current therapies could not block the progression of the pathology, AD is 
actually considered a clinical, social and economic problem, so it is considered the 3rd 
most important pathology, after cardiovascular disease and tumors (Castellani et al., 
2010). 
 
3. Etiology 
3.1 Age 
Age represents, by far, the single greatest risk factor in the etiology of AD. Even in 
genetically-predisposed individuals, the disease essentially does not occur in middle 
age. Therefore, regardless of whether one is genetically predisposed or not, aging is 
essential factor in AD, strongly suggesting that an age-related process is involved in the 
development of the disease. This age-related penetrance is not restricted to AD and is 
also a risk factor in a number of other chronic diseases including other 
neurodegenerative diseases, cancer, atherosclerosis, arthritis and emphysema indicating 
the possibility that there may be common etiologies with diverse consequences. 
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Nevertheless, it remains an open question whether AD is purely a manifestation of 
advanced age, as has been suggested, and if it still worths separating “senile dementia” 
as was known at the time of Alzheimer, from “Alzheimer disease.” 
A progressive neurological deterioration, beginning in the 6th decade with no family 
history, does occur. It differs dramatically from the slowly progressive memory loss in a 
patient in the 9th or 10th decade with concomitant atherosclerotic disease and the 
confounding effect of a multitude of comorbid illnesses, their complications, and a long 
medication list. 
The difficulties in AD diagnosing in the very old has also been experienced  since the 
original AD descriptions. Indeed, in one study, neuropathologists blinded to clinical 
history diagnosed AD in 76% of elderly subjects who were otherwise not clinically 
demented during life (Brayne et al., 2009). These data seem to emphasize again a 
discernible difference, clinical and pathological, between AD and senile dementia, the 
first is precipitated by a specific cause as yet unknown, and the latter is a manifestation 
of advanced age per se. 
 
3.2 Genetics 
Evidence for a significant genetic component has been shown in a substantial 
proportion of individuals with AD. First degree relatives of AD patients have a higher 
lifetime incidence of AD than the general population, and 15–35% of patients with AD 
have affected first-degree relatives. Using the traditional arbitrary distinction between 
early- (<65 years) and late- (>65 years) onset, it has been shown that the early familial 
form of the disease tends to be more aggressive, with particular familial forms having a 
characteristic age of onset (Bondareff et al., 1987).  
A number of mutated proteins have been implicated in familial cases of AD. 
Amyloid Precursor Protein . Transgenic mice overexpressing mutated APP form 
senile plaques (e.g., Tg2576), show age related deficiencies on cognitive-behavioral 
testing and show synaptic deficits, supporting a pathogenic role for mutated APP. 
A small number of early-onset familial AD cases are linked to mutations in AβPP. 
To date, 89 families affected by germline AβPP mutations have been described 
worldwide (http://www.molgen.ua.ac.be/ADMutations/default.cfm). Interestingly, such 
cases comprise only about 9% of familial AD families, while the most common 
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germline mutations linked to familial early onset disease are linked to presenilin 1 
(~40%).  
ApoE protein. One of the major risk factors for the development of AD is carrying 
the ε4 allele of APOE either in heterozygous or homozygous state (Sherrington et al., 
1995). The mechanism by which ApoE influences the pathogenesis of AD is unknown; 
however, ApoE, a serum cholesterol transport protein, is a component of both senile 
plaques and NFT (Namba et al., 1991).  
Interestingly, oxidative stress would also be important in the action of ApoE, since 
the formation of ApoE/Aβ complexes is increased in oxygenated buffer and completely 
abolished under reducing condition (Strittmatter et al., 1993). Moreover, oxidized ApoE 
ε4 forms complexes with Aβ at a significantly higher rate than in similar experiments 
with ApoE ε3. Therefore, the oxidation of ApoE, alone or bound with Aβ protein, might 
affect receptor affinity and/or other catabolic interactions by a mechanism analogous to 
the oxidation of low density lipoprotein in diabetic renal disease (Gupta et al., 1992). 
Presenilin 1 and Presenilin 2. The majority (~70%) of early-onset familial AD cases 
are associated with mutations in two genes, presenilin 1 and presenilin 2, located on 
chromosomes 14 and 1, respectively (Sherrington et al., 1995). To date, over thirty 
different pathogenic mutations in these genes have been described from over sixty 
unrelated kindred (Tanzi et al., 1996). The presenilins comprise part of the γ-secretase 
complex, necessary for the synthesis of Aβ peptides. Mutations at these sites evidently 
alter Aβ processing in favor of increased synthesis and deposition. Familial early onset 
AD cases associated with presenilin mutations are noteworthy in the extensive deposits 
of Aβ throughout the brain, including white matter and extensively within blood vessels 
(Castellani et al., 2008). There is considerable homology between the gene products of 
presenilin 1 and presenilin-2 which are transmembrane proteins of 463 and 448 amino 
acids, respectively, with between six and nine hydrophobic membrane spanning 
domains (Sherringhton et al., 1995). 
CLU and PICALM. CLU (which encodes clusterin) and PICALM 
(phosphatidylinositol-binding clathrin assembly protein, also known as CALM, clathrin 
assembly lymphoid-myeloid leukemia gene)  genes were identified as loci involved in 
the emerging disease (Harold et al., 2009). 
Clusterin is a multifunctional molecule: it interacts with the soluble form of Aβ in 
animal models of disease and binds soluble Aβ in a specific and reversible manner, 
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forming complexes that have been shown to cross the blood-brain barrier. Notably, 
ApoE also appears to act as a molecular chaperone for Aβ and influences when Aβ 
aggregates and deposits; ApoE also influences Aβ conformation and toxicity. In a 
similar manner similar to ApoE, clusterin may regulate both the toxicity of Aβ and its 
conversion into insoluble forms. ApoE and clusterin have been shown to cooperate in 
suppressing Aβ deposition, and they may critically modify Aβ clearance at the blood-
brain barrier, which could suggest a role for clusterin in the amyloidogenic pathway. 
Levels of ApoE protein appear to be inversely proportional to APOE ε4 allele dose 
levels, with protein levels reduced in ε4 homozygotes compared with heterozygotes. 
Conversely, clusterin levels are increased in proportion to APOE ε4 allele dose levels, 
suggesting an induction of clusterin in individuals with low ApoE levels (Holtzman, 
2004). 
PICALM is ubiquitously expressed in all tissue types with prominent expression in 
neurons, where it is non-selectively distributed at the pre- and postsynaptic structures. 
PICALM protein is involved in clathrin-mediated endocytosis, an essential step in the 
intracellular trafficking of proteins and lipids such as nutrients, growth factors and 
neurotransmitters. Of relevance to AD, PICALM appears to be involved in directing the 
trafficking of VAMP2. VAMP2 is a soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) protein that has a prominent role in the fusion of 
synaptic vesicles to the presynaptic membrane in neurotransmitter release, crucial 
process to neuronal function. Genetically directed changes in PICALM function may 
lead to synaptic dysfunction, possibly through synaptic vesicle cycling, thereby 
increasing risk for AD. Alternatively, PICALM could influence AD risk through APP 
processing via endocytic pathways, resulting in changes in Aβ levels. 
Other proteins. In 2013 a genome-wide association study of AD involving 74,046 
individuals identified 11 new susceptibility loci for AD (Lambert et al., 2013). 
1. The HLA-DRB5–DRB1 region (encoding major histocompatibility complex, 
class II, DRβ5 and DRβ1, respectively) is associated with immunocompetence 
and histocompatibility and, interestingly, with risk of both multiple sclerosis and 
Parkinson disease (Sawcer et al., 2011; Nalls et al., 2011). 
2. The SORL1 gene (encoding sortilin-related receptor, L(DLR class) 1) is 
associated with increased risk of both autosomal dominant and sporadic forms of 
AD (Pottier et al., 2012) and represents the first gene that directly connects 
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aberrant trafficking and metabolism of the APP to late-onset AD (Rogaeva et al., 
2007). 
3. The PTK2B locus (encoding protein tyrosine kinase 2β), is only approximately 
130 kb away from CLU; the protein encoded by PTK2B may be an intermediate 
between neuropeptide-activated receptors or neurotransmitters that increase 
calcium flux and the downstream signals regulating neuronal activity such as 
mitogen-activated protein kinase (MAPK) signaling (Pandey et al., 1999); 
PTK2B is involved in the induction of long-term potentiation in the hippocampal 
CA1 (cornu ammonis 1) region, a central process in the formation of memory 
(Huang et al., 2001). 
4. The SLC24A4 gene [encoding solute carrier family 24 (sodium/potassium/ 
calcium exchanger), member 4] encodes a protein involved in iris development 
and hair and skin color variation in humans in addition to being associated with 
the risk of developing hypertension (Sulem et al., 2007; Adeyemo  et al., 2009); 
SLC24A4 is also expressed in the brain and may be involved in neural 
development (Larsson et al., 2011). 
5. The ZCWPW1 gene (encoding zinc finger, CW type with PWWP domain 1) 
encodes for a protein that modulates epigenetic regulation (He et al., 2010). 
6. Another locus was within the CELF1 gene (encoding CUGBP, Elav-like family 
member 1), whose gene product is a member of the protein family that regulates 
pre-mRNA alternative splicing (Gallo and Spickett, 2010). 
7. Another gene is MADD (encoding MAP kinase–activating death domain), the 
reduced expression of which may affect long-term neuronal viability in AD (Del 
Villar and Miller, 2004). 
8. The FERMT2 gene (encoding fermitin family member 2) is expressed in the 
brain; its corresponding protein localizes to cell matrix adhesion structures, 
activates integrins, is involved in the orchestration of actin assembly and cell 
shape modulation, and is an important mediator of angiogenesis (Pluskota et al., 
2011). 
9. The  CASS4 gene (encoding Cas scaffolding protein family member 4): little is 
known about the function of the encoded protein; however, the Drosophila CASS 
family ortholog (p130CAS) binds to CMS, the Drosophila ortholog of CD2AP 
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(CMS), a known AD susceptibility gene that is involved in actin dynamics 
(Kirsch et al., 1999). 
10. The  INPP5D gene (encoding inositol polyphosphate-5-phosphatase, 145 kDa) is 
expressed at low levels in the brain, but the encoded protein has been shown to 
interact with CD2AP, whose corresponding gene is one of the AD genes 
previously identified (Bao et al., 2012), and to modulate, along with GRB2, 
metabolism of APP (Brauer et al., 2012). 
11. The MEF2C gene (encoding myocyte enhancer factor 2). The MEF2C protein 
limits excessive synapse formation during activity-dependent refinement of 
synaptic connectivity and thus may facilitate hippocampal-dependent learning 
and memory (Akhtar et al., 2012); mutations in this locus are associated with 
severe mental retardation, stereotypic movements, epilepsy and cerebral mal-
formation (Le Meur et al., 2010). 
The newly associated loci reinforce the importance of some previously suspected 
pathways such as APP (SORL1 and CASS4) and tau (CASS4 and FERMT2) in 
pathology. Several candidate genes at these loci are involved in pathways already 
shown to be enriched for association signal in AD such as immune response and 
inflammation (HLA-DRB5–DRB1, INPP5D and MEF2C), which is also supported by 
the described association of AD with cell migration (PTK2B) and lipid transport and 
endocytosis (SORL1). These recent results suggest the existence of new pathways 
underlying AD. These pathways could include hippocampal synaptic function (MEF2C 
and PTK2B), cytoskeletal function and axonal transport (CELF1 and CASS4), regulation 
of gene expression and post-translational modification of proteins, and microglial and 
myeloid cell function (INPP5D) (Lambert et al., 2013). 
 
4. Clinical presentation 
The diagnosis of AD requires clinical evidence of memory loss and impairment of at 
least one other cognitive domain, with evidence of disturbance in social or occupational 
function. AD must be differentiated from other causes of dementia: vascular dementia, 
dementia with Lewy bodies, Parkinson’s disease with dementia, fronto-temporal 
dementia (FTD) and reversible dementias. Wide variability in initial clinical 
presentation may be expected based on the brain regions affected: dysfunctions 
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concerning speech, personality and judgment, vision, sensory-motor function and 
memory impairment, are well known. 
Braak and Braak in 1991 popularized the concept of a more or less predictable 
progression of pathology and clinical signs (Braak et al., 2006). 
An attempt to refine the early diagnostic features of AD is reflected in the new 
nosologic entity, Mild Cognitive Impairment (MCI), in which patients have cognitive 
dysfunction that can be identified objectively, and are not demented (Peterson, 2004). 
While the attempt to identify early AD is strategic, if not predictable, in terms of 
targeting the disease for intervention, it is important to point out that MCI is not a 
distinct entity. Rather, MCI lacks a pathological substrate, genetic predispositions and 
discernible treatment benefits, whereas a given patient with this diagnosis may progress 
to neurodegenerative disease, remain clinically stable for many years, and even improve 
over time. However, in a subset of patients  MCI represents a transition state between 
normal aging and AD. 
Unfortunately, genuine AD is progressive, in spite of all available therapy thus far. 
Initial insidious memory impairment converts, over months and years, to disorientation, 
personality and judgment dysfunctions, speech abnormalities and apraxias, among other 
signs. The ability to care for one’s self is lost over time. With aggressive management, 
AD patients often live out their final months and sometimes years in a vegetative state, 
bed bound, with sacral decubiti (Castellani et al., 2010). 
The proximate cause of death in most patients is pneumonia, which comes as a 
merciful ending to a prolonged and tragic illness that has long since robbed the affected 
patient of their individuality and dignity. 
 
5. Clinical forms and symptoms 
Several clinical forms of AD have been reported, depending on the onset of age: 
Early onset form (EOFAD): is a familiar form of AD (FAD) that affects people under 
40, it represents 5-10% of the total cases ; it is hereditary since the main cause is 
mutation in three genes, coding for Amyloid Precursor Protein (APP), presenilin 1 and 
presenilin 2 (PSEN1, PSEN2), located respectively on chromosomes 21,14 and 1. 
Late onset form (LOFAD): it affects people over 65 years, it represents the 90% of 
the total cases, and it is a sporadic form; have been reported some predisposing factors, 
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such as the ε4 allele of the ApoE gene, located on the chromosome 19 and the  allele 2 
of the α-2-macroglobulin, located on the chromosome 12 (Colacicco et al., 2009). 
AD is characterized by a chronic and progressive impairment of memory functions. 
Firstly, the loss of memory involves recent events, then non-cognitive deficits appears 
such as mood alterations, behavioral and neurovegetative disturbs with sleep disorders. 
Later cognitive defects set on: short-term and long-term memory dysfunction, cognitive 
deficits (Làvadas and Berti, 2002), language deficits (Luttazzi, 1996) and emotion 
processing disturbs (Passafiume et al., 2002 and 2006). 
 
6.  Senile plaques and neurofibrillary tangles 
AD is characterized by the presence of senile plaques, containing the β-amyloid 
peptide (Aβ) and neurofibrillary tangles (NFT), consisting of hyperphosphorylated 
forms of tau protein; in AD a selective death of the cholinergic system, atrophy and 
synaptic and neuronal loss occurs; all these features contribute to the progressive 
cognitive decline that characterizes AD (Selkoe, 2002, Ling et al., 2003). 
The main component of the senile plaques is a fibrillar polymeric form of amyloid 
peptide 1-42 (Aβ42), generated from the proteolysis of Amyloid Precursor Protein 
(APP) (Selkoe, 1991). Currently the amyloid plaques are thought to be the main 
responsible of the cognitive  impairments that occur in AD (Selkoe, 1991). 
Moreover, a massive atrophy of the cerebral cortex (Fig.1), a wide neuronal loss in 
both cerebral cortex and cerebellum, basal ganglia and forebrain, encephalic trunk and 
bone marrow occur. The cell death involves first the cholinergic basal nuclei, then it 
involves amygdale and pyramidal cortex neurons (Rasool et al., 1986) 
Senile plaques (Fig. 2a) are extracellular deposits consisting of the small peptide Aβ 
(about 4 kDa) that aggregates (Kang et al. 1987). During the preclinical stages of the 
pathology, amorphous aggregates of Aβ consisting mainly of non-fibrillar Aβ42 
peptide, named diffuse plaques have been observed (Yamaguchi et al., 1988; Tagliavini 
et al., 1988). During the clinical stages, senile plaques are composed by extracellular 
compact deposits of Aβ40 and Aβ42 peptides, soluble oligomers and insoluble fibrils.  
The β-sheet structure of Aβ is kept by several proteins that are associated with α-1 
antichymotrypsine (α-1 ATC), apolipoprotein E2 and E4, complement protein and 
proteoglycans (Selkoe, 1999). In senile plaques a central “core” of amyloid is 
surrounded by degenerated neurons with dystrophic dendrites and axons projected 
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towards the core, and two types of glial cells: microglial cells penetrating the plaque and 
astrocytes located around it (Selkoe, 1999). 
The NFT (Fig. 2b) are filamentous inclusions consisting of hyperphosphorylated 
forms of tau protein. In physiologic conditions, tau protein is soluble in the cytoplasm 
and promotes the microtubules assembling and stabilization (Grundke-Iqbal et al., 
1986); otherwise, in pathologic conditions tau protein is subjected to an abnormal 
phosphorylation that makes it insoluble and let it aggregate in large filaments (Hanger et 
al., 1991). 
 
 
 
Figure 1. Comparison between healthy and AD brain. In AD patients the volume of the cortex is 
decreased, lateral ventricules are wider, showing the effect of the massive neuronal loss that causes 
cerebral volume loss as well. 
 
 
Figure 2. a) senile plaques b) neurofibrillary tangles 
 
6.1 APP metabolism in Alzheimer’s disease 
I n t r o d u c t i o n  | 13 
Alzheimer’s  Disease 
Aβ peptide consists in 39-43 amino acids, and it is generated by an abnormal 
proteolysis of the APP. Human APP gene is located in the chromosome 21, it belongs to 
a family genes that includes APLP1 and APLP2 (human), Appl (fly) and apl-1 (worm). 
All these genes code for a membrane glycoprotein, but only the APP gene contains the 
region coding for Aβ peptide. 
APP protein is a small transmembrane protein, it consists in a long extracellular N-
term domain, an intracytoplasmic domain and an intramembrane portion that contains 
the last 14 aminoacids of the Aβ peptide sequence. APP protein is also located on 
endoplasmic reticule, Golgi apparatus and on endosomes (Selkoe, 1994). 
APP protein has several roles in order to maintain cellular functions: cell adhesion, 
endocytosis and synaptogenesis. 
After the alternative splicing of the APP at least three forms have been thought to be 
the main responsible of the pathology: APP-695, mostly expressed in central neurons, 
APP-751 and APP-770, ubiquitari expressed in the periphery (Selkoe, 1994). 
Aβ peptide is generated by an abnormal cleavage of APP operated by specific enzymes; 
APP can be cleaved by three secretases: α, β and γ (Fig. 3). 
APP metabolism can follow two pathways: non-amyloidogenic, when α-secretase 
cleaves APP, and amyloidogenic, when β and γ secretases work. 
 
 
Figure 3. APP metabolism mediated by the secretases: α, ß e γ. 
 
The non-amyloidogenic pathway involves three α-secretases enzymes: ADAM 9, 
ADAM 10 and ADAM 17 (Lammich et al., 1999). The α-secretases cleave APP 
between aminoacids 16 and 17 releasing the soluble bAPPs in the extracellular space 
(Postina, 2008) and a 83-aa C-term fragment, named C83, that remains in the plasma 
membrane. Then C83 is cleaved by the γ-secretase, a multiproteic transmembrane 
complex composed by nicastrin, APH-1 (antheriorpharynx-defective phenotype-1), 
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PEN-2 (PS enhancer 2) and presenilin-1 (PS), generating a smaller fragment, called P3 
(Haas et al., 1993). 
The amyloidogenic pathway involves β and γ-secretases generating Aβ peptides. The 
β-secretase, also called BACE 1 (β-APP-cleavage-enzyme 1), is an aspartyl-protease 
and cuts APP generating a soluble βAPP (βAPPs) in the extracellular space and a 99-aa 
C-term fragment (C99), that remains in the plasma membrane. Then the γ-secretase 
cleaves the C99 fragment generating Aβ peptides and a small intracellular fragment 
called AICD (APP intracellular domain), a transcriptional activator (Pangalos et al., 
2005). Depending on the cut site of the γ-secretase, different peptides are generated: if 
the cleavage is between 712 and 713 aa, a short Aβ peptide is produced (39-40aa), 
otherwise if the γ-secretase cut between 713 and 714, a longer peptide is generated (42-
43 aa), the main form found in senile plaques, due to its trend to aggregate. Another 
enzyme with α-secretase activity has been identified, BACE 2, that has 50% identity of 
aa sequence of BACE1; it can cleave APP  between amino acids 19 and 20, suggesting 
a role against BACE1 activity (Farzan et al., 2000). 
Intracellular insoluble Aβ has been reported (LaFerla et al., 2007), in fact during the 
early stages of AD Aβ is generated inside neurons (Mora et al., 2001) and then it 
aggregates to form cerebral plaques (Wirths, 2001). Several studies on AD animal 
models correlate intracellular Aβ with the cognitive decline (Billings et al., 2005). 
Intracellular Aβ can result from intracellular APP proteolysis (Kinoshita et al., 2003) or 
it can be the result of extracellular Aβ re-uptake (Deane at al., 2003).   
Endosomal-lysosomal APP cleavage is mediated by β and γ-secretases, generating 
potentially amyloidogenic derivates (Golde et al., 1992). The trans-Golgi APP 
metabolism involves the α-secretase and produces a soluble Aβ (Haass et al., 1993), that 
has trophic effects on neuronal growth (Selkoe, 1994). 
In basal conditions, cerebral Aβ is degraded by neprilysin, a metal proteases zinc-
dependent regulated by nicastrin, an enzyme of the γ-secretases complex (Pardossi-
Piquard et al., 2006), and by a metal proteases endotelin-converter. Furthermore, the 
cerebral Aβ is regulated by systemic blood flow through the Receptor for Advanced 
Glycation End products (RAGE) and the Low-density Lipoprotein Receptor related 
Protein 1 (LRP1) (Tanzi et al., 2004). Some AD patients show RAGE upregulation and 
LRP1 downregulation, anomalies that contribute further to increase the amount of 
cerebral Aβ (Donahue et al., 2006). 
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6.2. Amyloid and oligomers 
The aggregation and accumulation of amyloid-β plays a significant role in the 
pathogenesis of AD. Aβ oligomeric aggregates are believed to be the main toxic species 
and the causative agent underlying the pathological mechanism for AD, aggregating and 
accumulating within and around neurons. Excised from the APP, Aβ peptide has 
intrinsic property of forming aggregates with β-pleated sheet structure (Hardy and 
Selkoe, 2002). 
The amyloid hypothesis has undergone several modification, mainly concerning the 
type of Aβ thought to cause AD: initially this was the amyloid plaque, followed by 
increased concentrations of Aβ42, then increased Aβ42:Aβ40 ratio, and finally pre-
fibrillar oligomers (Pimplikar, 2009). Results from clinical trials have shown that 
removing plaques will not reserve the damage or stop AD (Hardy, 2009). Recent 
evidence suggest that this toxicity may be linked to the aggregation state of the peptide, 
implicating oligomers, rather than insoluble fibrils, as the primary toxic species 
(Baglioni et al., 2006). While both are found in the brains of post mortem AD patients, 
soluble Aβ oligomers are better correlated with the disease severity than are the classic 
amyloid plaques containing insoluble Aβ fibrillar deposits (McLean et al., 1999). 
Furthermore, oligomers are found both extracellularly, and are capable of moving 
between the interior of the cell and the extracellular space (Gaspar et al., 2010). 
However, Aβ oligomer structure, size, conformation and inter-relationship with other 
amyloid aggregates, as well as the exact mechanism of Aβ oligomer-induced 
neurotoxicity, remain elusive. 
Monomeric Aβ undergoes conformation transition and proceeds to form low 
molecular oligomers (dimer/trimer) and then soluble high molecular aggregates and 
progress to form spherical oligomers which are composed of 12 to 24 monomers, which 
prolong to protofibrils and finally become insoluble fibrils (Glabe, 2008). These various 
structures differ not only in aggregation state, but also in their toxic effects. Recently, 
many have reported that fibrils, which were once thought to exhibit the highest level of 
toxicity, are actually second in toxicity to intermediate aggregates of Aβ (spherical 
oligomers and protofibrils) (Glabe, 2006). 
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The presence of a variety of Aβ oligomer conformations have been reported and 
oligomeric species differ not only in mechanism formation but also in mechanism of 
toxicity (Kayed and Lasagna-Reeves, 2013). 
 
 
 
 
7. Neuroinflammation 
Biochemical and neuropathological studies of brains from individuals with AD 
provide clear evidence for an activation of inflammatory pathways. Some components 
of this complex molecular and cellular machinery are most likely promoting 
pathological processes leading to AD, whereas other components serve to do the 
opposite. 
 
7.1. Cellular mediators 
Microglia. Microglia are generally recognized as the brain’s resident macrophages, 
and are considered to be pivotal players in innate immune/inflammatory responses in 
multiple neurologic disorders, including PD (Rogers et al., 2007), HIV dementia 
(Garden, 2002), multiple sclerosis (Muzio et al., 2007), amyotrophic lateral sclerosis 
(Dewil et al., 2007), AD (Mandrekar-Colucci and Landreth, 2010) and others. There is 
also general consensus on mechanisms of microglial actions in both the normal and 
diseased central nervous system (CNS), from the remarkable ability of these cells to 
survey vast extents of the brain (Davalos et al., 2005; Nimmerjahn et al., 2005; Wake et 
al., 2009) to their expression of classic pro- and anti-inflammatory mediators and 
receptors (Lue et al., 2001a, 2001b; Wyss-Coray, 2006; Cameron and Landreth, 2010). 
Microglia in the developing brain ultimately derive from the mesenchyme, in which 
myeloid progenitors give rise to cells that migrate to the CNS and proliferate as 
microglia (Rezaie and Male, 2002). Migration of blood-derived macrophages into the 
CNS has also been suggested to occur later in fetal development (Chan et al., 2007). 
Throughout development, microglia may play an important role in remodeling of the 
brain by removing presumably redundant, apoptotic neurons (Bessis et al., 2007; 
Caldero et al., 2009). 
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Microglia constantly sample their immediate environment, including neighboring 
glia, blood vessels and neurons, by extending and retracting their processes for 
distances up to some 80 µm (Nimmerjahn et al., 2005). In this manner, the microglial 
population may survey the entire brain every few hours. Loss of synapses encountered 
by microglial processes has been reported using in vivo microscopy supporting the 
potential role of microglia in normal synaptic remodeling (Wake et al., 2009). 
Microglia also contribute to a healthy CNS by attacking and removing potential 
pathogens and detritus, and by secreting tissue rebuilding factors (Wyss-Coray, 2006).  
Alternatively, several reports of microglial attack mechanisms in neurologic disease 
suggest a more complex view. Microglial cells, in vitro, secrete a wide range of 
inflammatory factors, many of which can automodulate microglial phenotype and 
impact bystander neurons and their processes. These include reactive oxygen species 
(Coraci et al., 2002); Th1 cytokines such as IL-1β, IL-6, TNF-α, and interferon γ (INF-
γ) (Lue et al., 2001a); chemokines such as Macrophage Inflammatory Protein 1α 
(MIP1α), MIP1β, CXCL8, RANTES, and Monocyte Chemotactic Protein 1 (MCP1) (El 
Khoury and Luster, 2008); growth factors such as macrophage colony stimulating factor 
(Lue et al., 2001a); and complement components such as C1q, C3, C4, and C9 (Walker 
et al. 2001). They also express receptors associated with inflammatory activation, attack 
and phagocytosis, including cytokine receptors (John et al., 2003), chemokine receptors 
(Cartier et al., 2005), complement receptor 3 (Sedgwick et al., 1991), the Receptor for 
Advanced Glycation Endproducts (RAGE) (Walker and Lue, 2005), Fc receptors (Okun 
et al., 2010), CD40 (Tan et al., 1999), Formyl Peptide (FP) receptors (Brandenburg et 
al., 2008), various scavenger receptors (El Khoury and Luster, 2008) and Toll-Like 
Receptors (TLRs) (Landreth and Reed-Geaghan, 2009). Elevation of these factors in 
culture and animal models typically results in neurodegeneration, and all have been 
reported to be elevated in pathologically-vulnerable regions of the AD brain (Landreth 
and Reed-Geaghan, 2009). 
Microglial cells are also capable of secreting anti-inflammatory mediators and 
growth factors such as IL-4, IL-10, IL-13, and TGF-β, just as peripheral monocytes do 
in the tissue-rebuilding phase that follows inflammatory attack (Wyss-Coray, 2006; 
Colton, 2009). Although there are multiple stimuli for the inflammatory responses of 
microglia in the AD brain, including simple detritus from other pathogenic reactions, 
aggregated Aβ deposits appear to be especially potent, as indicated by the dense 
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accumulations of microglia expressing MHCII and other markers of activation within 
and around such deposits (Rogers et al., 1988). In fact, human elderly microglia in 
culture have been shown to migrate to aggregated Aβ spots dried down to the well floor, 
and to internalize portions of the Aβ (Walker and Lue, 2005). Similarly, microglia 
cultured on sections of AD cortex accumulate on Aβ deposits and appear to remove 
them (Bard et al., 2000). Additional studies have suggested, however, that microglia 
may not be able to degrade the Aβ they have taken up (Majumdar et al., 2008), 
potentially leading to a state of “frustrated phagocytosis” and to phenotypic and 
functional changes in the microglia. 
In transgenic mouse models of AD, recruitment of microglia to newly-formed 
plaques occurred within a few days and was followed by establishment of a dynamic 
interface between microglial processes and Aβ deposits (Meyer-Luehmann et al., 2008; 
Yan et al., 2009). Internalization and lysosome colocalization of Aβ was observed by 
Bolmont and colleagues (2008), and damage to neighboring neurons, coincident with 
the arrival of microglia, has also been reported (Meyer-Luehmann et al., 2008). 
Alternatively, Meyer-Luehmann and coworkers (2008) did not observe resolution of 
plaques over “days to weeks,” and it remains to be shown whether or not the 
neurodegeneration following microglial recruitment to plaques is directly caused by the 
microglia. 
Mechanistic studies of the inflammatory factors and receptors mediating microglial 
localization and responses to Aβ have also been carried on. In vitro, Aβ has been shown 
to stimulate expression of nearly all the proinflammatory mediators secreted by 
microglia (Lue et al., 2001a; Walker et al., 2001), and many of the innate immune 
response receptors found on microglia have Aβ either as a direct or indirect ligand. 
Microglial cell type is neuroprotective primarily by virtue of its capacity for attack. 
Microglia do not prevent apoptosis, neurodegenerative debris, bacterial invasion, or 
Aβ deposits; they attempt to remove such pathologies before further damage is 
performed. They also secrete anti-inflammatory mediators and growth factors. For these 
and other reasons, microglia are certainly vital to promoting a healthy CNS. 
After initial pro inflammatory responses to pathogens or injury, alterations to 
macrophage and microglial function occur and are mediated primarily by the Th2 
cytokines, IL.4, IL-10, IL-13 and TGF-β. These alterations include the frustrated 
phagocytosis of Aβ (Bogdan, 2008)  
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Some of microglial activation state nomenclatures are based on peripheral 
macrophage responses (M1, M2a, M2b, M2c) and reflect macrophage populations that 
are induced by specific Th2 cytokines and other factors (e.g., immune complexes, 
apoptotic cells) (Gordon and Taylor, 2005). Colton (2009), has summarized an 
activation nomenclature that embraces many of the findings that have been reported for 
macrophages but works particularly well for microglia. 
 
Three activation states are proposed: 
1. classical activation, which is stimulated by IFN-γ and characterized functionally 
by attack mechanisms; 
2. alternative activation, which is stimulated by IL-4 and IL-13 and characterized 
functionally by tissue restorative, anti-inflammatory mechanisms; 
3. acquired deactivation, which is stimulated by TGF-β, IL-10, apoptotic cells and 
is characterized functionally by immunosuppression. 
A mixture of classical activation, acquired deactivation, and increasing alternative 
activation is observed in AD suggesting the complex roles that microglia may play in 
neurodegenerative diseases. (Colton, 2009; Wyss-Coray and Rogers, 2012). 
Astrocytes. Astrocytes are an essential neurosupportive cell type in brain. They 
interact with neurons through many ways: secretion and recycling of transmitters, ion 
homeostasis, regulation of energy metabolism, synaptic remodeling and modulation of 
oxidative stress. Tiling the entire brain in contiguous, each single gray matter astrocyte 
has been estimated to envelope as many as 100,000 synapses (Halassa et al., 2007). 
Thus, perturbation of the many neurosupportive astrocyte functions can have extremely 
deleterious consequences for the CNS (Belanger and Magistretti, 2009). 
Moreover, like microglia, astrocytes respond quickly to pathology with changes in 
their morphology and function and these reactive states have been increasingly 
recognized as a continuum with potentially beneficial and destructive consequences 
(Sofroniew and Vinters, 2010). 
In brains of AD patients and AD transgenic mouse models reactive astrocytes occupy 
peri-plaque positions, encircling Aβ deposits in a manner reminiscent of glial scarring, a 
mechanism by which the cells may provide a barrier between healthy tissue and areas of 
injury or infection (Sofroniew and Vinters, 2010; Rodriguez et al., 2009). 
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Many mechanisms may account for the dense accumulation of reactive astrocytes 
observed at sites of aggregated Aβ deposition: MCP1, which is highly concentrated in 
Aβ plaques, is chemotactic for adult astrocytes; astrocyte cells express receptors that 
bind Aβ, including RAGE, low density lipoprotein receptor-like protein, membrane-
associated proteoglycans and scavenger receptor-like receptors (Wyss-Coray et al., 
2003). 
Several studies suggest that plaque-localized, reactive astrocytes take up and may 
degrade Aβ (Koistinaho et al., 2004). In Tg2576 transgenic mice such effects may be 
linked to insulin degrading enzyme (IDE), which appears to play a key role in Aβ 
degradation. Astrocyte expression of IDE is increased after Aβ exposure and is 
pronounced within glial fibrillary acidic protein (GFAP) immunoreactive astrocytes 
surrounding Aβ deposits (Leal et al., 2006). Extracellular clearance of Aβ may also 
occur via astrocyte secretion of matrix metalloproteinases (Yin et al., 2006). Exposure 
to Aβ, in turn, appears to disrupt astrocyte calcium homeostasis, with subsequent 
increases in GFAP (Glial Fibrillar Astrocyte Protein), a typical marker of astrocyte 
reactivity, as well as degeneration of neurons in astrocyte-neuron cocultures (Abramov 
et al., 2004; Chow et al., 2010). 
Reactive astrocytes may provoke neuropathology through expression or 
overexpression of a number of inflammation-related factors. For example, S100b, a 
neurotropin that induces neurite proliferation, is overexpressed in AD brain and its 
levels are correlated with numbers of dystrophic neurites within Aβ deposits (Mrak et 
al., 1996).  
Exposure of cultured astrocytes to Aβ significantly increases IL-1β, TNF-α, iNOS, 
and NO production, with differential temporal effects depending on whether the Aβ is 
in fibrillar, oligomeric or non-fibrillar form (White et al., 2005). 
NF-kB and CEBP transcription factor mechanisms regulate the secretion of the pro-
inflammatory cytokines IL-1β, IL-6, and TNF-α. Astrocyte CEBPδ is upregulated in 
AD cortex (Li et al., 2004), and astrocyte NF-kB is activated on exposure to Aβ, leading 
to increased expression of IL-1β and IL-6 (Bales et al., 1998). NF-kB mechanisms in 
astrocytes also control the secretion of chemokines and the adhesion of molecules that 
might permit invasion by peripheral leukocytes, further fueling the inflammatory 
response (Moynagh, 2005; Wyss-Coray and Rogers, 2012). 
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Oligodendrocytes. Oligodendrocytes, and the myelin sheath they produce, envelope 
axons and are critical for neurotransmission. Studies revealed lesions and myelin 
abnormalities in AD white matter (Roth et al., 2005); focal demyelination of axons 
associated with Aβ deposits in grey matter has been shown both in familial and sporadic 
AD, as well as in transgenic mouse models of AD (Mitew et al., 2010). Stereotaxic 
injection of nM quantities of Aβ into the corpus callosum induces microglial 
proliferation, with damage to myelin and losses of oligodendrocytes (Jantaratnotai et al., 
2003). 
In vitro, oligodendrocyte toxicity has been reported for Aβ25-35 (Xu et al., 2001), 
Aβ40 (Xu et al., 2001; Lee et al., 2004) and Aβ42 (Roth et al., 2005). Perhaps because 
of their low glutathione and high iron content, oligodendroglia are also extremely 
vulnerable to oxidative stress, one of the main weapons of inflammatory attack 
(Juurlink, 1997). 
 
7.2. Molecular mediators 
The complement system. The complement system represents a key inflammatory 
pathway for the activation and execution of immune responses. Complement appears to 
be activated in neurodegenerative diseases and complement proteins are associated with 
plaques and tangles in AD. 
The complement system is capable of recognizing molecular patterns on pathogens 
or molecular patterns associated with injured tissues and dying cells. Recognition may 
be through C1q or mannose binding proteins, which contain collagen-like receptor 
binding domains or through interactions with the multifunctional protein C3 (Tenner, 
1999; Sahu and Lambris, 2001). Depending on the entity that triggers the complement 
system, two pathways could be activated: the classical pathway and the alternative one 
(Fig. 4). Once activated, a diverse array of almost 30 proteins in the complement 
pathway can attract and activate immune cells, amplify antigen-specific immune 
responses, promote phagocytosis, facilitate complement-mediated cytolysis by the 
Membrane Attack Complex (MAC) (Fig. 4) and regulate cell proliferation and 
differentiation (Holers, 1996). 
Glial cells and neurons in the CNS can synthesize complement proteins and their 
production is increased in brain injury and neurodegeneration (D’Ambrosio et al., 2001; 
Gasque, 2004), including AD (Gasque et al., 2000). The complement proteins C1q and 
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MAC colocalize with amyloid plaques and tangle-bearing neurons (Fonseca et al., 
2004). More recent studies showed that complement gene expression is increased in 
AD, suggesting the activation of complement in the disease  (Katsel et al., 2009). 
Aggregated Aβ activates the complement system in vitro through the classical 
pathway by binding C1q and through the alternative pathway by binding C3b (Jiang et 
al., 1994). Isolated tangles or tau aggregates can also activate the classical pathway by 
binding C1q (Shen et al., 2001). The accumulation of Aβ and tau may therefore promote 
the activation of complement and possibly neuroinflammation. 
 
 
Figure 4. Scheme of the complement system. The classical pathway of complement is triggered by 
antigen binding C1q and then activated C1r and C1s, followed by C4, C2, and C3. Bacteria can activate 
the alternative pathway by binding C3b and Factor B. Both the pathways result in the formation of 
multiprotein catalytic activities, the C3 convertases, generating two proteolytic C3 fragments: C3a, 
which is released in the fluid phase and involved in the chemotaxis of phagocytes, and C3b, which can 
bind covalently to acceptor molecules in solution or on cellular surfaces. C3b binding can mediate 
phagocytosis or may activate the lytic pathway involving C5, C6, C7,C8 and C9, which then form the 
MAC, C5b-9, and may lead to cytotoxicity. This pathway also leads to the formation of C5a, another 
small proinflammatory peptide (Wyss-Coray and Rogers, 2012). 
 
The complement can recognize degenerating or dying cells and has an important role 
in the clearance of dead or degenerating cells in various tissues (Taylor et al., 2000). 
Although there is no direct support for this mechanism in AD, C1q has been shown to 
tag apoptotic neurons or neuronal blebs and promote their uptake by microglia in cell 
culture (Fraser et al., 2010; Wyss-Coray and Rogers, 2012). 
Thus, complement is activated in AD, where it may exert regulatory functions and 
aid in the clearance of degenerating cells and protein aggregates. However, it is likely 
also to promote unwanted inflammation. 
 
Cytokines and chemokines. The soluble network of communication factors includes 
cytokines, chemokines and relates immune proteins; these proteins are potent regulators 
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of inflammation and immune function, have pleiotropic effects in many tissues, 
including CNS, and regulate diverse cellular processes such as proliferation, survival 
and differentiation. 
In AD many of these proteins have altered levels (Akiyama et al., 2000) cytokine or 
chemokine changes in the brain parenchyma are often accompanied by changes in 
protein levels in the CSF, and some of these proteins appear to be dysregulated in the 
periphery as well (Hu et al., 2010). Thus far, the consequences of cytokine and 
chemokine changes on brain function and neurodegeneration relevant to AD are 
unknown. 
Genetic studies in mice show that these proteins have potent effects on amyloidosis, 
neurodegeneration and cognition (Wyss-Coray, 2006) 
Tumor necrosis factor (TNF)-α is able to promote Parkinson’s disease (PD) progression 
(McCoy et al., 2006), whereas TNF receptor 1 knockout protects against AD- and PD-
like disease in mice (Sriram et al., 2002; He et al., 2007). The cytokine transforming 
growth factor (TGF)-β1 is increased in human AD brains at the transcript and protein 
level, whereas TGF receptor expression is decreased (Tesseur et al., 2006). TGF-β1 
promotes cerebrovascular amyloidosis but delays parenchymal Aβ accumulation in APP 
mice that also overproduce this cytokine from astrocytes (Wyss-Coray et al., 2001).  
Several other cytokine mRNAs or proteins are expressed at increased or decreased 
levels in AD brain or periphery (Wyss-Coray, 2006). A number of these have also been 
studied in AD mouse models, including IL-1β and IL-6, which surprisingly both appear 
to have beneficial effects on amyloidosis. 
Short-term expression of IL-1β in adult APP mice resulted in strong activation of 
glial cells, induction of various inflammatory factors and reduced amyloid pathology 
(Shaftel et al., 2007). Similarly, viral overexpression of IL-6 in the hippocampus led to 
massive gliosis and neuroinflammation, reduced amyloidosis and improvement of 
cognitive deficits in APP mice (Chakrabarty et al., 2010). Interestingly, lifelong stable 
overexpression of IL-1 receptor antagonist or IL-6 had no effect on pathogenesis in 
another APP mouse model consistent with the concept that acute but not chronic 
activation of certain types of immune responses in the brain may be beneficial (Wyss-
Coray 2006 and 2012). 
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8. Treatment strategies 
8.1. Cholinergics 
Reduction in the activity of the cholinergic neurons is a well-known feature of AD. 
Acetylcholinesterase inhibitors are employed to reduce the rate at which acetylcholine 
(ACh) is broken down, thereby increasing the concentration of ACh in the brain and 
combating the loss of ACh caused by the death of cholinergic neurons. (Stahl et al., 
2000). The nucleus basalis of Meynert, a distinct population of basal forebrain neurons, 
is a major source of cholinergic innervation to the cerebral cortex. In 1982, Whitehouse 
and colleagues found that these neurons are selectively (>75%) degenerated in patients 
with AD (Whitehouse, 1982 and 2006). The loss of cholinergic function has been found 
to be closely related to cognitive dysfunction (Farlow et al., 1988). Over the last two 
decades, a number of therapeutics targeting cholinesterase inhibition, choline 
precursors, post-synaptic cholinergic stimulation with muscarinic agonists, and 
presynaptic cholinergic stimulation with nicotinic agonists has been investigated 
(Hebert et al., 2003). These drugs stabilize cognitive decline for up to 3–6 months, 
although no modification of disease duration or general disease progression has been 
accomplished (Giacobini, 2000 and 2001). 
Acetylcholinesterase inhibitors (ChEIs) are the best developed therapy and are used 
for mild to moderate disease. The mechanism by which ChEIs slow progression of 
disease is thought to be by decreasing levels of APP and production of Aβ and 
amyloidogenic compounds (Giacobini et al., 1996). 
Tacrine was the first widely used ChEI. A 30-week randomized control clinical trial 
showed a significant dose-related improvement in cognitive function (Knapp et al., 
1994). However, subsequent studies were less impressive and a short half-life, 
hepatotoxicity, and cholinergic side effects have limited the use of this drug. Second 
generation cholinergics, including donepezil (trade name Aricept®, Eisai Company and 
Pfizer Inc.), galantamine (Hoechst Marion Roussel Inc., Shire Pharmaceutical Group, 
and Janssen Pharmaceutical, trade names Reminyl and Nivalin, U.S. trade name 
Razadyne) and rivastigmine (trade name Exelon, Novartis Pharmaceuticals) have been 
developed. These drugs have fewer side effects, longer half-lives and greater efficacy. 
Typically, ChEIs are started at low doses to minimize side effects such as facial 
flushing, dyspepsia, nausea, vomiting, and diarrhea, all linked to cholinergic excess. 
These side effects arise in approximately 10-20% of users and are mild to moderate 
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severity. Less common secondary effects include muscle cramps, decreased heart rate 
(bradycardia), decreased appetite and weight, and increased gastric acid production 
(Birks et al., 2006). The dose is then titrated up to the maximum tolerated dose 
(Mulugeta et al., 2003). 
Precursor (lecithin and choline) and nicotine supplementation have not been found to 
improve overall cognition (Farlow et al., 1998). 
Direct activation of postsynaptic cholinergic receptors by muscarinic agonists may 
decrease secretion of Aβ and increase secretion of nerve growth factor (Mulugeta et al., 
2003). A Phase 2 clinical study is going on testing EVP-6124, a partial selective agonist 
of the α-7 nicotin acetylcholine receptor that improves memory performance by 
potentiating the acetylcholine response (Prickaerts et al., 2012). 
 
8.2. Neurotropins 
Beginning in 1986, the infusion of Nerve Growth Factor (NGF) into the adult rat 
brain was found to completely prevent the death of basal forebrain cholinergic neurons 
both spontaneously and after injury (Fischer et al., 1987). Over the next decade, studies 
in rodent models went further to show improvement in cognitive deficits (Markowska et 
al., 1994). Primate studies in the 1990s confirmed the ability of NGF to prevent 
degeneration of basal forebrain cholinergic neurons in monkeys (Koliatsos et al., 1991; 
Kordower et al., 1994). However, the inability of the NGF protein to cross the blood 
brain barrier, its short half-life, and its broad ranging effect of biological signals has 
made efficacious delivery of these neurotropins difficult to attain in the clinical setting. 
Administration of mouse NGF in AD patients and clinical trials of growth factors in 
patients with either amyotrophic lateral sclerosis or PD failed secondary to adverse side 
effects and lack of efficacy (Eriksdotter et al., 1998; Kordower et al., 1999 ). In 
response to this dilemma, multiple CNS gene delivery studies were initiated. 
Ex vivo preclinical studies demonstrated targeted, efficacious, sustained responses to 
NGF with no associated toxicity (Smith et al., 1999). In 2001, human clinical trials were 
initiated. A Phase 1 clinical trial with eight early stage AD patients was performed 
where in autologous NGF secreting cells were injected into the nucleus basalis of three 
dose cohorts. In the patients who received injection without complications, there were 
no adverse events observed over 2 years and no signs of non-targeted NGF spread 
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(Tuszynski et al., 2005), and the phase 2 study is going on using CERE-110 (Ceregene 
Inc) (Mandel 2010). 
 
8.3.Antioxidants 
Oxidative stress is an important pathogenic process associated with aging and AD, 
while markers of oxidative stress have been shown to precede pathological lesions in 
AD, including senile plaques and NFT (Nunomura et al., 1999). Antioxidants may thus 
blunt the cognitive decline in AD or slow disease progression (Perrig et al., 1997). The 
Alzheimer’s Disease Cooperative Study compared selegiline, α-tocopherol, or both with 
placebo (Sano et al., 1997). Given the delay in progression to adverse outcome in the 
treatment groups, an American Academy of Neurology practice parameter states that 
vitamin E likely delays time to clinical worsening. Vitamin E in combination with 
vitamin C is also associated with a decrease in the prevalence and incidence of AD 
(Zandi et al., 2004). 
Since several beneficial effects have been reported, dietary supplementation with 
some of the main antioxidants (resveratrole, epigallocatechin-gallate, docosahexanoic 
acid [DHA] and α-tocopherol) represent one of the several phase 3 clinical trials for AD 
in 2013 (www.alzhforum.org). 
 
8.4. Statins 
Cerebral Aβ levels have been shown to be decreased in vivo with simvastatin and 
results in the specific neuropathologic change in statin use of decreased NFT burden at 
autopsy (Fassbender et al., 2001; Li et al., 2007). 
The Adult Changes in Thought (ACT) Study also showed a significant protective 
effect of statins against dementia; however, a later analysis of a larger sample from 
ACT suggested a protective effect in subjects who began statin use before age 80 (Li et 
al., 2004). In line with these results, numerous early epidemiologic studies indicated 
that the use of statins significantly reduces the risk of AD (Jick et al., 2000). The pattern 
of results obtained thus far suggests that statins may slow progression of the 
neurodegenerative process, but may not be able to reverse neuronal degeneration once it 
has occurred, so both were not approved for the treatment of AD by the FDA. 
 
8.5. Non steroidal anti inflammatory drugs (NSAIDs) 
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Aβ deposition and plaque formation are associated with an innate immune response 
that includes activation of complement, secretion of pro-inflammatory cytokines, 
expression of chemokines, and excretion of nitric oxide which mediates apoptosis 
(Dickson et al., 1993). NSAIDs downregulate pro-inflammatory signals, microglia, and 
astrocytes and may reduce risk of AD by lowering Aβ1–42 production (Breitneir et al., 
1994). Case control studies of individuals taking NSAIDs for arthritis, a small clinical 
trial of indomethacin, and a number of familial studies also indicated protection from 
development of AD or progression of disease (Andersen et al., 1995). NSAIDs may 
help prevent cognitive decline if started in midlife. 
 
8.6. Hormone replacement therapy 
Estrogen enhances cerebral blood flow, prevents atrophy of cholinergic neurons, 
reduces oxidative stress, and modulates the effects of nerve growth factors (Goutte et 
al., 2002). It may also reduce neuronal injury by decreasing formation of Aβ. Three 
prospective, population-based epidemiologic studies suggested that post-menopausal 
estrogen replacement therapy (HRT) may delay the onset of AD and showed some 
improvement in cognitive function (Bard et al., 2000). However, other randomized trials 
actually showed an increase in the development of dementia in healthy individuals and 
no improvement in cognitive or functional outcome (Becher et al., 2000). As such, 
further work is clearly needed to explore the use of HRT in AD and whether any effects 
are direct or indirect (Casadeus et al., 2007). 
 
8.7. Blocking of exitotoxicity 
Glutamate is a useful excitatory neurotransmitter of the nervous system, although 
excessive amounts in the brain can lead to cell death through a process called 
excitotoxicity, which consists in the overstimulation of the glutamate receptor NMDA. 
Excessive activation of NMDA receptors by glutamate increases the vulnerability of 
CNS neurons leading to neuronal degeneration. Memantine (trade name Namanda, 
Forest) is a non-competitive NMDA receptor antagonist, it blocks glutamate gated 
NMDA channels, thereby blocking pathological activation, inhibiting their 
overstimulation by glutamate and preserving physiological activation (Kornhuber et al., 
1989). Memantine has been shown to be moderately efficacious in the treatment of 
moderate to severe AD. In contrast with ChEIs, which are approved for patients with 
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mild to moderate  AD, memantine is approved for patients with moderate to severe AD. 
Reported adverse events with memantine are infrequent and mild, including 
hallucinations, confusion, headache and fatigue. There is evidence that combination 
therapy with donepezil may provide better outcomes with regards to cognition, global 
outcome and behavior (Tariot et al., 2004). 
 
8.8. Immunotherapy 
In the attempt to avoid adverse T cell mediated immune response, many vaccination 
modalities under current investigation are directed towards the humoral response. Nasal 
immunization of an AD mouse model with AdPEDI-(Aβ1–6) demonstrated a 
predominantly IgG1 response and reduced Aβ load in the brain (Kim et al., 2007). 
Transcutaneous immunization has also been studied in mice with aggregated Aβ 1–42 
plus the adjuvant cholera toxin. This animal study showed significant decreases in 
cerebral Aβ1–40/42 levels in the setting of increased circulating levels of Aβ1–40/42 
without the side effects of brain T cell infiltration or microhemorrhage (Nikolic et al., 
2007; Asuni et al., 2006). Aβ derivatives in alum adjuvant also promote humoral 
immunity and decrease the Aβ burden (Asuni et al., 2006). Preliminary clinical results 
indicate that intravenous immunoglobulin (IVIg) has the potential to deliver a controlled 
immune attack on the Aβ peptide (Solomon et al., 2007). Clinical trials testing the 
safety and tolerability of the monoclonal antibody Bapineuzumab (AAB-001), an Aβ 
peptide antibody, have been conducted by Wyeth and Elan in patients with mild to 
moderate AD.  Phase 3 trials were terminated on August 6, 2012 because two large 
Phase 3 studies showed no clinical benefit. Biomarker analyses indicated that 
bapineuzumab engaged its target but had no benefit.  
The Aβ vaccine trials. Removal of Aβ excess from the brain occurs by a reactive T 
cell response. In 1999, active immunization of transgenic mice producing human Aβ 
was shown to produce a significant reduction of Aβ plaques (Schenk et al., 1999). For 
the immunization of the PDAPP transgenic mouse model Aβ was administered prior to 
the onset of AD-type neuropathologies or once these changes were already established. 
Immunization of the young animals prevented the development of Aβ plaque formation, 
neuritic dystrophy and astrogliosis. Treatment of the older animals reduced the extent 
and progression of these neuropathologies (Schenk et al., 1999). 
There is evidence for a number of mechanisms of plaque removal: 
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1) solubilization by binding of antibody to Aβ; 
2) phagocytosis of opsonized Aβ by microglial cells; 
3) the “sink” hypothesis in which Aβ antibodies remain in the plasma and extract Aβ 
from the brain by altering equilibrium across the blood brain barrier to retain functional 
effects following immunization (Janus et al., 2000; Morgan et al., 2000). 
Following these animals, clinical trials of the immunogen AN-1792 [Aβ1–42 with 
adjuvant (QS-21)] (Janseen, Pfizer) were performed by Elan Pharmaceuticals/Wyeth. 
Phase 2a clinical trials were suspended when 6% of patients in the active treatment 
group developed meningoencephalitis characterized by subacute neurologic 
deterioration, lymphocytic pleocytosis, and white matter abnormalities on imaging 
(Orgogozo et al., 2003). Five patients receiving the trial drug died, with one death 
(secondary to cerebral infarction) considered to be related to study treatment (Gilman et 
al., 2005). 
Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar 
affinity to a conformational epitope on Aβ fibrils. It encompasses both N-terminal and 
central amino acids of Aβ. The therapeutic rationale for this antibody is that it acts 
centrally to disassemble and degrade amyloid plaques by recruiting microglia and 
activating phagocytosis. Gantenerumab preferentially interacts with aggregated brain 
Aβ, both parenchymal and vascular. In APP/PS-1 transgenic mice, gantenerumab binds 
to cerebral Aβ, reduces small plaques by recruiting microglia, and prevents new plaque 
formation. Gantenerumab does not alter plasma Aβ (Bohrmann et al., 2012). It is being 
studied as a potential combination therapy with the Roche BACE inhibitor R7129 in 
mouse models of Aβ amyloidosis. 
Phase 1 BACE inhibitor and its Phase 3 antibody reduced Aβ levels and plaque 
burden more strongly in a transgenic mouse overexpressing mutant human APP than 
did either treatment alone (Novakovic et al., 2013). 
 
 
 
 
 
8.9. Secretase effectors 
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Memapsin 2 (β-secretase, BACE1) is the protease that initiates cleavage of APP 
leading to the production of Aβ. Immunization of transgenic AD mice (Tg2576) with 
BACE has also resulted in Aβ reduction and cognitive improvement in the absence of 
an inflammatory response (Chang et al., 2007). A nonselective γ-secretase inhibitor, 
LY450139 (Eli Lilly) was evaluated in PDAPP transgenic mice and found to result in a 
60% reduction of Aβ40 in plasma, CSF and the hippocampus. There was also a 
reduction in the median value for Aβ plaque burden in the cortex and hippocampus. 
Two clinical trials showed dose dependent reduction of plasma Aβ, however, 
following the inhibitory phase, plasma Aβ levels exceeded baseline levels. 
Gastrointestinal side effects and eosinophilia were also properties of concern 
(LY450139 Dihydrate or semagacestat). Phase 3 study showed that the drug increased 
the risk of skin cancer and infections and had no efficacy. Both cognition and function 
were not improved but rather worsened in all treatment groups (Doody et al., 2013). 
Lilly terminated development of semagacestat because disruption of hippocampal 
network function was found (Hajos et al., 2013). 
The Phase 2 trial of  another BACE inhibitor by Eli Lilly & co. (LY2886721) was 
discontinued in 2013 due to liver abnormalities showed up in four out of 45 patients 
during routine testing (www.alzforum.org). 
Tarenflurbil (MPC-7869; Myriad Pharmaceuticals) is a γ-secretase modulator in the 
class of drugs referred to as Selective Amyloid Lowering Agents (SALAs). As these 
drugs do not interfere with γ-secretase substrates, they are well tolerated. A phase 2 
study in 207 patients with mild to moderate AD showed improvement on ADLs, global 
function, and cognition in patients with mild AD, with a significant plasma 
concentration to response relationship. There was no benefit observed in patients with 
moderate AD. The phase 3 study of Tarenflurbil showed that  it does not slow cognitive 
decline or the loss of activities of daily living in patients with mild AD, it was 
discontinued (Green et al., 2009). 
 
 
 
 
 
8.10. Diet  
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The Mediterranean diet (MD) was recently demonstrated to be associated with lower 
AD risk (Singh et al., 2014). A recent study has now shown that the Mediterranean diet 
is also associated with lower mortality in AD. This diet is characterized by high intake 
of vegetables, fruits, and cereals; a low-to-moderate intake of saturated fatty acids, 
moderately high intake of fish, low-to-moderate intake of dairy products, low intake of 
meat and poultry, and a moderate amount of ethanol. 
This thesis will provide an insight in the benefits that MD has against AD onset. 
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AUTOPHAGY 
 
1. History 
The term “autophagy” was chosen to distinguish the lysosomal degradation, or 
“eating” (phagy), of part of the cell’s self (auto) from the breakdown of extracellular 
material (heterophagy). 
Autophagy is a ubiquitous process in eukaryotic cells that results in the breakdown of 
cytoplasm within the lysosome in response to stress conditions and that allows the cell 
to adapt to environmental and/or developmental changes. 
Christian de Duve is considered to be the founding father of autophagy research area: 
autophagy is a degradative mechanism that is part of the lysosomal system an de Duve 
carried out the pioneering biochemical work that helped lead to the discovery of the 
lysosome as a distinct entity in 1955. He conied the term “lysosome” and received the 
Nobel Prize in Physiology and Medicine in 1974, mostly for his work on this organelle. 
De Duve also came up with the term “autophagy”, which he introduced at the CIBA 
Foundation Symposium on Lysosomes in 1963. 
The descriptive name “autophagy” was intended to illustrate observations from 
electron microscopy studies, which showed novel single- or double-membrane vesicles 
that contained parts of the cytoplasm, including organelles, in various degrees of 
disintegration (Ashford et al., 1962; Clark et al., 1957; de Duve et al., 1966; Novikoff, 
1959).  At the time, de Duve and others suggested that the sequestering organelle, or 
“autophagosome” was derived from a preformed membrane such as smooth 
endoplasmic reticulum, but the current view is that the autophagosome forms in a 
largely de novo process, starting with a core membrane that expands through vesicular 
addition. Whereas autophagy was, and still is, considered to be primarily non-specific 
(Kopitz et al., 1990), de Duve suggested the possibility of selective types of autophagy 
that might allow the targeted degradation of abnormal cellular constituents, an aspect of 
autophagic function that has gained considerable prominence in recent years (Klionsky, 
2007). 
Whereas the initial studies of de Duve and others primarily examined the terminal 
stages of the process, and focused on steps just before or after fusion with the lysosome, 
Seglen’s laboratory began to study the early and intermediate steps using electroinjected 
I n t r o d u c t i o n  | 33 
Autophagy 
radioactive probes (Seglen et al., 1987); these analyses identified the phagophore, the 
initial sequestering organelle that develops into an autophagosome, as well as  the 
amphisome (Gordon et al., 1988), which marks the convergence of the autophagic and 
endocytic pathways. 
The identification of autophagy genes in higher eukaryotes made it possible to 
analyse mammalian cells that express autophagy proteins tagged with fluorescent 
markers. Time-lapse studies provide images which suggest that autophagosome 
formation proceeds in a step-wise manner, marked by the expansion of the sequestering  
membrane (Mizushima et al., 2001). 
Analysis of autophagy in the yeast system lagged behind considerably until 1992, 
when a study by Yoshinori Ohsumi’s laboratory demonstrated that the autophagy 
morphology in yeast was similar to that documented in mammals (Takeshige et al., 
1992). This result was crucial as a foundation for further studies in this genetically 
tractable organism. In yeast, the autophagic machinery is concentrated at a perivacuolar 
site (the vacuole is the yeast equivalent to the lysosome), termed the “pre-
autophagosomal structure” (PAS), which acts as a phagophore assembly site (Kim et al., 
2002; Suzuki et al., 2001). 
Autophagy research clearly has its roots in the mammalian system, however, 
significant breakthroughs in our understanding of the molecular basis of autophagy only 
occurred following analyses in the yeast system. Ohsumi’s group carried out the first 
genetic screen for autophagy mutants (Tsukada and Ohsumi, 1993), and this was rapidly 
followed by various similar screens (Klionsky, 2003): the first gene, Atg1 (autophagy-
related gene 1) has been published in 1997 (Matsuura et al., 1997), ten years on, the 
thirty-first gene (Atg31, according to the unified nomenclature, Klionsky 2003) was 
recently identified (Kabeya et al., 2007). 
The identification of the Atg genes in yeast allowed the subsequent  explosion of 
research into the molecular analysis of autophagy in higher eukaryotes. Mizushima and 
colleagues identified the first mammalian autophagy genes, Atg5 and Atg12, and 
demonstrated that the Atg12-Atg5 conjugation system, necessary to trigger autophagy, 
is conserved from yeast to human (Mizushima et al., 1998). Another important step for 
autophagy analysis in higher eukaryotes was the identification of the mammalian Atg8 
homologue MAP1LC3 (also known as LC3) by Yoshimori and Mizushima (Kabeya et 
al., 2000) and the subsequent development of LC3-based assay for monitoring 
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autophagy in mammals and other higher eukaryotic systems (Mizushima, 2004). It is 
important to note, however, that steady state LC3 levels alone are not sufficient for 
evaluating autophagy, as it is crucial to follow flux through the entire pathway 
(Klionsky et al., 2007; Klionsky, 2007). 
 
2. Types of autophagy 
At least three forms of autophagy have been identified: chaperone-mediated 
autophagy, microautophagy and macroautophagy (Fig. 5). 
The main degradation pathway is macroautophagy, it involves the sequestration of 
cytoplasmic components (long-lived proteins, damaged organelles and even invasive 
pathogens) into a double-membrane cytosolic vescicle, termed autophagosome, that 
transports the cargo to the lysosome; there, the outer-membrane and the inner vescicle, 
together with the cargo, is degraded; the resulting macromolecules can be recycled back 
to the cytosol for reuse during starvation (Yorimitsu and Klionsky, 2005). This 
sequestration process is controlled by the mammalian target of Rapamycin (mTOR) 
kinase pathway, the major negative regulator of autophagy, which in turn, is regulated 
by insulin via the phosphoinositol 3 kinase/serine threonine protein kinase (PI3K/AKT) 
pathway by specific amino acids via AMP kinases (Petiot et al., 2000).  
Microautophagy involves the direct engulfment of cytoplasm at the surface of the 
lysosome by protrusion and/or invagination of the limiting membrane. It is an active 
process in basal conditions, and it is responsible of the intracellular components 
turnover, it is not activated by stress or starvation. 
Although initially described in the liver, most of recent molecular characterization of 
this pathway has been done in yeast (Ahlberg and Glaumann, 1985). This type of 
autophagy involves the direct engulfment of cytoplasm at the surface of the lysosome 
by protrusion and/or invagination of the limiting membrane (Fig. 5). It is an active 
process in basal conditions, and it is responsible of the intracellular components 
turnover (Ahlberg and Glaumann, 1985). In addition, studies have shown that 
microautophagy is responsible for the selective removal of organelles when they are no 
longer needed, for example after treatment with drugs that induce proliferation of 
peroxisomes, normal numbers of this organelle are attained through their degradation by 
microautophagy (Farré and Subramani, 2004, Martinez-Vicente and Cuervo, 2007). 
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The chaperone-mediated autophagy is a lysosomal pathway of proteolysis that is 
responsible for the selective degradation of 30% of cytosolic proteins under conditions 
of prolonged nutrient deprivation; CMA can mediate the degradation of soluble proteins 
containing a particular pentapeptide consensus motif (KERFQ) that can be detected by 
the cytosolic chaperone HSC70 (heat-shock protein 70) and its co-chaperones, that 
selectively bring the protein to the lysosome for the degradation. The complex 
substrate-chaperone moves toward lysosomes, where the lysosome-associated 
membrane protein 2 (LAMP-2A) receptor recognizes the protein, that then is traslocated 
through the lysosomal membrane (Kon and Cuervo, 2010). CMA activity is present in 
most tissues, but maximum activation occurs under condition of stress (Massey et al., 
2006). The first response to nutritional starvation is activation of macroautophagy as a 
source of amino acids; however, if starvation persists, this random degradation of 
intracellular components cannot be maintained, and it is then that CMA becomes the 
new supplier of amino acids for the synthesis of new proteins (Massey et al., 2006). The 
selectivity of this pathway is also particularly useful under conditions that result in 
protein damage (oxidative stress, exposure to different toxic compounds, etc.) because it 
allows removal of the altered proteins without affecting neighbouring healthy ones 
(Kiffin et al., 2004). CMA can be reduced by inhibitors of glucose-6-phosphate 
dehydrogenase and of the heat shock protein of 90 kDa; reduction of levels of LAMP-
2A using RNAi strategies reduces CMA activity, but macroautophagy is activated as 
result (Dice, 2007). The decrease in CMA causes cells to be more susceptible to 
oxidative and other stresses. 
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Figure 5. Types of autophagy. In chaperone mediated autophagy, proteins marked with the KFERQ 
motif are detected by chaperones, brought to the lysosome and translocated into the lumen through 
LAMP2 for degradation. In microautophagy small cytosolic components  are carried  through 
invagination of the lysosomal membrane. In macroautophagy Atg proteins generate the 
preautophagosomal structure which engulfs cytoplasmic components and organelles as it matures into a 
full double-membraned autophagosome then it fuses with the lysosome forming an autophagolysosome, 
degrading the components trapped within (Martinez-Vicente and Cuervo, 2007). 
 
3. The process of macroautophagy 
Macroautophagy is a general term for the degradation of cytoplasmic components 
within lysosomes (Cuervo, 2004; Levine and Klionsky, 2004; Shintani and Klionsky, 
2004; Klionsky, 2005; Mizushima and Klionsky, 2007). This process is quite distinct 
from endocytosis-mediated lysosomal degradation of extracellular and plasma 
membrane proteins. 
The term “autophagy” usually indicates macroautophagy. Autophagy is mediated by 
a unique organelle called the autophagosome. As autophagosomes engulf a portion of 
cytoplasm, autophagy is generally thought to be a nonselective degradation system. This 
feature is in contrast to the ubiquitin-proteasome system, which specifically recognizes 
only ubiquitinated proteins for proteasomal degradation. It is therefore reasonable to 
assume that the ubiquitin-proteasome system has numerous specific functions because it 
can selectively degrade thousands of substrates. However, recent studies have clearly 
demonstrated that autophagy has a greater variety of physiological and 
pathophysiological roles than expected, such as starvation adaptation, intracellular 
protein and organelle clearance, development, antiaging, elimination of 
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microorganisms, cell death, tumor suppression, and antigen presentation (Mizushima, 
2005).  
To understand the various roles of autophagy, it may be useful to subclassify 
macroautophagy into “induced autophagy” and “basal autophagy” (Mizushima, 2005). 
The former is used to produce amino acids following starvation, while the latter is 
important for costitutive turnover of cytosolic components. 
The autophagy process is divided into mechanistically distinct steps, including 
induction, cargo recognition and selection, vesicle formation, autophagsome-vacuole 
fusion, and breakdown of the cargo followed  by release of the degradation products 
back into the cytosol. 
Different sets of Atg proteins are involved in these steps and consist of the core 
autophagic machinery. 
 
3.1. Induction of autophagy 
Basal-level autophagy is very low under normal conditions; therefore, an efficient 
mechanism to induce autophagy is crucial for organisms to adapt to stress and 
extracellular cues. A central inhibitor of autophagy is the serine/threonine protein kinase 
TOR (target of rapamycin). In yeast and Drosophila, Tor/dTOR integrates input 
information from multiple upstream signal transduction pathways and negatively 
regulates another serine/threonine kinase, Atg1, in nutrient-rich conditions (Chang et 
al., 2009). In yeast, upon Tor inhibition by starvation or rapamycin treatment, the kinase 
activity of Atg1 is activated and Atg1 binding affinity to Atg13 and Atg17 may also 
increase, which promotes the formation of an Atg1-Atg13-Atg17 scaffold and the 
recruitment of multiple Atg proteins to the PAS to initiate autophagosome formation 
(Suzuki et al., 2007). Thus, a role of the Atg1 kinase complex in protein recruitment is 
indispensable for autophagy induction. Moreover, in Drosophila, Atg1 is able to inhibit 
the phosphorylation and activation of a downstream TOR effector, S6K, during nutrient 
starvation, yet it is not clear how S6K signaling modulates other autophagy proteins 
and/or autophagy activity (Lee et al., 2007). 
There are two mammalian homologs of Atg1 that appear to function in autophagy, 
the Unc-51-like kinase 1 (ULK1) and -2 (ULK2), and one homolog of yeast Atg17, 
FIP200 (the focal adhesion kinase family-interacting protein of 200 kD), which forms a 
complex with ULKs and mammalian Atg13 and localizes to the phagophore upon 
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starvation (Hara et al., 2008). Regarding the substrates of the Atg1 kinase during 
autophagy, it is suggested that mammalian Atg13 and FIP200 are phosphorylated by 
ULKs, and ULKs also undergo autophosphorylation, which is conducive to a 
conformational change and autophagy induction (Chan et al., 2009). Different from 
what has been reported in yeast, ULKs-Atg13-FIP200 seem to form a stable complex 
regardless of nutritional conditions in mammalian cells. mTOR interacts with, 
phosphorylates, and inactivates ULKs and Atg13 under nutrient-rich conditions. Upon 
mTOR inhibition by starvation or rapamycin, ULK1 and ULK2 are activated and 
phosphorylate Atg13 and FIP200, which are essential for autophagy activity (Jung et al., 
2009). These studies raise an interesting hypothesis that Atg13 is phosphorylated by 
TOR or Atg1/ULKs on different residues, which may exert opposite effects on 
autophagy induction dependent on nutrient status. Indeed, yeast Atg13 is rapidly 
dephosphorylated during starvation, whereas Atg13 phosphorylation is enhanced during 
autophagic conditions in Drosophila (Kamada et al., 2000; Chang Y-Y et al., 2009); it 
is likely that phosphorylation of Atg13 is dependent more on Tor in yeast, and to a 
greater extent on Atg1 in Drosophila. Atg101, a newly identified protein component in 
the ULKs-Atg13- FIP200 complex, binds and stabilizes Atg13, and is required for 
autophagy in mammals (Mercer et al., 2009). 
 
3.2. Cargo recognition and selectivity 
In selective autophagy, cargos are recognized through interactions with specific 
receptor proteins. The yeast Cvt pathway delivers prApe1 into the vacuole and 
generates the mature enzyme Ape1. The cargo prApe1 contains a vacuolar targeting 
signal, which can be recognized and bound by the receptor protein Atg19. An adaptor 
protein, Atg11, binds Atg19 and recruits the Atg19-prApe1 complex to the PAS, where 
Atg19 interacts with one of the key components in the vesicle-forming machinery, 
Atg8, for packaging the receptor-cargo complex into Cvt vesicles (analogous to 
autophagosomes) (Shintani et al., 2002). 
In multicellular organisms, an important function of autophagy is the clearance of 
cytosolic ubiquitinated substrates or aggregateprone proteins. Recent studies suggest 
that this degradative process is also selective and mediated through the mammalian 
protein p62/sequestosome 1 (SQSTM1), the Drosophila homolog of p62 (Bjørkøy G et 
al., 2005); p62 directly binds both poly- or monoubiquitin via its ubiquitin-associated 
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(UBA) domain and the mammalian Atg8 homolog, LC3 (microtubule-associated 
protein 1 light chain 3), and links the ubiquitinated cargos to the autophagy machinery 
for autophagic degradation (Pankiv et al., 2007). The structural and functional similarity 
between a C-terminal motif in mammalian p62 and yeast Atg19 suggests that p62 is an 
Atg19 analog in higher eukaryotes and acts as a receptor for ubiquitinated proteins or 
organelles in selective autophagy (Noda et al., 2008).  
 
3.3. Autophagosome formation 
In the first step of autophagosome formation, cytoplasmic constituents, including 
organelles, are sequestered by a unique membrane called the phagophore or isolation 
membrane, which is a very flat organelle. Complete sequestration by the elongating 
phagophore results in formation of the autophagosome, which is typically a double-
membraned organelle. This step is a simple sequestration, and no degradation occurs 
(Suzuki et al., 2001). 
In yeast, 31 Atg (autophagy-related) proteins have been identified, and many of them 
gather at a site that can be identified by fluorescence microscopy as a punctate spot very 
close to the vacuolar membrane. Since autophagosomes are generated from this site, it 
is called the “preautophagosomal structure” (PAS) (Kim et al., 2001; Suzuki and 
Ohsumi, 2007). Equivalent structures have not been observed in mammalian cells. 
Yeast cells may have a stable PAS because it is shared with the cytoplasm-to-vacuole 
targeting (Cvt) pathway, a costitutive transport pathway for amino peptidase 1 (Ape1) 
and α-mannosidase (Ams1) from the cytosol to the vacuole (Klionsky and Ohsumi, 
1999). 
Among the 31 Atg proteins, 18 Atg proteins (Atg1-10, Atg12-14, Atg16-18, Atg29, 
and Atg31) are involved in autophagosome formation and are called “AP-Atg proteins”. 
A recent systematic analysis showed that the AP-Atg proteins depend on each other for 
recruitment to the PAS (Suzuki et al., 2007); in particular, Atg17 was found to be a 
scaffold for PAS organization. The recently identified Atg29 (Kawamata et al., 2005) 
and Atg31 (Kabeya et al., 2007) appear to function together with Atg17. Atg11 is also 
important for PAS organization but is essential only for the Cvt pathway (Suzuki et al., 
2007).  
Multiple Atg proteins are recruited to the phagophore to participate in 
autophagosome formation, and this step requires the highly regulated coordination of all 
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of these proteins. The nucleation and assembly of the initial phagophore membrane 
require the class III phosphatidylinositol 3-kinase (PtdIns3K) complex, which is 
composed of the PtdIns3K Vps34 (vacuolar protein sorting 34), a myristoylated 
serine/threonine kinase Vps15 (p150 in mammalian cells), Atg14 (Barkor or mAtg14 in 
mammalian cells) and Atg6/Vps30 (Beclin 1 in mammalian cells) (Italkura et al., 2008). 
The function of Beclin 1 in autophagy is regulated by Bcl-2 (B-cell 
lymphoma/leukemia-2), an antiapoptotic protein that inhibits autophagy by binding and 
sequestering Beclin 1 under nutrient-rich conditions; dissociation of Beclin 1 from Bcl-
2 is required for autophagy induction. The PtdIns3K complex produces PtdIns3P 
(phosphatidylinositol 3-phosphate) and is involved in PAS targeting of a number of 
yeast Atg proteins that bind PtdIns3P, such as Atg18, Atg20, Atg21, and Atg24 (Obara 
et al., 2008). In yeast, Atg20 and Atg24 interact with the Atg1-Atg13-Atg17 complex, 
and the latter mediates autophagy induction; however, the mammalian homologs of 
Atg20 and Atg24 are either not identified (Atg20) or not well characterized in 
autophagy (Atg24). The PtdIns3K complex, in part together with the above Atg 
proteins, further recruits two interrelated ubiquitin-like (Ubl) conjugation systems, 
Atg12-Atg5-Atg16 and Atg8-PE (phosphatidylethanolamine), to the phagophore, which 
play an essential role in regulating the membrane elongation and expansion of the 
forming autophagosome. The two Ubl proteins, Atg12 and Atg8, undergo conjugation 
in a similar manner as ubiquitin. Atg12 is activated by Atg7 (E1 activating enzyme), 
transferred to Atg10 (E2 conjugating enzyme) and attached to an internal lysine of the 
substrate protein Atg5 covalently. In contrast to ubiquitination, Atg12-Atg5 conjugation 
is constitutive and irreversible, and apparently no substrate-specific E3 ligase 
counterpart is required in this process (Geng and Klionsky, 2008). The Atg12-Atg5 
conjugate further interacts with a coiled-coil protein Atg16, which links the Atg12-
Atg5-Atg16 complex into a tetramer by self-oligomerization and attaches it to the 
phagophore (Mizushima et al., 2003). In the Atg8 conjugation system, Atg8 is first 
processed by a cysteine protease, Atg4, exposing a C-terminal glycine residue. The 
same E1 enzyme Atg7 activates Atg8 and transfers it to Atg3 (E2). Atg8 is finally 
conjugated to the target lipid PE via an amide bond, facilitated by the E3-like Atg12– 
Atg5 conjugate (Fujita et al., 2008) . In nutrient rich conditions, the majority of Atg8 is 
cytosolic; upon autophagy induction, Atg8 largely exists as the lipid-conjugated form 
and is localized to both sides of the phagophore. Atg8 controls the size of the 
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autophagosome, which may result from its ability to determine membrane curvature 
(Xie et al., 2008). The lipidation of Atg8 and its mammalian homolog LC3 is widely 
used to monitor autophagy induction. Various sources, including mitochondria, the 
Golgi complex, the ER and the plasma membrane, are proposed to be the origins of the 
autophagosomal membrane  (Hailey et al., 2010; Hayashi-Nishino et al., 2009; 
Ravikumar et al., 2010; van der Vaart et al., 2010; Yen et al., 2010; Yla-Anttila et al., 
2009). Clathrin-mediated endocytosis provides membrane that contributes to the 
formation of  preautophagosomal structures and the subsequent generation of 
phagophores and mature autophagosomes (Ravikumar et al., 2010). 
SNAREs (N-ethylmaleimidesensitive factor attachment protein receptors) have 
recently been shown to regulate autophagosome formation in both mammalian cells and 
in yeast (Moreau et al., 2011; Nair et al., 2011) In mammalian cells, the SNAREs 
vesicle-associated membrane protein (VAMP)7, syntaxin-7, syntaxin-8, and VTI1B 
regulate the homotypic fusion of phagophore precursors (Moreau et al., 2011). These 
fusion events enable the growth of these structures into a tubular network leading to the 
formation of phagophores and autophagosomes (Moreau et al., 2011). Indeed, the fusion 
of small, apparently single-membrane phagophore precursor vesicles to form 
tubulovesicular structures may be a mechanism contributing to the genesis of double-
membraned phagophores or autophagosomes (Moreau et al., 2013). 
Atg9 is the only identified integral membrane protein required for autophagosome 
formation. In yeast, Atg9 localizes to the PAS and peripheral structures and is suggested 
to cycle between the two sites. Atg11, Atg23, and Atg27 are essential in the anterograde 
transport of Atg9 to the PAS, and the Atg1- Atg13 complex, Atg2, Atg18, and the 
PtdIns3K complex are involved in its retrograde transport (Legakis et al., 2007; 
Reggiori et al., 2004). Thus, Atg9 may function as a carrier in supplying membrane and 
may also play a role during phagophore expansion through its dynamic self-interaction. 
Similarly, mammalian Atg9 (mAtg9) transports from the trans-Golgi network (TGN) to 
late endosomes, which are co-labeled with LC3, when autophagy is induced. In 
mammalian cells, it is the redistribution of mAtg9 from the TGN to late endosomes that 
is dependent on ULK1 and human Atg13 (Chan et al., 2009).  
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3.4. Expansion of the phagophore 
Canonical macroautophagy is controlled by two central enzymatic pathways that 
drive the formation and expansion of the phagophore through the recruitment of various 
autophagy proteins. The first involves the formation of the Atg5-12-16 complex, Atg12 
is first covalently conjugated to Atg5 by the catalytic activities of Atg7 and Atg10. 
Atg16 then interacts with the Atg5-12 complex and homo oligomerizes to form a 
tetrameric Atg5-12-16 complex. This complex is then recruited to the phagophore 
assembly site, where it helps to promote the second pathway, namely, the processing of 
LC3. LC3 is cleaved to LC3-I by Atg4, activated by Atg3 and Atg7, and then 
conjugated to phosphatidylethanolamine (PE), forming LC3-II. This reaction is thought 
to be targeted to the developing phagophore by the Atg5-12-16 complex (rew. Levine 
and Kroemer, 2008). Since the full Atg5-12-16 complex is required for LC3-II 
formation and autophagic function, components of the Atg5-12-16 complex make 
attractive targets for impairing autophagy (Fig. 6). 
 
 
 
Figure 6. The two major conjugation systems that drive autophagic vescicle elongation. The 
enzymatic activities of Atg7 and Atg10 act for the formation of the Atg5-12-16 complex which 
then homo-oligomerizes to form a tetrameric structure; LC3 is cleaved by Atg4 and activated by 
Atg7 before being covalently conjugated to PE by Atg3 and the Atg5-12-16 complex, forming 
LC3-II. The  Atg5-12-16 complex also correctly localizes LC3-II to the developing phagophore 
(Levine and Kroemer, 2008). 
 
As the phagophore expands the Atg5-12-16 complex continues to recruit LC3-II. The 
Atg5-12-16 complex primarily localizes the outer surface of the phagophore, while 
LC3-II is present throughout the membrane surface (Levine and Kroemer, 2008). LC3-
II is believed to function as a scaffolding protein, helping to maintain the structure of 
the autophagosome and recruit membrane to the developing phagophore. LC3-II drives 
the maturation of the phagophore and expansion of the membrane. As the 
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autophagosome continues maturing and approaches closure, the Atg5-12-16 complex 
dissociates from the outer membrane. Since LC3-II only forms on autophagosomes, it 
has traditionally been used as a marker for autophagy, in western blot it runs at lower 
molecular weight than LC3-I (Tanida et al., 2005). 
As the phagophore matures, it expands in size and eventually closes, forming a 
mature autophagosome. In this process LC3-II may help bring the two membrane 
surfaces close enough to fuse. Following closure, autophagosomes are trafficked by 
dynein motors along microtubules to the lysosomes in the perinuclear region. There 
they fuse with the lysosomes through a process mediated by the SNARE proteins 
Vamp3, Vamp7 and Vti1, that are involved in fusing the two membranes together 
(Levin and Kroemer, 2008). 
 
3.5. Vesicle fusion and autophagosome breakdown 
When autophagosome formation is completed, Atg8 attached to the outer membrane 
is cleaved from PE by Atg4 and released back to the cytosol. Autophagosome-lysosome 
fusion is mediated by the same machinery that is involved in homotypic vacuole 
membrane fusion. In mammalian cells, the fusion event requires the lysosomal 
membrane protein LAMP-2 and the small GTPase Rab7, although the mechanism is 
less characterized (Jaeger et al., 2004). In yeast, the machinery consists of the Rab 
family GTPase Ypt7 (the homolog of Rab7), the NSF(N-ethylmalemide-sensitive fusion 
protein) homolog Sec18, the SNARE proteins Vam3, Vam7, Vti1, and Ykt6, the class C 
Vps/HOPS complex proteins, and two other proteins, Ccz1 and Mon1 (Klionsky, 2005). 
After fusion, degradation of the inner vesicle is dependent on a series of 
lysosomal/vacuolar acid hydrolases, including proteinases A and B (encoded by PEP4 
and PRB1, respectively) and the lipase Atg15 in yeast and cathepsin B, D (a homolog of 
proteinase A), and L in mammalian cells (Tanida et al., 2005; Teter et al., 2001). The 
resulting small molecules from the degradation, particularly amino acids, are 
transported back to the cytosol for protein synthesis and maintenance of cellular 
functions under starvation conditions. The identification of Atg22, together with other 
vacuolar permeases (such as Avt3 and Avt4) as vacuolar amino acid effluxers during 
yeast autophagy, has helped in the understanding of the mechanisms of nutrient 
recycling; these permeases represent the last step in the degradation and recycling 
process (Yang et al., 2006). 
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4. Non-Atg components required for autophagy 
Besides the Atg proteins, certain subcellular systems, including the secretory 
pathway, the endocytic pathway, and the cytoskeletal network, may also carry out 
essential functions during autophagy, such as providing membrane, facilitating 
autophagosome transport, and enabling clearance of autophagic substrates. 
 
4.1. The secretory and endocytic pathways 
Autophagy involves dramatic subcellular membrane remodeling. The role of the 
secretory pathway in autophagy is largely studied in yeast, where a functional ER and 
Golgi complex are required for autophagy and the Cvt pathway (Reggiori et al., 2004). 
A subset of GTP exchange factors, including Sec12 and Sec16, and two coatomer 
subunits of the COPII coat, Sec23 and Sec24, are needed for the biogenesis of 
autophagosomes but not Cvt vesicles, although it is possible that a defect in the Cvt 
pathway is more subtle compared with nonselective autophagy because of the relatively 
reduced need for membrane (Ishihara et al., 2001). 
Although completed autophagosomes can directly fuse with lysosomes, when cells 
are overloaded with aggregate-prone proteins, fusion of autophagosomes with the 
endocytic compartments is essential to facilitate efficient autophagic removal of these 
proteins. In Drosophila and mammalian cells, the ESCRT (endosomal sorting 
complexes required for transport) machinery and multivesicular body (MVB)-localized 
Rab11 play an important role in the fusion of MVBs with completed autophagosomes, 
and the Drosophila endosomal PtdIns3P 5-kinase Fab1 is involved in fusion of the 
resulting amphisomes with lysosomes (Rusten at al., 2007). Both steps are required for 
promoting degradation of aggregate-prone substrate proteins sequestered by 
autophagosomes. 
 
4.2. Cytoskeleton 
Efficient protein trafficking during autophagosome formation is presumably 
mediated by cytoskeletal networks. A functional actin cytoskeleton and the Arp (actin-
related protein) 2/3 complex, which nucleates branching of actin filaments, are required 
for Atg9 anterograde transport to the PAS and selective autophagy activity in yeast 
(Reggiori et al., 2005). Microtubules are involved in autophagy in higher eukaryotes. In 
primary rat hepatocytes, the microtubule depolymerising drug nocodazole inhibits 
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autophagosome formation (Kochl et al., 2007). In addition, microtubules, the tubulin 
deacetylase HDAC6, and the microtubule motor protein dynein are required for the 
autophagic clearance of various aggregate prone proteins in flies and mammalian cells 
(Iwata et al., 2005). In mammalian cells, it appears that autophagosomes are formed at 
random locations in the cell, but transported directionally toward the nucleus after 
completion (Jahreiss et al., 2008). Several lines of evidence suggest that 
autophagosomes associate with microtubule tracks, move to the microtubule-organizing 
center, and fuse with endosomes or lysosomes, and the dynamic process is driven by the 
dynein motor (Jahreiss et al., 2008). 
 
5. Signalling pathways regulating autophagy 
5.1. Nutrient signalling 
During nutrient deprivation, autophagosome formation is dramatically induced. In 
both yeast and mammalian cells, two well-characterized signaling cascades that sense 
nutrient status, activate cell division and growth, and negatively regulate autophagy are 
the TOR and Ras-cAMP-PKA pathways. 
TOR complex 1. TOR complex 1 (TORC1) is sensitive to inhibition by rapamycin. 
Inactivation of TORC1 by rapamycin stimulates autophagy in the presence of nutrients, 
suggesting that TOR downregulates autophagy (Noda and Ohsumi, 1998). Extracellular 
amino acids enter mammalian cells through transporters such as SLC1A5 (solute carrier 
family 1 member 5) and SLC7A5, and it is proposed that mTORC1 directly senses and 
is phosphorylated in response to nutrient signals (Long et al., 2005); however, recent 
observations in Drosophila and mammals suggest that Rag proteins, the Ras-related 
small GTPases, activate TORC1 in response to amino acids (Kim et al., 2008) through 
mediating translocation of TORC1 to a specific subcellular compartment that contains 
the TORC1 activator Rheb (Ras homolog enriched in brain) (Rusten et al., 2007). Other 
studies indicate that amino acids also activate mTOR via class III PtdIns3K (hVps34) 
(Nobukuni et al., 2005). The presence of amino acids stimulates hVps34, which leads to 
mTOR activation and autophagy inhibition. However, this creates a discrepancy with 
the role of the class III PtdIns3K in promoting nucleation and assembly of Atg proteins 
at early steps of autophagosome formation (Juhasz et al., 2008). A possible explanation 
is that the PtdIns3K exists in distinct subpopulations or protein complexes in the cell, 
which carry out different functions, or function at different times. Besides regulating the 
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Atg1/ULK complex, in yeast TORC1 also suppresses autophagy via phosphorylation of 
Tap42, which activates the catalytic subunits of PP2A (the serine/threonine protein 
phosphatase 2A), a negative regulator of autophagy (Yorimitsu et al., 2009). 
The Ras/PKA pathway. The Ras/cAMPdependent protein kinase A (PKA) signalling 
pathway plays an important role in glucose sensing from yeast to mammals. Yeast PKA 
contains a heterotetramer composed of the regulatory subunit Bcy1 and three apparently 
redundant catalytic subunits, Tpk1, Tpk2, and Tpk3. In nutrient-rich conditions, the 
small GTPases Ras1 and Ras2 are active and enhance cAMP generation by the adenylyl 
cyclase. Elevated cAMP binds to Bcy1 and releases its inhibitory effect on PKA. 
Constitutive activation of the Ras/PKA pathway suppresses autophagy induced by TOR 
inhibition in yeast (Schmelzle et al., 2004), suggesting that the Ras-PKA pathway 
downregulates autophagy in parallel with the TOR-Tap42 pathway. Autophagy 
inhibition by Ras/PKA may be mediated through regulation of Atg1, which is identified 
as a phosphorylation substrate of PKA. In the presence of nutrients, PKA 
phosphorylation causes Atg1 to be largely cytosolic and dissociated from the PAS, 
whereas during starvation, Atg1 is dephosphorylated and localized to the PAS. 
In addition to PKA, the protein kinase Sch9, the closest yeast homolog to the 
mammalian protein kinase B (PKB)/Akt as well as to the TOR target S6 kinase (S6K), 
is involved in nutrient sensing (Zhang et al., 2008). Simultaneous inactivation of PKA 
and Sch9 induces autophagy, which can be further increased by inactivation of TORC1, 
suggesting that autophagy is negatively regulated by at least three parallel pathways in 
yeast, TORC1, Ras/PKA, and Sch9. Ras/PKA and Sch9 may regulate autophagy at the 
transcriptional level, as the transcription factors Msn2/4 and the Rim15 kinase are 
required for autophagic flux induced by inactivation of both PKA and Sch9, but not for 
that induced by inactivation of TOR (Yorimitsu et al., 2007). 
 
5.2. Insulin/Growth Factor Pathways 
When growth factors are withdrawn from the extracellular milieu, in spite of 
sufficient nutrients, autophagy is induced to maintain cellular functions and energy 
production (Lum et al., 2005). In higher eukaryotes such as Drosophila and mammalian 
cells, the pathways through which hormones regulate autophagy are different from those 
of nutrients, but both converge on TOR (Fig. 7). Insulin and insulin-like growth factors 
regulate mTOR through the class I PtdIns3K. Upon insulin binding, 
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autophosphorylation of the insulin receptor on tyrosine residues results in the 
recruitment and phosphorylation of IRS1 and IRS2 (insulin receptor substrate 1 and 2), 
which creates a docking scaffold that allows binding of adaptor proteins, including 
subunits of the class I PtdIns3K such as p85. Generation of PIP3 [phosphatidylinositol 
(3,4,5)-trisphosphate; Fig. 7 , red circles in the membrane] by the class I PtdIns3K 
increases membrane recruitment of both protein kinase B (PKB)/Akt and its activator 
PDK1 (phosphoinositide-dependent protein kinase 1), leading to phosphorylation and 
activation of PKB/Akt by PDK1 (Stokoe et al., 1997). The 3-phosphoinositide 
phosphatase PTEN reverses PIP3 production, decreasing the downstream PKB/Akt 
signalling, positively regulates autophagy (Arico et al., 2001), but has been recently 
observed that this effect in promoting autophagy could be independely of its lipidic 
phosphatase activity (Errafiy et al., 2013). 
Recently Renna et al. (2013) reported  that IGF-1 (insulin- growth factor)  inhibition 
attenuates autophagosome formation; the reduced amount of autophagosomes present in 
IGF-1R depleted cells has beeen, at least in part, explained by a reduced formation of 
autophagosomal precursors at the plasma membrane. In particular, IGF-1R depletion 
inhibits mTORC2, which, in turn, reduces the activity of protein kinase C (PKCα/β). 
This perturbs the actin cytoskeleton dynamics and decreases the rate of clathrin-
dependent endocytosis, which impacts autophagosome precursor formation. 
Basically, when hormones are absent, mTOR is inactivated, which releases the 
inhibitory effect on autophagy. Besides TOR, Ras signaling also plays a role in 
autophagy regulation by growth factors (Fig. 7). Ras transduces signals from growth 
factor receptor tyrosine kinases to intracellular effectors, such as Raf-1/MAP (mitogen-
activated protein) kinases and the class I PtdIns3K (Furuta et al., 2004).  
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Figure 7. Autophagy is induced by deprivation of nutrients, hormones, and energy. 
Regulatory pathways of autophagy by amino acids, hormones, and energy in mammals (He and 
Klionsky, 2009) 
 
5.3. Energy Sensing 
During periods of intracellular metabolic stress, activation of autophagy is essential 
for cell viability. In mammalian cells, a reduced cellular energy (ATP) level is sensed 
by AMPK (5’-AMP-activated protein kinase) (Fig. 7). AMPK is activated by a 
decreased ATP/AMP ratio through the upstream LKB1 kinase (encoded by the Peutz-
Jeghers syndrome gene). Active AMPK leads to phosphorylation and activation of the 
TSC1/2 complex, which inhibits mTOR activity through Rheb (Inoki et al., 2003). 
Autophagy stimulated by mTOR downregulation results in elevated ATP production via 
recycling of nutrients. In addition, the LKB1-AMPK pathway phosphorylates and 
activates p27kip1, a cyclin-dependent kinase inhibitor leading to cell cycle arrest, which 
is essential to prevent cells from undergoing apoptotic death and to induce autophagy 
for survival in response to bioenergetic stress during growth factor withdrawal and 
nutrient deprivation (Liang et al., 2007). Similarly, Snf1, the yeast homolog of 
mammalian AMPK, also positively modulates autophagy, possibly through independent 
mechanisms involving regulation of Atg1 (Wang et al., 2001). 
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5.4. Stress Response 
Various extra- and intra-cellular stresses potently induce autophagy, which is 
important for organisms to adapt to, or overcome, unfavourable conditions. Recent 
studies have provided insight into the molecular mechanisms that regulate autophagy in 
response to different stresses. 
ER stress. The ER is the key compartment in the cell to facilitate folding of newly 
synthesized proteins and initiate the pathway of vesicular movement of membrane and 
proteins to various organelles and the cell surface. In mammalian cells, the ER also 
serves as the major intracellular Ca2+ reservoir. A number of ER stress stimuli, for 
example, expression of aggregate prone proteins, glucose deprivation (resulting in 
reduced glycosylation and decreased energy for chaperone activity), hypoxia and 
oxidative stress (causing decreased disulfide bond formation), and Ca2+ efflux from the 
ER, lead to the accumulation of unfolded proteins in the ER, which exceeds its folding 
capacity. Autophagy is induced by ER stress in organisms from yeast to mammals. 
However, the signalling mechanisms linking ER stress to autophagy vary, dependent on 
the specific stress conditions and the organisms is still studied (Fig. 8). In yeast, ER 
chemical stressors blocking formation of disulfide bonds or protein glycosylation, such 
as DTT and tunicamycin, effectively trigger autophagy, which requires Atg1 kinase 
activity (Yorimitsu et al., 2006). ER stress-induced autophagy is required for cell 
survival in the presence of tunicamycin, likely through compensatory removal of 
expanded and disorganized ER (which results from the unfolded protein response; 
UPR), along with the misfolded proteins within (Bernales et al., 2006). The UPR 
signaling pathway in yeast is mediated by Ire1 (inositol-requiring kinase 1), an ER 
transmembrane protein with a lumenal stress sensing domain and a cytosolic 
endoribonuclease domain. In response to the accumulation of unfolded proteins, an ER-
specific member of the heat shock protein 70 family, Grp78/BiP, dissociates from its 
ER-sensing domain and activates the cytosolic endonuclease domain of Ire1, which 
triggers the splicing of the Ire1 substrate Hac1. The latter encodes a transcription factor 
(the yeast homolog of mammalian XBP1) that activates transcription of target genes 
involved in protein modification/folding, vesicle transport, phospholipid biosynthesis, 
and ERAD (ER-associated degradation) (Mammucari et al., 2007). Although the Ire1-
Hac1 pathway is required for autophagy induction by ER stress, it is dispensable for the 
transcriptional upregulation of ATG genes (Bernales et al., 2006). In mammalian cells, 
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knockdown of the upstream UPR regulator Grp78/BiP by siRNA inhibits 
autophagosome formation induced by both ER stress and nutrient deprivation, but does 
not affect the conversion of LC3-I to LC3-II, suggesting that Grp78/BiP is necessary for 
autophagy and may function at the phagophore expansion rather than induction step (Li 
et al., 2008). But the knockdown of Grp78/BiP is an artificial condition that 
spontaneously activates UPR pathways and induces LC3 conversion, and this situation 
makes it difficult to differentiate between the roles of Grp78/BiP and UPR signaling in 
autophagy induction. 
Mammalian UPR signaling is more complex than in yeast and involves three distinct 
downstream pathways, IRE1 (similar to yeast Ire1), ATF6 (activating transcription 
factor 6), and PERK (RNA-dependent protein kinase-like ER kinase). These factors 
signal misfolded protein levels in the ER and activate transcription of different target 
genes. One downstream target of IRE1 is c-Jun N-terminal kinase (JNK), which is 
essential for lipid conjugation of LC3 induced by tunicamycin or by accumulation of 
cytosolic misfolded proteins due to proteasome inhibition in MEFs and cancer cells 
(Ogata et al., 2006). 
Data using murine cells suggest that in response to ER stress induced by expression 
of misfolded polyQ72 or mutant dysferlin proteins, phosphorylation of eIF2α 
(eukaryotic initiation factor 2α) by the eIF2α kinase PERK is required for mediating 
LC3 conversion and autophagic degradation of the mutant proteins in the ER (Kouroku 
et al., 2007). Thus, both the IRE1-JNK and the PERK-eIF2α pathways seem to play an 
important role in UPR-induced autophagy. 
In addition to UPR signaling, ER stress also induces release of lumenal Ca2+ to the 
cytosol. Calcium-activated calmodulin-dependent kinase kinase-β (CaMKKβ) is 
stimulated by the increase in the intracellular Ca2+ level and further activates AMPK, 
the latter potently inducing autophagy (Høyer-Hansen et al., 2007). Elevated Ca2+ levels 
also trigger phosphorylation of protein kinase Cθ (PKCθ), which induces LC3 
conversion and autophagy in immortalized hepatocytes in response to the ER stressors 
thapsigargin and tunicamycin (Sakaki and Kaufman, 2008). Although some studies 
show that ER stress-induced autophagy has a pro-survival role in mammalian cells, 
others suggest that ER stressors may cause autophagic cell death. Injection of 
tunicamycin into renal tubules in mice induces kidney tubular cell death via both 
apoptosis and autophagy, which are mediated by the catalytic activity of the tumor 
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suppressor DAPk (calmodulin-regulated serine/threonine kinase death-associated 
protein kinase). DAPk is activated by PP2A-like phosphatase-dependent 
dephosphorylation of an inhibitory serine that is derived from autophosphorylation and 
activated DAPk induces autophagy likely through its ability to phosphorylate Beclin 1 
and promote Beclin 1 dissociation from Bcl-2 (Gozuacik et al., 2008). 
It is possible that autophagy plays dual roles in determining cell fate, depending on 
specific cell types and stimuli (Ding et al., 2007). 
 
 
Figure 8. Autophagy regulation in response to stress. ER stress stimulates autophagy through 
the PERK-eIF2α pathway, the IRE1-JNK1 pathway and Ca2+ release. Activation of eIF2α by 
PERK may upregulate transcription of certain autophagy genes, such as ATG12. 
Phosphorylation and activation of eIF2α by two other eIF2α kinases, GCN2 and PKR, upon 
amino acid starvation and viral infection, respectively, are also depicted. (He and Klionsky, 
2009) 
 
Hypoxia. Low levels of oxygen at or below 1% (hypoxic stress) versus 2–9% 
(normoxia for most mammalian cell types) exist in physiologically developing embryos 
as well as many pathological conditions, such as solid tumors, cardiovascular ischemia, 
and brain injuries. 
Hypoxia can induce autophagy in mammalian cells, and the signalling pathways 
responsible for autophagy induction and its cellular consequences seem to be different, 
contingent on the types of cells and autophagic pathways (Fig. 9). Enhanced 
mitochondrial autophagy (mitophagy) during hypoxia is suggested to be an adaptive 
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response, reducing the levels of reactive oxygen species (ROS) and protecting cell 
integrity, although in several glioma and breast cancer cell lines, prolonged hypoxia 
mediates autophagic cell death (Azad et al., 2008). 
Hypoxia-inducible factor-1 (HIF-1) is the primary transcription factor acutely 
induced by hypoxic conditions, and it drives transcription of hundreds of genes that 
promote erythropoiesis and angiogenesis and decrease mitochondrial biogenesis and 
respiration, counterbalancing deleterious effects caused by O2 deficiency. In MEFs, 
mitochondria are removed by mitophagy in response to hypoxia, which is dependent on 
HIF-1 and the induction of its downstream target BNIP3 (Bcl-2 adenovirus E1a 
Nineteen kDa Interacting Protein 3; a pro-death Bcl-2 family member) (Zhang et al., 
2008). In addition, during reticulocyte maturation in mice, another HIF-1-induced 
target, BNIP3L (BNIP3-like protein or NIX), is required for programmed mitochondrial 
clearance by autophagy (Sandoval et al., 2008). BNIP3 competes with Beclin 1 for 
binding Bcl-2 and thus releases Beclin 1 for participating in mitophagy. 
Besides being under the control of HIF-1, BNIP3 is also a target gene of the E2F 
transcription factors, which are inhibited by the RB tumor suppressor during RB-
induced cell cycle arrest (Tracy et al., 2007). Therefore, hypoxia induces BNIP3 
transcription via binding of HIF-1 and/or E2F to the BNIP3 promoter, and the RB-E2F-
BNIP3 signalling is also involved in hypoxia-induced autophagy. 
Upregulation of bulk autophagy by hypoxia in tumor cells seems independent of the 
HIF-1 pathway: the AMPK-mTOR andPKCδ (protein kinaseCδ)-JNK1 cascades are 
responsible for signaling autophagy induction (Chen JL et al., 2008; Papandreou et al., 
2008). 
In addition, hypoxia inhibits TOR and blocks eIF4F (eukaryotic initiation factor 4F) 
complex formation and mRNA translation (Brugarolas et al., 2004). Thus, autophagy 
induced by hypoxia can be at least partially TORdependent, and hypoxia-stimulated ER 
stress may also play a role in autophagy induction. 
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Figure 9. Autophagy regulation in response to stress.Autophagy induction by mechanisms 
sensing hypoxia or oxidative stress. JNK1, DAPk and BNIP3 induce autophagy by disrupting 
the Bcl-2-Beclin 1 interaction and activating Beclin 1.  
 
Oxidative stress. A common intracellular stress that effectively leads to induction of 
autophagy is the formation of Reactive Oxygen Species (ROS). Mitochondria are the 
major source generating ROS, which will in turn damage these organelles. ROS 
generating agents (such as hydrogen peroxide and 2-methoxyestradiol), or chemicals 
inhibiting the mitochondrial electron transport chain, induce ROS production and 
autophagic cell death in transformed and cancer cell lines (ChenY et al., 2008). These 
drugs induce a much lower level of ROS in non-transformed primary mouse astrocytes 
compared with cancer cells and fail to stimulate autophagy, suggesting that normal cells 
effectively maintain ROS at a tolerable level and are able to protect themselves from 
mitochondrial damage, likely through antioxidant mechanisms such as superoxide 
dismutase (SOD), catalase, and the redox system, because applying chemical ROS 
scavengers or overexpressing SOD2 reduces autophagy (Chen Y et al., 2007). 
Impaired mitochondria may be selectively degraded through mitophagy in yeast and 
mammalian cells, which may constitute another mechanism to reduce ROS levels and 
maintain cell survival (Priault et al., 2005). The link between ROS and autophagy 
induction may be the cysteine protease Atg4 (Fig. 9), which cleaves Atg8/LC3 from the 
autophagosome outer-membrane before, or soon after, autophagosome-lysosome fusion. 
ROS targets a conserved Cys81 on Atg4, which is in the vicinity of the catalytic Cys77 
residue; oxidation of cysteines inhibits Atg4 protease activity and promotes lipidation of 
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Atg8/LC3, an essential step for autophagy (Scherz-Shouval et al., 2007). It is not 
known, however, how ROS levels might be temporally and spatially controlled inside 
the cell, so that Atg4 can be locally activated to allow de-lipidation and recycling of 
Atg8/LC3, or whether another mechanism is involved. 
In addition, Atg4 seems to not be the only molecule that underlies the oxidative 
regulation of autophagy. A recent study suggests that hydrogen peroxide activates 
poly(ADP-ribose) polymerase-1 (PARP-1), which stimulates the LKB1-AMPK 
pathway and leads to autophagy induction (Huang et al., 2009). It is likely that DNA 
damage induced by oxidative stress is involved in the activation of PARP-1 and 
autophagy (Munoz-Gamez et al., 2009). 
  
5.5. Pathogen infection 
Autophagy has an important role in eliminating invading pathogens, and pathogen-
induced autophagy appears to be TOR-independent (Fig. 10). 
The innate immune system is an evolutionarily ancient and conserved defense 
mechanism and is found in almost all types of multicellular organisms, including 
insects, plants, and mammals. In Drosophila, which depend nearly entirely on innate 
immunity to fight against infection, the peptidoglycan-recognition protein (PGRP) 
family members play crucial roles in surveillance and microbe sensing. The PGRP 
receptors are present in immune cells, recognize bacteria-derived peptidoglycans, and 
activate the production of anti-microbial peptides. 
A PGRP family member, PGRP-LE, is the first identified cytoplasmic sensor in 
insects that recognizes the presence of intracellular bacteria and triggers autophagy in 
host cells, which is required for suppressing the growth of Listeria monocytogenes in 
hemocytes and enhancing host viability (Yano et al., 2008).The pathway that transduces 
signals from the PGRP-LE receptor to the autophagy machinery, and whether it cross-
talks to the classical signaling pathways downstream of PGRP receptors that activate 
genes encoding antimicrobial peptides, remain to be investigated. 
Signalling of Toll-like receptors (TLRs) triggers autophagy during mammalian 
innate and adaptive immunity. TLRs are membrane receptors localized at the cell 
surface and endosomes, and TLR signalling activates transcription of genes responsible 
for T-cell stimulation, inflammation, and antiviral immune responses. Different TLRs 
are involved in autophagy induction upon binding their specific pathogen-derived 
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ligands. For example, viral ssRNA (single-stranded RNA) induces autophagy via TLR7, 
zymosan stimulates LC3 translocation to phagosomes by activating TLR2 and 
lipopolysaccharide (LPS), which is derived from cell walls of Gram negative bacteria, 
triggers autophagy through TLR4. TLRs recruit adaptor proteins to transduce signals to 
downstream effectors (Del Gado et al., 2008; Sanjuan et al., 2007). 
In human and murine macrophages, the TLR4 adaptor protein TRIF (Toll-interleukin-1 
receptor domain-containing adaptor-inducing interferon-β) is suggested to mediate LPS-
induced autophagy, and the same downstream signalling pathway is shared by both 
innate immunity and autophagy upregulation (Xu et al., 2007). 
Moreover, interferon (IFN)-γ and its effector Irgm1 (the IFN-inducible immunity-
related GTPase family M member 1; also known as LRG-47) are also required to 
stimulate autophagy in macrophages and inhibit the survival of intracellular 
mycobacteria (Singh et al., 2006). 
In response to viral infection, the antiviral eIF2α kinase signaling pathway, including 
eIF2α and the IFN-inducible double-stranded RNA-dependent protein kinase R (PKR), 
is activated and upregulates autophagy (Tallòczy et al., 2002). Some viral proteins may 
antagonize autophagy induction by directly modulating Atg proteins: the HSV-1 (herpes 
simplex virus type 1)-encoded neurovirulence protein ICP34.5 inhibits autophagy via 
interaction and sequestration of Beclin 1 (Orvedhal et al., 2007). It is also reported that 
viral infection, such as infection with hepatitis C virus, induces ER stress, and 
autophagy is triggered through the unfolded protein response, including the downstream 
IRE1, ATF6, and PERK signalling pathways (Sir et al., 2008). 
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Figure 10. Different mechanisms that regulate autophagy by pathogen invasion (he and 
Klionsky, 2009) 
 
6. Quality control and starvation-induced autophagy 
Autophagy can be distinguished into two forms: quality control (QC) autophagy and 
starvation-induced autophagy. 
QC autophagy is present in normal cell function to degrade proteins and organelles 
that become mutated, misfolded or oxidized and recycle the remaining component 
lipids, nucleic acids, amino acids and micronutrients back to the cytosol as nutrients. 
Damaged cytosolic components are selected for degradation by QC autophagy through 
ubiquitin tags. Then Histone deacetylase 6 (HDAC6) binds ubquinated proteins and 
organelles, selecting them for degradation (Lee et al., 2010). 
Starvation-induced autophagy does not require ubiquitination of substrates for 
degradation. Starvation-induced autophagy is regulated through mTOR inhibition to 
compensate for limited nutrients in the environment (Hosokawa et al., 2009). 
Macroautophagy is also regulated through mTOR by nutrient supply and environmental 
toxins that cause intracellular damage; mTOR is itself the target of multiple signalling 
pathways. To ensure that autophagy does not become overactive and cytotoxic, certain 
amino acids released from protein degradation act as negative feedback regulators 
(Tassa et al., 2003). Activation of the metabolic state sensor AMPK by AMP at low 
energy levels inhibits mTOR to upregulate autophagy (Fig. 11). When AMP levels rise 
from consumption of ATP, AMPK phosphorylated mTOR, a protein kinase that 
phosphorylates ULK1/2 and Atg13. mTOR has two subunits: mTORC1 and mTORC2, 
buy only mTORC1 directly inhibits autophagy along with protein synthesis and mitosis 
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(Raught et al., 2001). mTORC1 inhibits the ULK1/2-Atg13 complex through 
phosphorylation. When mTORC1 is inactive, dephosphorylation of ULK1/2 activates 
its kinase activity, phosphorylating Atg13, FIP200 and ULK1/2 itself (Jung et al., 
2010). Active ULK1/2-Atg13 complex is localized to the isolation membrane, aiding in 
vesicle nucleation (Hara et al., 2008). Rapamycin is a useful drug that directly inhibits 
mTORC1 to activate autophagy. Intracellular signals that inhibit mTOR activity include 
inadequate energy supply and protein. When the amount of available energy reaches a 
certain threshold, AMPK is activated. The kinase activity of AMPK phosphorylates 
TSC1/2, a point of convergence for multiple autophagy regulators (Inoki et al., 2005). 
One intracellular protein that regulates mTOR activity is the tumor suppressor p53; 
depending on where it resides in the cell, p53 can either stimulate or inhibit the process 
of autophagy (Tasdemir et al., 2008). 
Litium and amino acids regulate autophagy through mTOR independent pathways. 
Litium inhibits the activity of inositol monophosphate (IMPase), so the levels of myo-
1.4.5-triphosphate (IP3) decrease in the cell. Low IP3 levels induce autophagy 
independently of mTOR activity. The specific mechanism for IP3 regulation of 
autophagy is still unknown (Sarkar et al., 2005).  
Certain amino acids that are released when autophagy digests proteins (leucine, 
phenylalanine, alanine, methionine and glutamine) inhibit autophagy, since they are 
negative feedback regulators of autophagy through the PI3 K-III complex  (Fig. 11). 
Amino acid inhibition of the PI3 K-III complex stops vesicle nucleation, downstream of 
mTOR. Conversely, low levels of these amino acids induce autophagy through PI3 K-
III activation (Tassa et al., 2003). 
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Figure 11. Regulation of autophagy is regulated by both extracellular and intracellular signals. 
Low AMP/ATP, growth factor deprivation or nutrient restriction inhibit mTOR activity to 
promote autophagy, although amino acids and lithium act independently of mTOR. The 
inhibition of mTOR induces autophagy, protein synthesis and mitosis. Hexagon = cellular 
processes regulated by mTOR. (Barnett and Brewer, 2011) 
 
As an important catabolic pathway, autophagy maintains crosstalk with several other 
regulatory pathways including the ubiquitin proteasome system (UPS) and ER 
associated degradation. For example, impairment of the proteasome results in 
upregulation of autophagy, and autophagy cooperates with ER associated degradations 
to degrade certain disease proteins (Kroeger 2009). 
In mammals the importance of autophagy in maintaining homeostasis and 
modulating cytoplasmic contents also makes it very important in cell death and 
proliferation. As a pathway controlling cellular stress such as oxidative damage and 
protein misfolding, activation of autophagy can promote cell survival (Eskelinen 2005). 
Conversely, loss of these pro-survival activities by inhibition of autophagy can result in 
apoptosis. During cell proliferation autophagy can act as a sensor of stress, helping 
determine if the cell is at an appropriate stage to divide. 
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8. Autophagy and diseases 
A basal and constitutive level of autophagy is necessary for intracellular homeostasis 
and quality control for healthy individuals. Mounting evidence has demonstrated that 
disruption of its physiological function is strongly related to human diseases, including 
neurodegeneration, cancer, liver and heart diseases, ageing, myopathies, and infections 
(Mizushima et al., 2008).  
Neurodegenerative diseases such as AD, PD, amyotrophic lateral sclerosis, prion 
diseases, Huntington’s disease (HD) and spinocerebellar ataxias have the common 
characteristic of protein aggregation (Sarkar and Rubinsztein, 2008). For example, β-
amyloid and tau aggregates accumulate in AD. Expanded polyglutamine (PolyQ) stretch 
caused by the expansion of CAG trinucleotide repeat within several gene exons seen in 
HD and several types of spinocerebellar ataxias. α-synuclein fibrils linked to familial 
PD self-aggregate and deposit in the brain (Honson et al., 2007; Williams et al., 2006). 
These protein aggregates, the neurotoxic components, are substrates of the autophagy 
degradation system. Boland et al (2008) suggested that the basal expression of 
autophagy is crucial in primary cortical neurons and there is no large amount of 
autophagosome accumulation in healthy brains because of efficient lysosomal 
hydrolysis of newly formed autolysosomes. 
It is known that autophagy plays a role in the protection against neurodegeneration 
but  in patients with diverse neurodegenerative diseases the autophagic clearance system 
may reach saturation and thereby become unable to eliminate excess aggregate-prone 
mutant proteins, or dysregulation or defection may occur in the autophagy pathway. 
Impaired autophagic vacuoles (AVs) clearance during autophagosome transport to 
lysosomes or during substrate degradation within the lysosome may lead to AVs 
accumulation with morphologies that are observed in AD (Boland et al., 2008). 
Contrary to the beneficial effect of basal autophagy, an excess accumulation of 
autophagosomes promotes neuronal cell loss under certain circumstances, such as 
dysfunctional endosomal sorting complex required for transport III (ESCRT-III), which 
is associated with FTD (Lee and Gao 2009). This implies that either excessive 
autophagosome synthesis or reduced autophagosome-lysosome fusion may contribute to 
the pathogenesis of neurodegeneration by the dysfunctional autophagic process. Owing 
to the protective role of autophagy in neuron systems, it may be a therapeutic target 
against neurodegenerative diseases. Upregulation of autophagy may improve the 
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clearance of neurotoxic aggregate-prone proteins. The inhibition of TOR, a negative 
regulator of autophagy, by rapamycin or its analogue CCI-779 is protective in 
Drosophila and mouse models of HD (Ravikumar et al., 2004). mTOR is required for 
various cellular events, including protein synthesis (e.g. the initiation of mRNA 
translation, ribosome biogenesis, transcription), cell growth and proliferation, and 
cytoskeletal reorganization (Sarbassov et al., 2005), but its inhibition by rapamycin 
causes some adverse effects such as cell cycle arrest, poor wound healing, and mouth 
ulcers (Bissler et al., 2008). Small molecule enhancers of rapamycin (SMERs), 
however, induce autophagy in an mTOR independent mechanism. They enhance the 
elimination of mutant huntingtin and α-synuclein, and protect against neurodegeneration 
in the HD model of Drosophila (Sarkar et al., 2007). Recently, autophagy induction by 
a group of new drugs, L-type Ca2+ channel antagonists, K+ ATP channel opener 
minoxidil, and Gi signaling activator clonidine in an mTOR independent pathway were 
reported in HD mammalian cell, fly and zebrafish models (Williams et al., 2008). 
Nevertheless, it is important to understand the pathology underlined by autophagy in 
different neurodegenerative diseases. Pharmacologically enhancing autophagosome 
formation in AD where the autophagosome clearance system is defective may 
exacerbate the accumulation of the unmatured autophagosomes, some of which may 
generate toxic proteolytic product Aβ and/or others (Yu et al., 2005; Boland et al., 
2008). Therefore, improvement in the late stages of the autophagy process may be the 
best therapeutic modulation of autophagy in AD. In addition, the inhibition of 
autophagy by small molecules might be promising therapeutic strategies for the early 
stages of some forms of FTD or other neurodegenerative diseases where excess 
produces autophagosomes (Lee and Gao, 2009). 
The impairment of autophagy clearance for intracellular proteins and organelles is 
associated with the pathogenesis of several diseases, such as neurodegeneration, PD and 
ageing. Therefore, targeting autophagy may be a potential strategy for the treatment of 
these diseases (Bao et al., 2010; Rubinsztein et al., 2012). 
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8.1. Autophagy and Alzheimer’s disease 
Cytoplasmic, nuclear and extracellular inclusions composed of aggregated and 
ubiquitinated proteins are key pathological hallmarks of numerous neurodegenerative 
diseases. It is believed that protein aggregation contributes to organelle damage, 
synaptic dysfunction and neuronal degeneration, so clearance pathways for intracellular 
protein aggregates have been suggested as a potential therapeutic approach for such 
disorders. It is now apparent that aggregate-prone proteins and damaged organelles 
observed in a variety of neurodegenerative disorders are eliminated more efficiently via 
the autophagy–lysosome pathways than via the ubiquitin–proteasome machinery. 
Efficient autophagosome trafficking along microtubules is essential for autophagic 
degradation in neurons given the distance between neuronal processes, where 
endosomes and autophagosomes are formed, and the neuronal soma, where lysosomes 
are concentrated. 
In AD there is massive accumulation of autophagosomes within large swellings 
along dystrophic and degenerating neurites, primarily due to deficits in the maturation 
of autophagosomes and their retrograde transport towards the neuronal cell body 
(Nixon, 2007). 
The general consensus is that autophagy is activated in AD primarily because of 
impaired clearance of autophagosomes that contain both APP and its processing 
enzymes, thereby increasing the propensity to generate toxic Aβ peptides (Yu et al., 
2005). Although most Aβ formed during autophagy is normally degraded within 
lysosomes via macroautophagy, Aβ also accumulates within the large pool of 
autophagosomes in dystrophic neurites and becomes a major intracellular reservoir of 
toxic peptides in AD brains. It is well established that Aβ can disrupt autophagosome 
membranes and trigger the release of hydrolytic enzymes into the cytoplasm. It has been 
suggested that local accumulation of autophagosomes in dystrophic neurons can 
contribute to Aβ generation within plaques and that increased autophagy in the neuropil 
could be a major source of Aβ (Nixon et al., 2005). This is achieved via increased 
turnover of APP and enrichment of the γ-secretase complex inside autophagosomes that 
cleaves APP to Aβ. In fact, autophagosome membranes are rich in presenilin 1, a 
component of the APP-cleaving γ-secretase complex, which is encoded by the 
presenilin gene, mutations of which lead to early-onset forms of autosomal dominant 
AD. Human AD brains with mutant presenilin 1 show accumulation of extensive 
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lysosomal pathology, together with amyloid pathology and neurodegeneration (Cataldo 
et al., 2004). 
It was recently demonstrated that neurons and blastocysts from presenilin1 
hypomorphic mice and fibroblasts from presenilin 1 mutant AD patients show loss of 
macroautophagy, resulting in increased Aβ accumulation due to impaired maturation of 
the V0a1 subunit of the bimodular v-type H+-ATPase proton pump that acidifies the 
lysosome (Lee et al., 2010). 
Furthermore, levels of beclin 1 (or Atg6), which is required for autophagosome 
formation, are consistently reduced in postmortem AD brains (Pickford et al., 2008). In 
a transgenic mouse model of AD that expresses human APP, genetic reduction of beclin 
1 expression stimulated Aβ accumulation and neurodegeneration due to a decrease in 
autophagy. Conversely, increased expression of beclin 1 in APP transgenic mice 
significantly reduced amyloid pathology and neurodegeneration. If reduced induction of 
autophagy is the underlying mechanism for the higher levels of Aβ peptides and 
aggregate observed, then these results are consistent with findings that autophagosome 
maturation can be impaired in AD (Pickford et al., 2008). 
However, Aβ levels are affected by both production and clearance (Selkoe 2001). 
Therefore, defects in autophagosome maturation could enhance Aβ production, whereas 
reduced autophagy through beclin 1 deficiency might inhibit Aβ clearance by altering 
APP metabolism (Jaeger et al., 2010). Studies indicate ultrastructural alterations in 
mitochondrial morphology, such as reduced size, broken cristae and abnormalities in 
mitochondrial dynamics, in AD (Santos et al., 2010). 
In patients with sporadic AD, fibroblasts and cells overexpressing the Swedish 
variant of APP demonstrate an imbalance in mitochondrial fission–fusion proteins, 
either via post-translational modification such as S-nitrosylation or by alterations in 
their expression leading to an increase in mitochondrial fission (Wang et al., 2008, Cho 
et al., 2009). It has been suggested that increased mitochondrial fission is probably an 
attempt to segregate and eliminate damaged mitochondria via a macroautophagy 
process known as mitophagy, which is consistent with reductions in the level and size of 
mitochondria observed in human post-mortem tissue (Hirai et al., 2001). 
It has been suggested that alterations in mTOR pathway, which plays a central role in 
signaling induced by nutrients and growth factors, support autophagic failure in AD. 
Accumulation of Aβ peptides increases signaling of the mTOR pathway, whereas a 
I n t r o d u c t i o n  | 63 
Autophagy 
decrease in mTOR signaling reduces Aβ levels: in a mouse model of AD, 
pharmacological inhibition of mTOR signaling by rapamycin (an FDA-approved drug) 
rescues cognitive deficits and ameliorates amyloid and tau pathology by increasing 
autophagy (Spilman et al., 2010). Rapamycin-induced inhibition of mTOR led to 
increased neuronal autophagy in mutant AD mice, suggesting that reductions in Aβ 
levels and improvements in cognitive function are due in part to increased autophagy 
via mTOR inhibition. 
Considering that age is an important risk factor for the development of AD and many 
other neurodegenerative disorders, rapamycin administration in animals extended 
lifespan in multiple recent studies (Anisimov et al., 2010). This effect of rapamycin on 
lifespan due to increased autophagy reinforces the benefits of promoting autophagy in 
age-related neurodegenerative disorders 
Thus, autophagy induction might serve as a potential therapeutic target for blocking 
of AD pathogenesis. 
 
9. Autophagy and development 
During embryonic development, cells undergo several and various processes like 
proliferation, differentiation and death. Autophagy plays a role in the development of all 
organisms, from unvertebrates like Drosophila (Tracy and Baehrecke, 2013) to 
vertebrates as zebrafish and mice (Di Bartolomeo, 2010). 
During critical mammalian developmental stages in which nutrients are restricted, 
autophagy is important; one such stage is pre-implantation development of embryos 
(Tsukamoto et al., 2008a). Autophagic activity is low in unfertilized oocytes and 
increases shortly after fertilization (Fig.12); it is transiently suppressed between the late 
one-cell and middle two-cell stages and is then activated again after the late two-cell 
stage. 
Atg5-deficient oocytes fertilized by Atg5-null sperm failed to develop beyond the 
four- and eight-cell stages, but could develop if fertilized by wild-type sperm. It is not 
known whether the main role of autophagy in pre-implantation development is to 
provide nutrients to the growing embryo or to clear maternal proteins (Tsukamoto et al., 
2008a, 2008b). Other possible consequences of autophagy deficiency are also possible, 
including secondary effects on the ubiquitin-proteasome system, which may have an 
impact on the coordination of the levels of critical proteins required for regulating cell 
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division. It is possible that some of these secondary consequences of autophagy 
compromise may contribute to the necessity for autophagy during development (Wu et 
al., 2013). Sudden termination of the fetal nutrient supply from the mother presents a 
stressful situation for the newborn infant before it establishes breastfeeding. During this 
transition period, autophagy provides necessary nutrients to the infant through increased 
turnover of proteins. This has been shown experimentally in a transgenic mouse model 
expressing GFP-tagged LC3 to visualize autophagosomes in vivo (Ravikumar et al., 
2004). In these mice, autophagy in various tissues increases soon after birth, peaks at 
~6 h after birth, and declines back to basal levels within 24-48 h (Ravikumar et al., 
2004). To assess the specific role of autophagy, the effect of starvation during this 
critical period in Atg5- and Atg7-knockout mice was studied. Whereas mice generated 
from animals with conditional deletion of Atg5 in oocytes and Atg5-null sperm cannot 
develop beyond the four- and eight-cell stages, conventional Atg5−/− mice generated by 
mating Atg5+/− mice survive until after birth, since the maternally derived Atg5 proteins 
stored in oocytes is sufficient to rescue the autophagy-deficient phenotype of early 
embryogenesis (Tsukamoto et al., 2008).  
Atg5- and Atg7-knockout mice die within 1 day of birth (Ravikumar et al., 2004; 
Komatsu et al., 2005). Under forced starvation conditions, the survival time of the Atg5-
knockout mice was nearly half (12–13 h) that of their Atg5+/− or wild-type littermates 
(21–24 h) (Ravikumar et al., 2004). These experiments support the role of autophagy in 
normal developmental processes that occur in the context of diminished nutrient supply, 
lending importance to the need for the functional turnover of amino acids. However, it 
is possible that other mechanisms may also be relevant. 
Autophagy is also important for neuronal development: inactivation of Ulk1 (Atg1) 
in immature granule cells impairs axon outgrowth and differentiation of neurons; Ulk1 
activity at the growth cone is thus crucial for the formation of fibres, and allows the 
progression of cerebellar development (Di Bartolomeo et al., 2010; Wu et al., 2013).  
It is necessary to consider also that embryogenesis and neuronal development is 
controlled by central signalling pathways, such as Shh (Sonic Hedgehog), TGFβ 
(transforming growth factor β) and Wnt. In embryogenesis, these pathways are essential 
for patterning, formation of the body axis, limb development and formation of the 
neural tube (Copp et al., 2003; Tabata 2001; Harvey 2002;  Raya and Izpisua 
Belmonte,2006). Furthermore, each pathway regulates individual cell fate in embryonic 
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and adult tissue. It has been reported that autophagy interacts with these developmental 
pathways. The interaction is a likely cause for the defects in development observed in 
the knockout mice, since the pathways are important for formation of embryonic 
structures (Wu et al., 2013). 
The Shh signalling pathway plays an important role in patterning of the central 
nervous system, neural tube development and limb development. Previously, we 
reported that the Hedgehog signalling pathway inhibits autophagosome synthesis, both 
in basal and in autophagy-induced conditions (Jimenez-Sanchez et al., 2012; Han et al., 
2008). On the other hand, Shh induces autophagy in hippocampal neurons (Petralia et 
al., 2013). This might be due to dual functions of Shh serving as mitogen in NSCs, but 
as an autophagy enhancer in differentiated neurons (Lai et al., 2003; Breunig et al., 
2008).  
TGFβ signalling is one of the most important players that drives developmental 
programmes that control cell behavior, and plays crucial roles in pluripotency and 
differentiation of embryonic stem cells in vitro (Massague, 2012). Recent evidence 
demonstrates that TGFβ activates autophagy through up-regulation of several 
autophagy-related genes, such as Beclin-1, Atg5, Atg7 and DAPK (death-associated 
protein kinase) (Suzuki et al., 2010). 
The Wnt signalling pathway is crucial for embryogenesis, planar cell polarity and 
maintenance of stem cell fate (MacDonald et al., 2009). Autophagy was found to 
negatively regulate Wnt signaling (Gao et al., 2010). On the other hand, GSK3β (an 
inhibitor of Wnt signalling) was reported to stimulate autophagy through an mTOR-
dependent mechanism (Zhai and Sadoshima, 2012).There may be a feedback 
mechanism through the master sensor GSK3β, which regulates Wnt signalling by 
multiple mechanisms. 
Since embryogenesis is mainly governed by developmental pathways, such as Shh, 
TGFβ, Wnt and FGF, and there is an intensive cross-talk of autophagic proteins with 
these pathways (with implications in differentiation and proliferation of a variety of cell 
types), autophagy might regulate embryogenesis through these routes. However, it is 
likely that there are further mechanisms and regulatory loops to be discovered (Wu et 
al., 2013). 
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Figure 12. Autophagy is activated in fertilized mouse embryos. Small bright dots represent 
LC3-positive autophagosomes and are shown in oocytes only after fertilization. Autophagy may 
be important to generate amino acids through degradation of maternal proteins, which is 
important for the synthesis of embryonic proteins. 
 
Also in zebrafish autophagy plays an important role, but unlike mammals, the fish 
are not dependent on the implantation in uterus, but develop from a fertilized egg to an 
adult outside the female in a transparent egg and the yolk provides nutrients to the 
embryo during all the early stages of development. In zebrafish Atg12 is ubiquitously 
expressed and the formation of the Atg12-Atg5 complex is dependent on Atg5; Atg5 is 
required in zebrafish for normal morphogenesis of brain regionalization and body plan. 
Atg5 also regulates expression of neural gene markers and is involved in regulation of 
LC3-II (Hu et al., 2011): that makes it an interesting target to study autophagy in 
development. 
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MEDITERRANEAN DIET 
 
The Mediterranean diet is a modern nutritional recommendation inspired by the 
traditional dietary patterns of countries of the Mediterranean area: Greece, Italy, Spain 
and Morocco.  
On November 17th 2010, UNESCO recognized this diet pattern as an Intangible 
Cultural Heritage of Italy, Greece, Spain and Morocco. 
The most commonly understood version of the MD was presented, among others, by 
Dr. Willet of Harvard University’s School of Public Health from the mid-1990s (Kushi 
et al., 1995) based on the food patterns typical of Greece and Southern Italy in the early 
1960s. This diet, in addition to a regular physical activity emphasizes abundant plant 
foods (vegetables, legumes, fruits and cereals), fresh fruits as daily dessert, olive oil as 
the principal source of fat, dairy products (principally cheese and yogurth), fish and 
poultry consumed in moderate amount, from zero to four eggs consumed weekly, low 
intake of red meat and wine (Trichopoulou et al., 2003). 
 
1. History 
In the 1975 the american scientist Ancel Keys of the University of Minnesota School 
of Power pointed out the correlation between cardiovascular disease and MD for the 
first time (Keys and Keys, 1975). In the fifties he discovered its healthy benefits by 
observing a phenomenon which could not, at first, provide a full explanation. The poor 
population of small towns of southern Italy was, against all predictions, much healthier 
than the wealthy citizen of New York, either of their own relatives who emigrated in 
earlier decades in the United States. Keys suggested that this dependon food, and 
focused his attention on foods that made up the diet of these populations. Thus, he led 
the famous “Seven Countries Study”, conducted in Finland, Holland, Italy, Greece, 
Jugoslavia, United States and Japan, in order to find out the relationship between 
lifestyles, nutrition and cardiovascular disease between different population, including 
through cross-sectional studies, being able to prove scientifically the nutrition value of 
the Mediterranean diet and its contribution to the health of the population that adopted it 
(Keys 1980). From this study emerged clearly that the populations that had adopted a 
diet based on the MD presented a very low rate of cholesterol in the blood and, 
consequently, a minimum percentage of coronary heart disease. This was mainly due to 
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the plentiful use of olive oil, bread, pasta, vegetables, herbs, garlic, red onions and other 
foods of vegetable origin compared to a rather moderate use of meat (Menotti et al., 
1996). 
Starting from Key’s studies, many other scientific researchers have analyzed the 
association between dietary habits and chronic diseases. There is a convergence of 
assessments agreed in the direction of full recognition of the beneficial qualities of the 
Mediterranean way of eating (World Cancer Research Fund, 1997;  Altomare et al., 
2013). Many studies and clinical trials have shown that the Mediterranean diet reduces 
the risk of cardiovascular disease and metabolic syndrome. In particular has been put 
into evidence a remarkable decrease of abdominal circumference, an increase in high 
density lipoprotein (HDL), a decrease in triglycerides, a lowering of blood pressure and 
a decrease in the concentration of glucose in the blood (Estruch et al., 2006; Fitò et al., 
2007).  
The MD may contribute to produce the benefits listed above, but other risk factors 
should be considered. In fact, ischemic heart disease depends not only on errors in the 
composition of the diet, to which attaches a dominant role, but also by other factors, 
such as a reduced or absent physical activity, caloric intake in excess of the energy 
needs of the organism, the presence of metabolic diseases such as diabetes and obesity, 
stress, cigarette smoking, high levels of homocysteine in the blood, high levels of 
triglycerides. Therefore, it is not surprising that about half of all cases of stroke occur in 
individuals with a normal level of cholesterol in the blood. To prevent a heart attack is 
therefore imperative to take not only a balanced diet, as is indeed the Mediterranean 
diet, but also a healthy lifestyle, as Ancel Keys had already pointed out (Altomare et al., 
2013). 
 
2. Mediterranean diet pyramid 
The Mediterranean Diet is characterized by the balanced use of foods rich in fiber, 
antioxidants and unsaturated fats, a healthy approach designed to reduce the 
consumption of animal fats and cholesterol in a diet with an appropriate balance 
between energy intake and expenditure. The relationships between the macronutrient 
energy answer to those recognized as adequate, ie 55–60% of carbohydrates of which 
80% complex carbohydrates (bread, pasta, rice), 10–15% of proteins about 60% of 
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animal origin (especially white meat, fish), 25–30% fat (mostly olive oil) (Arienti and 
Fidanza, 1998) . 
The guidelines developed by nutritionists to improve the eating habits of consumers 
can be represented by an effective image, the “Food Pyramid” designed for the first 
time in 1992 by the U.S. Department of Agriculture, which simply represents a fair and 
balanced way of eating, displaying the proportions and the frequencies with which 
foods should be consumed, style that coincides with the Mediterranean Model identified 
by the physiologist Ancel Keys. 
The pyramid is meant to provide an overall impression of healthy food choices rather 
than to define recommended weights of certain foods or proportions of energy obtained 
from them. Where the pyramid indicates relative frequencies, they are intentionally 
nonspecific because good health has been associated with considerable variation within 
the overall pattern. The Food pyramid is designed as a dietary guide for the general 
adult population and may need to be modified to meet the needs of children, pregnant 
women and other special population groups. 
The main concepts of the Food Pyramid are the “proportionality”, that is the right 
amount of foods to choose from for each group, the “portion” standard quantity of food 
in grams, which is assumed as the unit of measurement to be a balanced feeding, the 
“variety”, i.e., the importance of changing the choices within a food group, and 
“moderation” in the consumption of certain foods, such as fat or sweets.  
At the base of the pyramid are grains, followed by fruits and vegetables, legumes, olive 
oil, low-fat cheese and yogurt, which should be eaten daily. Meat is not excluded, but is 
given the preference to that of chicken, rabbit and turkey than beef. Along with fish and 
eggs should be eaten a few times a week, for the supply of high quality protein. Beef or 
red meat should be eaten a few times a month (Fig. 13). 
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Figure 13. Food pyramid in the Mediterranean diet (Altomare et al., 2013) 
Each group includes foods that provide nearly the same type of nutrients. Within the 
same group, foods can have small differences in terms of quality and quantity of 
patrimony in nutrients. However, this does not affect the concept of “interchangeability” 
of foods. The latter in fact, if they belong to the same group, being nutritionally 
equivalent, may be substitutes for each other, without, however, affecting the adequacy 
of the diet, provided you comply with the variety. It is necessary to vary as much as 
possible food choices and properly combine foods from the different groups to balance 
the diet. A very varied diet avoids the risk of nutritional imbalances and possible 
consequent metabolic imbalances, and it also satisfies the taste of fighting the monotony 
of flavors (Altomare et al., 2013) 
Each group expected is represented by at least a portion of the foods that constitute 
it, to vary the choices within the same group (Mariani Costantini et al., 2006). 
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2.1. Plant foods 
Plant foods constituted the core of the daily intake, whereas foods from animals were 
more peripheral. Examples of traditional Mediterranean dietary patterns with foods 
from plants at the center of the plate include the use of couscous, vegetables and 
legumes in North Africa; pasta, polenta, rice or potatoes along with vegetables and 
legumes in southern Europe; bulgur and rice, along with vegetables, chickpeas and 
other beans in eastern Mediterranean regions. Foods from plants also accompanied 
meals. Bread for example was a fundamental component of all meals. Fresh vegetables, 
salads, fruit, nuts, seeds and olives were consumed frequently and garlic, onions and 
herbs were used as condiments.  
Cereals and tubers. This group includes bread, pasta, rice, corn, oats, barley and 
potatoes. These foods are the most important source of starch, easily usable energy from 
our body; cereals should be consumed in proportion to their needs. Some of these foods 
contain vitamins of the B group and a fair amount of protein that, associated with 
legumes, constitute a meal with high protein intake and high biological value. This 
combination occurs frequently in the Mediterranean diet since the cereals and their 
derivatives are the basic ingredients for the preparation of many dishes. 
Fruits and vegetables are a source of fiber, vitamin A (found mainly in tomatoes, 
peppers, carrots, cantaloupe, apricots, etc), vitamin C (primarily in tomatoes, 
strawberries, citrus fruits, kiwi, etc), other vitamins and many minerals like potassium. 
In addition, plant foods contain minor components (antioxidant and others) which play 
an important protective action for the body and water that can reach even 95% of the 
weight (watermelon). Moreover, they contain relevant quantities of dietary fiber 
(cellulose, hemicellulose and pectin) that has a role in facilitating the intestinal transit 
and in moderating the levels of blood cholesterol and glucose. More consistent is, 
instead, the contribution in sugar (sucrose and fructose) made from fruit. The role of 
fruits and vegetables in the diet is also linked to its physiological regulator of water 
balance for their considerable supply of water. Finally, these foods has a role in the 
prevention of obesity, due to their high content of fiber and water and low in calories 
that provide compared to the volume ingested and the high satiating power (INRAN 
2003; Altomare et al., 2013). 
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This diet, when consumed in sufficient amounts, provided all of the known essential 
vitamins, minerals, fiber and other plant food substances believed to promote health 
(Allbaugh, 1953). Minimal processing, seasonal use and freshness of foods would be 
expected to maximize contents of dietary fiber, antioxidants, vitamins and minerals 
found in foods from plants (Willet et al., 1995). 
 
2.2. Olive oil as the principal fat 
Olive oil was the Mediterranean regions’ principal source of fat and was used instead 
of animal fats typical of northern European diets. Olive oil contains a large proportion 
of monounsaturated fat, is relatively low in saturated fat and is a source of antioxidants. 
All these features make oil preferable to animal fats. Olive oil contains a very high level 
of monounsaturated fats, most notably oleic acid, which is considered to be 
antithrombotic compared with saturated fatty acids (Ulbricht and Southgate, 1991); in 
fact epidemiological studies suggest it may be linked to a reduction in coronary heart 
disease risk (Keys et al., 1986). 
Diets high in polyunsaturated fat are thought to be involved in the oxidation of low-
density lipoproteins (LDLs), a process that increases the risk of atherogenesis and 
coronary heart disease (Reaven et al., 1991); on the other hand, substitution of olive oil 
for carbohydrates in certain short-term clinical studies has been shown to increase 
concentrations of high-density lipoproteins (HDLs) without increasing LDLs and should 
be expected, therefore, to reduce coronary risk (Mattson and Grundy, 1985; Mensink 
and Katan, 1987). 
There is also evidence that the antioxidants in olive oil improve cholesterol 
regulation and LDL cholesterol reduction, and that it has anti-inflammatory and anti-
hypertensive effects (Covas 2007). 
Olive oil facilitates the typical consumption of large amounts of vegetables and 
legumes throughout much of the Mediterranean region by enhancing taste and energy 
density. The proportion of energy from total fat in Mediterranean diet ranged from 28% 
in southern Italy to 40% in Greece (Keys, 1980). Proportions of energy from fat across 
this range appear to have been compatible with excellent adult health with diets in 
which most of the fat was derived from olive oil (Willet et al., 1995). 
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2.3. Dairy products 
Mediterranean diet typically included small amounts of dairy products from a variety 
of animals: goat, sheep, buffalo, cow and camel (Kromhout et al., 1989). Dairy products 
were consumed in low to moderate amounts. Since refrigeration was lacking and the 
climate was often hot, milk in the Mediterranean region was frequently preserved and 
consumed as yogurt and cheese. These foods represented a greater proportion of dairy 
food intake than is typical of modern diets in the U.S or in northern Europe (Willet et 
al., 1995). 
This food group provides calcium in a highly bioavailable form, that is easily 
assimilated by the body. Moreover, these foods contain high biological quality proteins, 
vitamins B2 and A. Within the group are preferred low-fat milk and low-fat cheese. The 
calcium in milk (either be partially or completely skimmed) and its derivates is the most 
significant nutrient and it is easily adsorbed and used in the body. The milk contains 
more than 1 gram of calcium per litre, while cheese, according to the technology of 
preparation, contains several more percent, so that in the hard cheeses and seasoned 
ones the quantity of calcium can be 10 times higher than that present in milk to equal 
weight. 
In addition to calcium, dairy products provide significant amounts of proteins of high 
biological value, among these casein is the most represented (the part that coagulates 
when the milk sours and which forms the basis for the preparation of cheese) and 
lactalbumin which together constitute 3.5%. 
The consumption of milk is therefore the most immediate way to intake these 
nutrients, but an equally valid alternative is represented by yogurt and cheeses, for 
people that have lactose intolerance, due to the lack or absence of the lactase, an 
intestinal enzyme responsible for the breakdown of lactose in the two compounds: 
galactose and glucose (INRAN 2003; Altomare et al., 2013). 
 
2.4. Meat, fish and eggs 
Traditional Mediterranean diet included foods from animals in limited amounts 
(Kromhout et al., 1989). Evidence increasingly support associations between western 
diets that include high intakes of meats such as beef, pork and lamb, and the incidence 
of chronic diseases such as coronary heart disease and cancer of the colon and other 
sites. Whether the fat in meat is the sole contributor to these relations is uncertain. Other 
74 | I n t r o d u c t i o n  
Mediterranean Diet  
factors may also be involved: research has suggested the possible involvement of the 
carcinogens formed during frying and cooking of meat, and the protein, cholesterol or 
iron content of the meat (Willet et al., 1995). 
The consumption of low amounts of red meat by traditional Mediterranean 
populations posed no evident risk to adult health and was consistent with better health 
profiles than those observed in industrialized countries where much higher amounts are 
consumed (Willet et al., 1994). 
Food in this group must be present in our diet a few times a week, with the exception 
of red meat, which should be eaten a few times a month. 
The meat has high protein content (from 15% to 25%) of high biological value, able 
to provide all the amino acids necessary for protein synthesis (essential amino acids) in 
optimal amounts. It also provides B-complex vitamins, iron, zinc and copper. However, 
not all foods in this group are the same: it is better to prefer lean bovine, lean pork, 
white meat and fish, and to moderate the consumption of fatter meat and sausages.   
The amount of fish consumed varied widely within the Mediterranean countries, but 
together with the data from japan and clinical evidence, has been observed that weekly 
consumption of low to moderate amounts of fish would be compatible with the 
excellent health (NDHSRG 1968; TJDA 1992). 
The consumption of zero to four whole eggs per week was typical of the 
Mediterranean diets of the early 1960s (Kromhout et al., 1989), this figure includes eggs 
used in baking and preparing foods (Willet et al., 1995). 
Any food of animal origin belonging to this group, whether fresh, chilled and frozen, 
provides protein of high biological value, trace elements and vitamins of the B complex, 
including in particular thiamine (vitamin B1), niacin (vitamin PP) and vitamin B12; 
some foods also provide other minerals, such as iodine in fish and vitamin A and D, 
contained primarily in the liver. 
The amount of protein contained in the food group is equal to 18-20% of the total 
weight, with higher values for preserved meats like salami, where it may reach up to 
37% due to the loss of water consequent to drying (Altomare et al., 2013). 
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3. Beneficial roles in preventing pathologies 
The Mediterranean diet has been widely reported to be a model of healthy eating for 
its contribution to a favourable health status and a better quality of life (USDA 2005). 
Since the first data from the seven countries study (Keys, 1980), several studies in 
different populations have established a beneficial role for the main components of the 
Mediterranean diet on the occurrence of cardiovascular diseases and chronic 
degenerative diseases (Serra-Majern et al., 2006). 
The meta-analysis by Sofi and colleagues showed, in an overall analysis comprising 
more than 2 million healthy subjects and 50,000 deaths or incident cases from any 
causes and/or from any cardiovascular, neoplastic, and neurodegenerative diseases, that 
the greater adherence to a Mediterranean diet is significantly associated with a reduced 
risk of overall mortality, cardiovascular mortality, cancer incidence and mortality, and 
incidence of PD and AD (Sofi et al., 2010). 
Adherence to the Mediterranean diet significantly determined a 8% reduction of 
death from any causes, a 10% reduction from death and/or incidence of cardio- and 
cerebrovascular diseases, a 6% reduction from death and/or the incidence of neoplastic 
diseases, and a 13% reduction of the incidence of neurodegenerative diseases.  
A diet rich in fruits, vegetables, legumes, and cereals, with olive oil as the only 
source of fat, moderate consumption of red wine especially during meals, and low 
consumption of red meat has been shown to be beneficial for all cause and 
cardiovascular mortality, lipid metabolism, blood pressure, and several different disease 
states such as endothelial dysfunction and overweight (Willet, 2006). 
Only recently, higher adherence to a Mediterranean-type diet was associated with 
decreased cognitive decline, although the MD combines several foods, micro- and 
macro-nutrients already separately proposed as potential protective factors against 
dementia and pre-dementia syndromes. In fact, recent prospective studies 
provided evidence that higher adherence to a Mediterranean-typ diet could be associated 
with slower cognitive decline, reduced risk of progression from MCI to AD, reduced 
risk of AD and a decreased all-cause mortality in AD patients (Scarmeas et al., 2006). 
These findings suggested that adherence to the MD may affect not only the risk of AD, 
but also of pre-dementia syndromes and their progression to overt dementia. 
Studies in rodents suggest that supplementation of the diet with polyphenols found in 
red wine and extra virgin olive oil are associated with better cognitive performances 
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(Pitozzi et al., 2010; Valls-Pedret et al., 2012). In fact polyphenols are highly bioactive 
molecules with beneficial effects that go beyond the modulation of oxidative stress to 
improve brain function, at least in experimental models of aging (Joseph et al., 2005). 
Furthermore, animals fed antioxidant and polyphenol-rich foods showed improved 
cellular signaling and neuronal communication that translated into better cognitive and 
motor performance (Joseph et al., 2009). 
However, following dietary advice for lowering the risk of cardiovascular and 
metabolic disorders, high levels of consumption of fats from fish, vegetable oils, 
vegetables, low glycemic index fruits and a diet low in foods with added sugars and 
with moderate wine intake should be encouraged. Hopefully this will open new 
opportunities for the prevention and management of dementia and AD (Solfrizzi et al., 
2011). 
 
4. Oleuropein Aglycone 
Cumulative evidence suggests that extra virgin olive oil (EVOO) may have a role in 
the protection against cognitive decline, in addition to protection other than against 
coronary disease and several types of cancer, because of its high levels of 
monounsaturated fatty acids and polyphenolic compounds (Solfrizzi et al., 1999). 
EVOO is a staple of the Mediterranean diet and is rich in antioxidants. Antioxidants 
are considered to be the primary reason for these benefits.  EVOO is a natural product 
particularly rich in monounsaturated fatty acids, mainly oleic acid, a constituent of the 
biological membranes that may progressively substitute polyunsaturated fatty acids. 
Cellular membranes rich in monounsaturated fatty acids have optimal fluidity and are 
less prone to lipid peroxidation, a process that requires two or more double links to take 
place (Scislowski et al., 2005). The antioxidants in EVOO include carotenes, alpha-
tocopherol, and hydrophilic and lipophilic phenolic substances. It is worth noting that 
while tocopherols and carotenes can be bound in other plant and animal fats, the simple 
polyphenols, such as phenyl acids and phenyl alcohols, like several oleuropein 
derivatives, are compounds found exclusively in olives and the oils extracted 
mechanically from them (Servili et al., 2004; Farr et al., 2012). Olive oil is rich in more 
than 30 phenolic compounds such as oleuropein, tyrosol, and hydroxytyrosol. 
Oleuropein, a secoiridoid glucoside characteristic of Oleaceae, is the main phenolic 
compound in leaves and fruit oil, and it is always present in extra virgin olive oil (Soler-
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Rivas et al., 2000) and can reach concentrations of up to 140 mg/g on a dry matter basis 
in young olives and 60-90 mg/g of dry matter in the leaves (Amiot et al., 1986; Le Tutor 
and Guedon, 1992). 
The amount of this polyphenol in olive fruit and oil varies depending on the 
maturation time of the olive fruit or on the oil tree subtype (Perri et al., 1999). In 
Mediterranean countries, it is estimated that the intake of olive oil varies between 30 
and 50 g/person/day; if we use the average of this amount of oil, one person consumes 
1.16 mg of oleuropein per day (Vissers et al., 2004). 
 
4.1. Chemistry 
Oleuropein belongs to the secoiridoids, compounds that are usually glycosilically 
bound and are produced from the secondary metabolism of terpenes as precursors of 
various indole alkaloids. The secoiridoids in Oleaceae are usually derived from the 
oleoside type of glucosides (oleosides), which are characterized by an exocyclic 8,9-
olefinic functionality, a combination of elenolic acid and a glucosidic residue. 
Oleuropein is an ester of 2-(3,4-dihydroxyphenyl)ethanol (hydroxytyrosol) and has the 
oleosidic skeleton that is common to the secoiridoid glucosides of Oleaceae (Soler-
Rivas et al., 2000), mainly in its aglycone form, which makes the sugar moiety 
insoluble in oil (Fig. 14). 
Oleuropein hydrolysis, carried out by an endogenous β-glycosidase during olive 
ripening and in the technological process of olive oil production, releases the aglycon 
moiety of the molecule in the olive oil (Soler-Rivas et al., 2000). Oleuropein aglycone 
(OLE) originates from deglycosylation of the polyphenol oleuropein during olive 
crushing (Brenes et al., 1999); the increased hydrophobicity of the aglycon allows it to 
cross the water/oil barrier and to be recovered in the oil, where it is far more abundant 
than its glycoside precursor (Cicerale et al., 2009). 
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Figure 14. Structures of oleuropein and oleuropein aglycone 
4.2. Biosynthesis 
The biosynthesis of oleuropein in Oleaceae proceeds via a branching in the 
mevalonic acid pathway from the secondary metabolism, resulting in the formation of 
oleosides (Damtoft et al., 1992). From these compounds, secoiridoids are derived 
(Damtroft et al., 1993). The sequences of the intermediate steps that lead to oleuropein 
biosynthesis may differ between plant species and times of the year (Damtoft et al., 
1995). A plausible biosynthetic route from deoxyloganic acid, 7-epiloganic acid, 7-
ketologanic acid, 8-epikingisidic acid, oleoside 11-methyl ester, 7-β-1-D-
glucopyranosyl 11-methyl oleoside and ligustroside to oleuropein was proposed by 
Damtoft et al. (1993) for Oleaceae (Fig. 15). 
In the development of the olive fruit, three phases are usually distinguished: a growth 
phase, during which accumulation of oleuropein occurs; a green maturation phase that 
coincides with a reduction in the levels of chlorophyll and oleuropein; and a black 
maturation phase that is characterized by the appearance of anthocyanins and during 
which the oleuropein levels continue to fall (Amiot et al., 1989). Therefore, oleuropein 
is very abundant in the early stages: in young fruits, it can reach 14% of dry matter. 
 
4.3. Bioavailability 
Phenolic compounds from virgin olive oil have been demonstrated to be highly 
bioavailable. Vissers et al. (2002) found that absorption of administered hydroxytyrosol, 
tyrosol and oleuropein aglycone was 55-60% in human subjects . 
Oleuropein is rapidly adsorbed after oral administration with a maximum plasma 
concentration occurring 2h after administration, and hydroxytyrosol is its most 
important metabolite. Both compounds are rapidly distributed and excreted in urine 
mainly as glusoronides or in very low concentrations as free forms (Tan et al., 2003; 
Boccio et al., 2003). Furthermore, the mechanism of absorption of olive oil compounds 
remains unclear. 
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Figure 15. Proposed biosynthesis pathway for oleuropein in Oleaceae (Damtoft et al., 1993) 
 
4.4. Pharmacology 
Oleuropein has been shown to possess several pharmacological properties, including 
antioxidant (Visioli et al., 2002), anti-inflammatory (Visioli et al., 1998), anti-
atherogenic (Carluccio et al., 2003) and anti-cancer (Owen et al., 2000) activities, and 
for these reasons, it is commercially available as food integrator in many countries. In 
addition, oleuropein has been shown to enhance ostoblastogenesis, to inhibit 
adipogenesis (Santiago-Mora et al., 2011), to be cardioprotective against acute 
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adriamycin cardiotoxicity (Andreadou et al., 2007) and to exhibit anti-ischemic and 
hypolipidemic activities (Andreadou et al., 2006). 
Further pharmacological activity of oleuropein includes diverse healing properties 
due to its vasodilatatory (Petkov and MAnolov 1978), anti-platelet aggregation (Petroni 
et al., 1995), hypotensive (Ribeiro et al., 1986), anti-rehumatic (Visioli et al., 1998), 
diuretic (Ribeiro et al., 1986) and antipyretic (Visioli et al., 1995) effects.  
Prevention of free radical formation by oleuropein occurs through its ability to 
chelate metal ions, such as Cu and Fe, which catalyze free radical generation reactions 
(Andrikopoulos et al., 2002) and through its inhibitory effect on several inflammatory 
enzymes like lipoxygenases (De la Puerta et al., 1999). Also, oleuropein has an anti-
hyperglycemic effect in diabetic rats (Gonzalez et al., 1992); oleuropein inhibits 
hypeglycemia and oxidative stress induced by diabetes, which suggests that 
administration of oleuropein is helpful in the prevention of diabetic complications 
associated with oxidative stress (Al-Azzawie and Alhamdani, 2006). 
 
4.5. Effects on amyloid toxicity 
 The protective effect of several polyphenols against amyloid cytotoxicity comes 
from their physical association with aggregation-prone proteins, rather than from their 
antioxidant activity (Porat et al., 2006).  OLE must be present during amyloid 
aggregation to prevent the formation of toxic species; it modifies the aggregation path 
of amylin inhibiting the formation of toxic amyloid species. In particular, OLE appears 
capable of interfering with the early steps of amylin aggregation hindering the proper 
reorganization of the polypeptide chain and the appearance of the most cytotoxic 
species, and delaying, but not suppressing, the growth of harmless amyloid fibrils likely 
structurally different from those grown in the absence of the polyphenol (Rigacci et al., 
2010). 
Recently, Oleuropein (the glycated precursor of OLE) has been shown to form a 
noncovalent complex with the Aβ peptide (Bazoti et al., 2006 and 2008), and in vitro 
studies  showed that the best protection against Aβ42 cytotoxicity was achieved when 
OLE was present during peptide aggregation. In fact, when OLE was given to cells 
together with Aβ42 aggregates grown in its absence, cell viability was still significantly 
reduced, although slightly less, respect to control cells (Rigacci et al., 2011). The relief 
of amyloid toxicity could, in part, result from the anti-oxidant activity of OLE; 
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however, the direct, early interaction of OLE with the amyloidogenic peptide, inhibiting 
the growth of toxic species, appears to provide the best protection. This behavior 
resembles that of other polyphenols and has led to hypothesize that the inhibitory 
activity of this class of substances results from the interference either in aromatic-
aromatic stacking or in the formation of hydrophobic clusters, or in both (Yang et al., 
2005; Mishra et al., 2009; Rivière et al., 2007; Ono et al., 2008). 
The interaction of oleuropein with Aβ40 was shown using ESI-MS and NMR (Bazoti 
et al., 2006, 2008; Benaki et al., 2009). Three peptide regions (4-11, 12-22 and 17-28) 
were shown to be involved in the interaction. It was proposed that while the sugar unit 
would be preferably accommodated into the polar N-terminal fragment (4-11) of the 
peptide, the hydrophobic (17-21) region of the latter would interact with the non-polar 
moiety of oleuropein (Bazoti et al., 2008). It is conceivable that OLE interacts with the 
same 17-21 hydrophobic region, which is also critical for Aβ fibrillization (Kallberg et 
al., 2001). 
The in vitro studies by Rigacci and colleagues showed that OLE abrogates the 
formation of toxic oligomeric species, both pre-fibrillar and fibrillar, not only during the 
whole path of Aβ42 aggregation but also once added to pre-formed amyloid fibrils 
(Rigacci et al., 2011). 
OLE would represent a very good candidate for amyloid cytotoxicity prevention, 
being able to interfere with the aggregation of amyloidogenic peptides by inhibiting the 
formation of early toxic oligomeric species while allowing deposition of stable fibrillar 
material (Rigacci et al., 2011). Oleuropein has also anti-amyloidogenic effects, since it 
promotes the α-secretase cleavage of the APP in vitro, causing a substantial decrease in 
the formation of Aβ oligomers; the potential anti-amyloidogenic activity of oleuropein 
adds to the multiple health benefits of olive oil and of the Mediterranean diet 
(Kostomoiri et al., 2013). 
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Aim of the study 
 
Mounting evidence supports the beneficial effects of the Mediterranean diet in 
preventing age-related dysfunctions, neurodegenerative diseases and in attenuating AD-
like pathology and cognitive deterioration. 
 
Rat study 
OLE counteracts in vitro aggregation of the Aβ42 peptide and protects cultured cells 
and model organisms against aggregates toxicity. 
We investigated the relative tissue toxicity of Aβ42 aggregated in vitro in the 
presence or in the absence of OLE by injecting the nucleus basalis magnocellularis 
(NBM) of adult rats with solutions containing Aß42 aggregated in the absence or in the 
presence of OLE.  
 
Mouse study 
Adherence to the Mediterranean diet is associated with a reduced risk of developing 
MCI and AD, and reduced risk of MCI conversion to AD. 
We aimed to detect in vivo the effects of dietary supplementation with OLE on AD 
physiopathology using the CRND8 transgenic mouse model of AD. Young and adult 
mice, which represent the early and intermediate stage of cerebral Aβ deposition, were 
fed with OLE diet and its effects in preventing/slowing down the neuropathology were 
investigated on memory functions, brain amyloid load and on autophagy. 
 
Zebrafish study 
Autophagy represents a potential therapeutic target in pathologies characterized by 
aggregates, and further studies will provide an insight into the role of this process in the 
brain; atg5-knockdown studies in zebrafish showed that Atg5 is required for normal 
morphogenesis of brain regionalization. 
In order to study the role of the autophagy in the embryonic zebrafish 
neurodevelopment, we aimed to generate  a Atg5-knockout zebrafish stable line using 
TALEN technology. 
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RAT EXPERIMENTS 
 
1. Animals 
Three-month old, 230–250 g male Wistar rats (Harlan, Milan, Italy) were used. The 
rats were housed in macrolon cages with ad libitum food and water and maintained on a 
12-h light/dark cycle at 23 °C. All experiments were carried out according to the EC 
Directive 86/609/EEC for animal experiments and National guidelines for animal care 
(Permit Number: 283/2012-B)  
 
2. Oleuropein deglycosylation 
Oleuropein (Extrasynthase) deglycosilation was performed according to Konno et al. 
(1999) with minor modifications (Rigacci et al., 2010). Briefly, a 10 mM solution of 
oleuropein in 0.1 M sodium phosphate buffer, pH 7.0, was incubated with 28.7 I.U./mL 
of β-glycosidase overnight at room temperature (RT) in the dark. The reaction mixture 
was centrifuged at 10,000×g for 15 min to precipitate the aglycone. The complete 
oleuropein deglycosylation was confirmed by assaying the glucose released in the 
supernatant with the Glucose (HK) Assay Kit (Sigma). GC-MS analysis showed the 
absence of any oleuropein in the precipitate and the substantially total recover of OLE 
in the same precipitate. A 100 mM Oleuropein Aglycone (OLE) stock solution in 
DMSO was stored protected from light until use. 
 
3. Aβ aggregation 
The Aβ42 peptide (Bachem) was dissolved and aggregated following the procedure 
described by Rigacci et al. (2011) 
An alkaline 500 µM monomeric peptide solution was obtained after sonication for 5 
min in a mixture of CH3CN/Na2CO3 (300 µM)/NaOH (250 mM) (48.3/48.3/3.4, v/v/v), 
this was diluted to 50 µM  in 10 mM phosphate buffer, pH 7.7, containing 11 mM NaCl 
(PBS), in the presence (Aβ-OLE) or in the absence (Aβ) of 450 µM OLE (obtained by 
enzymatic digestion of glycated oleuropein (Rigacci et al., 2010) and incubated at 25 °C 
for 24 h. The structural and morphological features of the aggregates grown at these 
conditions, as well as their toxicity to cultured cells (which was maximal after 24 h of 
aggregation in the absence of OLE), were previously characterized (Rigacci et al., 
2011). 
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4. Brain injections 
The rats were anesthetised with chloral hydrate (400 mg/kg i.p.) and 1.5 µl of a 
solution containing Aβ42 (50 µM) aggregated in the presence or in the absence of OLE 
(450 µM), or OLE (450 µM) alone, was injected by means of a Hamilton microsyringe 
into the right NBM at the stereotaxic coordinates: AP=-0.2, L=-2.8, from Bregma and 
H= 6.8 from the dura (Paxinos and Watson, 1997).Control rats were injected with 1.5 µl 
of PBS. 
Thirty days after injection, the rats were killed by decapitation, the brains were 
rapidly removed and postfixed in phosphate-buffered 4.0% paraformaldehyde, pH 7.4, 
at 4 °C for 48 h, rinsed in PBS and embedded in paraffin for immunohistochemistry. 
 
5. Immunohistochemistry  
Histochemical and immunohistochemical analyses were performed on 5.0 µm 
coronal paraffin-embedded sections obtained by microtome sectioning (Leica 
Microsystem, UK). Brain sections were placed on slides and incubated for 30 min in 
xylene at  RT to allow the removal of the paraffin; then section were rehydrated using 
decreasing ethanol concentrations solutions (100%, 95%, 90% and 70%) and distilled 
water. At the time of the experiment, sections were incubated overnight at 4 °C with the 
primary antibodies, at the optimized working dilution, made up in PBS 0.1 M (pH 7.4) 
with Triton X-100 (0.3%) and BSA (5 mg/ml). On the second day, sections were 
incubated for 1 h with the secondary antibody at 1:1000 dilution made up in PBS 0.1 
mM plus BSA (1 mg/ml) and the immunostaining was visualized using the avidin-biotin 
system (Vectastain: Vector Laboratories, Burlingame, CA) and 3,39-diaminobenzidine 
plus Nickel (DAB Kit: Vector Laboratories, Burlingame, CA) as the chromogen.  
Fluorescent staining 
Fluorescent labeling followed previously described protocols (Fiorentini et al. 2010). 
Coronal brain sections were rinsed 3 times then placed in blocking solution (PBS, pH 
7.4+0.3% Triton X-100, 2g/l BSA and 5% NGS for polyclonal antibodies or 5% NHS 
for monoclonal antibodies), for 30 min at RT. Primary antibodies were diluted in fresh 
blocking solution and applied overnight at 4°C. Next, sections were washed in PBS 
(3X10 min) at RT and subsequently incubated for 2 h in the dark with the appropriate 
fluorescent secondary antibody (monoclonal antimouse Alexa Fluor 594 red conjugated 
and polyclonal anti-rabbit or anti-goat Alexa Fluor 488 green conjugated, Invitrogen, 
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Eugene, OR) diluted 1:200 in blocking solution. Following 3 additional rinses, sections 
were coverslipped using Vectashield water-based mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA). The analysis of negative controls (omission of primary 
antibody) was simultaneously performed in order to exclude the presence of non-
specific immunofluorescent staining, cross-immunostaining, or fluorescence bleed-
through. An Olympus BX63 microscope coupled to CellSense Dimension Software 
(Olympus, MI, Italy) was used to acquire representative images.  
 
6. Determination of ChAT positive cells 
The number of ChAT-positive cells in the nucleus basalis magnocellularis was 
determined by two analysts blinded for the administration, using a 20X objective with a 
calibrated eyepiece grid. Eight sections (5.0 µm each) spaced about 60 µm from each 
other per animal were analyzed and the total number of ChAT-positive cells in the NBM 
was averaged. An Olympus BX63 microscope coupled to CellSens Dimension Software 
(Olympus, MI, Italy) was used to acquire representative images. GraphPad Prism 
version 5.0 for Windows was used for ChAT positive cell calculations and statistically 
significant differences were evaluated by One-way ANOVA followed by Bonferroni's 
post-hoc test. A P-value of less than 0.05 was considered significant. Data were 
expressed as mean ± standard error of the mean (S.E.M). 
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MOUSE EXPERIMENTS 
 
1. TgCRND8 mice 
The TgCRND8 mice express two mutated human APP genes implicated in AD 
(Swedish, KM670/672NL and Indiana, V717F) under the regulation of Syrian hamster 
prion promoter gene (Chishti et al., 2001). The mice were maintained on a hybrid 
(C57)/(C57/CH3) background by crossing transgenic heterozygous TgCRND8 males 
with wild-type female mice.  
The main feature of this model is a very rapid development of amyloid pathology in 
the brain: amyloid β deposits start quite early since the two mutations involve both the β 
and γ secretase APP cleavage sites; in fact, all mice display amyloid plaques in the 
cortex and hippocampus by three months of age (Chishti et al., 2001). These 
neuropathologic manifestations are accompanied by impaired acquisition and learning 
deficits. 
The transgenic mice were generated and supplied  by the group of Dr. P StGeorge 
Hyslop (Center for research in neurodegenerative Diseases, Toronto, Canada) and then 
the colony was  bred in our animal house, Ce.S.A.L. (Centro Stabulazione Animali da 
Laboratorio), University of  Florence. 
 
2. Genotyping 
Transgenic TgCRND8 mice were identified by DNA extraction from tail samples 
and PCR analysis using specific primers (5’-aggactgaccactcgacca-3’ and 5’-
tggattttcgtagccgttc-3’) for the human mutated (KM670/672NL+V717F)  cDNA insert 
(Bellucci et al., 2006). 
The primers directed against the insert used the following program: lid heating to 
105°C, five minutes at 99°C in order to degrade any DNAses, then five minutes at 95°C 
followed by 35 cycles: each cycle involved 1 min at 95°C, 1 min at 52°C and 1 min at 
72°C. After cycles were completed, samples were held at 72°C for an additional 5 
minutes and then were stored at 8°C. 
In order to check the presence of the transgene, the PCR product was  run in a gel 
electrophoresis using 0.5X Tris/borate/EDTA buffer and 0.8% agarose gel with etidium 
bromide (Sigma). DNA was visualized on a UV lightbox imaged with a camera. Only in  
transgenic samples a 300 bp band is detected. 
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3. Oleuropein Aglycone treatment 
Since several beneficial effects of OLE have been reported (Rigacci et al., 2010; 
Diomede et al., 2013), we decided to test its effect on transgenic mouse model of AD by 
oral administration of a diet containing OLE. 
After deglycosylation, the 100 mM OLE stock solution was protected from light, 
stored at -20°C and diluted in oil immediately before diet supplementation. 
The experimental diet was prepared using components purchased from Piccioni 
(Gessate, Mi, Italy). Fresh diet was put in the trough every two days. We used a 
modified low-fat American Institute of Nutrition (AIN)-76 diet (5.0% fat) composed of: 
50.0% sucrose, 5.0% fat, 20.0% casein, 15.0% corn starch, 5.0% powdered cellulose, 
3.5% AIN-76 mineral mix, 1.0% AIN-76A vitamin mix, 0.3% DL-methionine and 0.2% 
choline bitartrate. 
Different diet treatments were equally given to each age group of wt and Tg mice: 
for 8 weeks the 5.0% fat diet (10 g/day per mouse) was given either alone (untreated) or 
containing OLE (50 mg/kg of diet) (OLE-fed).  
The following 2 age groups of mice (equally divided for sex) were used: 1.5 month-
old wt (n=16) and pre-plaque Tg (n=16) mice and 4 month-old wt (n=16) and Tg (n=16)  
mice. These two ages correspond to different stages of the pathologies in terms of 
cerebral β-amyloid deposition. 
We decided to treat young mice, 1.5 month-old, that don’t show cerebral amyloid 
deposition yet since we would like to test if OLE could interfere in early stages of 
amyloid deposition or at least slow down the aggregation of cerebral Aβ peptide and we 
chose adult mice in order to evaluate any effect on an intermediate stage of the 
pathology.   
4. Body weight 
The animals were weighted once a week during the treatment; body weight was 
slightly, not significantly, increased in all mice. The treatment was not toxic and 
animals were healthy. 
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5. Behavioral experiments 
At the end of the diet treatment, 3.5 month-old and 6 month-old OLE-fed and 
untreated Tg and wt mice were pooled according to the treatment and genotype and 
memory performance was investigated by two widely used behavioural tests. 
TgCRND8 mice, as previously demonstrated in our laboratories by performing other 
behavioural tests as rotarod, hole platform and grip strength, don’t show any motor 
deficits or exploration impairment (Bellucci et al., 2006). 
 
5.1. Step down inhibitory passive avoidance task 
In this test, the animals learn to associate exploration of a compartment with a foot 
shock delivered through the floor grid. On subsequent exposure to the same 
environment, the mice will avoid stepping down or will increase the latency before 
‘‘stepping down’’ onto the floor grid.  
The term “passive avoidance” (Netto and Izquierdo, 1985) is used to indicate in vivo 
experiments in which the animal learns to avoid a specific event, usually concerned an 
innate behavior, that is dangerous due to a linked punishment. 
A mouse in an open field naturally spends most of the time in dark places, as near 
walls and corners; when the mouse is placed on an elevated-platform in the center of the 
field, it will try to get off the platform, to explore the environment and go near the 
walls. Based on this natural behavior, several different variants of the step down 
inhibitory avoidance task have been used (Abdel-Hafez et al., 1998;  Chorover and 
Schiller, 1981; Kubanis and Zornetzer, 1981; Zoernetzer et al., 1982)  
In this study, the following procedure was used: 
- the apparatus was an open field plexiglas box (40 × 40 cm) with a steel rod floor and a 
plexiglas platform (4 × 4 × 4 cm) set in the centre of the grid floor to which intermittent 
electric shocks (20 mA, 50 Hz) were delivered (Fig. 16). 
- on day 1 (training test, TT), each mouse was placed on the platform and received an 
electric shock (1 Hz, 0.5 s, 40 V DC)  for 3 s when it stepped down placing all paws on 
the grid floor (Hiramatsu et al., 1995) considering 180 s as the upper cut-off, then the 
mouse was put back into the cage. 
Responsiveness to the punishment in the TT was assessed by animal vocalization; only 
those mice that vocalized touching the grid (about 70% of mice) were used for retention 
test (RT). 
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- 24 h after TT, each mouse was placed on the platform again (RT). The latencies were 
measured, considering 180 s as the upper cut-off. The test ended when the mouse 
stepped down or when the cut-off time was over. During retention test no electric shock 
was released.  
- latencies recorded during TT and RT were compared: a latency longer in the RT than 
in TT meant the mouse learnt and could remember the punishment received the day 
before, otherwise the mouse showed memory impairment. 
 
 
Figure 16. A mouse performing the step down inhibitory avoidance task 
 
5.2. Context-dependent object recognition test 
The object recognition paradigm utilized the innate tendency of mice to explore a 
novel object over a familiar one. The test measures spontaneous behavior, and thus 
requires no length training or preparation (Ennaceur and Delacour, 1988).  
Pre-training: To avoid neophobic interference a habituation phase preceded the 
testing. Habituation consisted in placing the mice for 5 min into a square open-field 
arena (60 x 50x 25 cm). During this phase the mice could explore freely the empty 
arena with one object inside (Fig. 17). 
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Testing: The object recognition task was conducted 1 day after the habituation phase 
and comprised two trials (T1 and T2). During the T1 the animals could explore two 
identical objects while in the T2 one object was replaced by a novel one. Each trial 
lasted 5 min, with an intertrial interval of about 60 min. All objects were made of a 
biologically neutral material such as plastic or metal, and animals could not move them 
around in the arena. Objects were not known to have any ethological significance for 
the mice and they never had been associated with a reinforcer (Ennaceur et al., 2005). 
Fecal boli were removed after each tested animal. 
Frequency and duration of object exploration was recorded by a video-
tracking/computer-digitizing system (HVS Image, UK). 
Exploration of an object was defined as directing the nose towards an object at a 
distance of less than a half head length and/or touching the object with the paws. Sitting 
on an object was not considered as exploratory behaviour. Mice without any exploration 
behavior towards the objects were excluded from the analysis of learning behaviour. 
To analyze the object recognition test, a discrimination score was calculated: 
discrimination score=exploration time of the novel object (s)/total exploration time of 
both objects (s). A discrimination score above 0.5 indicates the ability of mice to 
discriminate between the familiar and novel objects while a score below or equal to 0.5, 
reflecting a novel object exploration time less or equal to the half of the total time spent 
between the two objects, indicates memory impairment in this task Mice with a total 
exploration time of less than 5 s in either the T1 or the T2 were excluded from the 
analysis of learning behaviour on this test day. 
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Figure 17. A view from above of the arena during a mouse  is performing the object recognition 
test. 
 
6. BrdU treatment 
BrdU is a synthetic nucleoside that is an analogue of thymidine; BrdU was used in 
the detection of proliferating cells since it can be incorporated into the newly 
synthetized DNA of replicating cells (during the S phase of the cell cycle), substituting 
for thymidine during DNA replication. 
In order to evaluate proliferation of neural progenitor cells, 5-bromo-2’-deoxyuridine 
(BdrU, Sigma-Aldrich, MI, Italy) (50 mg/kg of body weight) was administrated to the 
mice twice a day for three days. 24h after the last BrdU injection, mice were sacrificed. 
Cells marked by BrdU incorporation were detected using an anti-BrdU antibody. 
 
7. Animal tissue processing 
After completing the behavioral tests, mice were sacrificed by cervical dislocation 
and the brains were rapidly removed and divided sagittally. For protein analysis, 
cortical and hippocampal samples from one hemibrain were immediately sectioned, 
snap-frozen in dry ice or liquid nitrogen and stored at -80 °C. The other hemibrain was 
postfixed in phosphate-buffered 4.0% paraformaldehyde, pH 7.4, at 4 °C for 48 h, 
rinsed in PBS and paraffin embedded for immunohistochemistry and Thioflavin S 
staining. 
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8. Histology, histochemistry and immunohistochemistry 
Histochemical and immunohistochemical analyses were performed on 5.0 µm 
coronal paraffin-embedded sections obtained by microtome sectioning (Leica 
Microsystem, UK). Immunohistochemistry and immunofluorescence experiments were 
performed as previously described in “rat experiments”, using the antibodies reported in 
Table 1. 
 
8.1. Thioflavin S staining 
Thioflavin S staining was used to detect deposit containing β-sheet structures in 
mouse brains. We performed Thioflavin S staining following the protocol described by 
Yamamoto and Hirano (1986). 
The rehydrated sections were incubated with 0.25% KMnO4 for 4.0 min, washed 
twice with distilled water, incubated with a 0.1% NaBH4 solution for 5.0 min, washed 
twice with distilled water and placed in phosphate buffer (411 mM NaCl, 8.1 mM KCl, 
30 mM Na2HPO4, 5.2 mM KH2PO4), pH 7.2 for 30 min at 4 °C. The sections were 
washed, incubated in 0.05% Thioflavin S (in 50% ethanol) for 8.0 min in the dark, 
washed twice in 80% ethanol for 10 s and incubated in phosphate buffer for 30 min at 4 
°C. The sections were cover slipped using Vectashield mounting medium with or 
without DAPI (Vector Laboratories, USA). Representative images were acquired by an 
Olympus BX63 fluorescence microscope coupled to CellSens Dimension Imaging 
Software (Olympus, Italy). 
 
8.2. BrdU labelling and counting 
For BrdU labelling, sections were treated with 0.6% H2O2 in Tris-buffered saline 
(TBS 1X, pH 7.5) to block endogenous peroxidises. DNA was denaturated by exposing 
sections to 2N HCl for 15 min at 37°C followed by 0.1M borate buffer (pH 8.5) for 10 
min at RT. Sections were then incubated for 1h in TBS with 0.1% Tween-20, 1% BSA 
and 3% Normal Horse Serum (NHS), and then overnight at 4°C with the primary 
antibody anti-BrdU (1:100 dilution) in the same buffer. On the second day, sections 
were washed (3x10min) in TBS-Tween20 at RT and subsequently incubated for 2h in 
the dark with the appropriate fluorescent secondary antibody (polyclonal anti-rat 
AlexaFluor 488 green conjugated, Invitrogen, Eugene, OR) diluited 1:500 in blocking 
solution. After washing with TBS-Tween20 (3x10 min) and briefly with water, sections 
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were finally cover-slipped using Vectashield water-based mounting medium (Vector 
Laboratories, Burlingame, CA). An Olympus BX63 microscope coupled to Cell Sens 
Dimension software was used to acquire representative images from the examined 
specimens. 
Quantification of BrdU positive (BrdU+) cells was performed in the subgranular 
zone (SGZ) of the hippocampus in 6 coronal sections per mouse spaced at 80nm. The 
counts were conducted at 40X magnification with an Olympus BX63 microscope. The 
corresponding surface area of SGZ sampled was measured using the Cell Sens 
Dimension Software. The density of BrdU+ cells was calculated by dividing the number 
of BrdU+ cells by SGZ sectional area (mm2).  
 
9. Determination of Aβ plaque-load 
To quantify Aβ plaque burden, cortices and hippocampi of the sections stained with 
anti-Aβ (1–42) antibody were digitized (Olympus BX63, Olympus, Germany) under 
constant light and filter settings. Six to seven coronal brain sections, each separated by 
60 µm  interval, from each mouse (4-5 animals per group) were analyzed.  
Morphometry was conducted by using CellSens Dimension software (Olympus, 
Germany). Colour images were converted to greyscale by extracting blue to grey values 
to obtain best contrast between positive immunoreactivity and background. A constant 
threshold was chosen for all images to detect immunoreactive staining. Plaque number, 
size (maximum area, minimum area) and total area were determined automatically in 
the cortices and hippocampus. Brain regions were based on the Paxinos and Franklin 
mouse brain atlas. Data from the six-seven sections were summed to derive 
representative values for each animal for the total plaque area. Data were expressed as 
mean ± S.E.M. 
 
10. Western blot 
The western blot is an analytical technique used to detect specific proteins in the 
given sample of tissue homogenate. A gel electrophoresis is used to separate 
denaturated proteins by the length of the polypeptide; proteins are then transferred to a 
membrane, where they are stained with antibodies specific to the target protein. Proteins 
were then visualized using specific antibodies and a chemiluminescence detection 
system.  
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For western blotting analysis, TgCND8  and wt tissue brain samples were 
homogenized in ice-cold RIPA lysis buffer composed by: 
-2X lysis buffer (50 mM Tris-HCl pH 7.5; 50 mM NaCl; 10 mM EGTA; 5 mM EDTA); 
- Phosphatase inhibitors (2 mM NaPP; 4 mM PNFF; 1 mM Na3VO4) 
- Proteases inhibitor (1 mM PMSF, 20 µg/ml leupeptin; 30 µg/ml aprotinin) 
The samples were homogenized in 100 µl of RIPA buffer, then centrifuged for 15 min 
at 12,000 rpm and surnatant was recovered and used for the next steps. 
In order to detect the amount of proteins in each sample, a protein assay was 
performed. Dilutions ranging from 1µg/ml to 0.075 µg/ml of Bovine Serum Albumine 
(BSA) were prepared to outline the standard curve of reference. Into a 96-multi well 
plate 4µl of each sample (blank, BSA dilutions and surnatant of the homogenized 
tissues) and 200 µl of Bradford reagent (Bio Rad, Hercules, CA) were put in each well: 
the Bradford colouring depending on the amount of proteins, became from deep to light 
blue. After 10 min incubation at RT, samples were assayed with a spectrophotometer 
associated a computer (E1800, Universal Microplate Reader, Bio-Tex Instruments, Inc). 
Samples absorbance was detected and the standard samples were useful to correlate 
absorbance measurement detected to known proteins amount; comparing the absorbance 
values obtained with the standard curve, the amount of protein in unknown samples 
could be extracted. 
Forty µg of proteins were loaded on a gel and the final volume was adjusted by 
adding lysis buffer. Before loading on a gel, loading buffer (300 mM Tris-HCl pH 6.8; 
12% SDS; 60% glycerol; 0.6% bromophenol blue; 600 mM DTT; H2O) was added to 
unfold proteins and charge negatively: the samples were boiled for 5 min at 100°C in 
order to denature the proteins, then they were placed on ice, briefly centrifuged to spin 
down the samples to the bottom of the tubes, and finally loaded on a gel. 
Meanwhile, 10% running gel SDS-PAGE was prepared (10% acrylamide; 1.5 M 
Tris-HCl pH 8.8; 10% SDS, 10% (NH4)2S2O8; TEMED; H2O), poured into the gel 
mould and let solidified for at least 30 min, adding temporary some buthanol to avoid it 
could dry up. Once the gel was solidified, the buthanol was removed and the 5% 
stacking gel ( 5% acrylamide, 1mM Tris-HCl pH 6.8, 10% SDS, 10% ammonium 
persolphatum, TEMED, H2O) was poured on and a plastic comb was inserted to design 
the wells. After about 30 min the gel was solidified, the samples and a molecular weight 
standard solution (Biorad dual color standard) were loaded in the wells. The samples 
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were run in the gel at 4°C using Running buffer (100 ml 10X buffer; 5 ml 10% SDS), 
applying 95 V, constant voltage. 
When the run was over, the stacking gel is cut out, and the resolving gel containing the 
proteins was placed on a 0.45 µm nitrocellulose/PVDF membrane (Hybond-C, 
Amersham Life Science); in order to make proteins transfer from the gel to the 
membrane, a tight “sandwich” with sponges and filter paper was made to keep the gel 
against the membrane; the sandwich is then placed into a chamber containing cold 
Blotting buffer (100ml 10X Buffer; 10% SDS; 10% glycine; 100ml methanol) and 
current was applied to allow protein transfer on the membrane; the current could move 
the proteins from the gel since they had negative charges due to SDS, and stick them on 
the membrane. The transfer at 4°C could be performed overnight at 12 mA constant 
voltage or for 2 h at 80 V.  
Then the membrane was removed from the sandwich, washed with distilled H2O and 
the effective run and transfer was checked with the unspecific Ponceau staining (Bio 
Rad, Hercules, CA). 
Ponceau solution was washed out with H2O and the membrane was incubated overnight 
at 4°C in Blocking solution containing TBST (1X TBS, 0.05% Tween 20) and 5% milk 
for antigen retrieval. 
The membrane was incubated with the primary antibody diluted in Blocking solution 
for 2 h at RT or overnight at 4°C, all primary antibody concentrations were titrated to 
provide optimal staining (Table 1). The membrane was washed three times for 15 
minutes with TBST and incubated for 1 h RT with the HRP-conjugated secondary 
antibody (Bio Rad) diluted 1:7500 in TBST. The immunocomplexes were visualized 
using enhanced chemiluminescence (ECL chemiluminescence kit, Pierce, Rockford, 
USA) in the dark room. 
After washing out the secondary antibody with TBST for 10 min, the membrane was 
incubated 1 min RT with 1 ml of reagent A and 1 ml of reagent B from ECL kit. The 
peroxidase conjugated with the secondary antibody triggered a chemical reaction 
producing a chemiluminescent signal that could be detected and acquired using 
ImageQuant 350 system (GE Healthcare, UK). 
The membrane could then reused to perform further experiments: it could be put in 
10 ml of stripping buffer (Bio rad, Hercules, CA) shacking thoroughly for 15 min and 
after a 10 min wash with H2O it’s ready to be used again to determine house-keeping  
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proteins levels, like β-actin or GAPDH, necessary to normalize the samples levels 
detected and to check the amount of proteins loaded. 
The normalized data were collected and the statistical analysis was performed using 
Graph Pad (Graph Pad Prism Software version 4.0, San Diego, CA, USA). 
 
Table 1. Antibodies employed in the rat and mouse studies 
Name Target Dilution Experiment Study 
6E10 Aβ peptide, 
aa 1-16 
1:400 IHC Rat 
A11 Soluble amyloid 
oligomers 
1:500 IHC Rat 
Aβ42 Aβ peptide, 
aa 1-42 
1:200 IHC Mouse 
β-actin C-terminal β-actin 
fragment 
1:5000 WB Mouse  
1:200 IHC Mouse Beclin 1 Beclin 1 protein 
 1:1000 WB Mouse 
BrdU BrdU 
 
1:100 IHC Mouse 
1:100 IHC Mouse Cathepsin B Procathepsin B 
and mature 
cathepsin B 
1:1000 WB Mouse  
ChAT Cholinergic 
neurons 
1:200 IHC Rat 
GAPDH Glyceraldehydes 
3-phosphate 
dehydrogenase 
1:1000 WB Mouse 
GFAP Glial fibrillar 
acidic protein 
1:500 IHC Rat and mouse 
Iba1 Ionizied calcium 
adaptor molecule 
1:250 IHC Rat and mouse 
1:200 IHC Mouse LC3 Microtubule-
associated protein 
light chain 3 
1:1000 WB Mouse 
OC Amyloid fibrils 
and fibrillar 
oligomers 
1:1000 IHC Mouse  
P-p70S6K P-p70S6 kinase 
(Thr389) 
1:1000 WB Mouse  
p70S6K p70 S6 kinase 1:1000 WB Mouse  
1:200 IHC Mouse SQSTM1/p62 SQSTM1/p62 
protein 1:1000 WB Mouse  
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11. ELISA assay 
The Enzyme-Linked ImmunoSorbent Assay (ELISA) is a test that uses antibodies 
and color change to identify and quantify a specific substance. 
Soluble and insoluble Aβ fractions were isolated from cortex homogenates using a 
four step extraction protocol (Rasool et al., 2012). At each step, sonication in an 
appropriate buffer was followed by centrifugation at 100,000 x g for 1 hr at 4°C. The 
supernatant was then removed, and the pellet was sonicated in the next solution used in 
the sequential extraction process. For four-step extraction, sonication of the frozen 
tissue began in Tris-buffered saline (TBS) (20 mM Tris and 137 mM NaCl, pH 7.6), 
which contained protease inhibitors (protease inhibitor cocktail from Sigma St. Louis 
USA). The next three sequential extraction steps used 1% Triton X-100 in TBS with 
protease inhibitors, 2% SDS in water with the same protease inhibitors, and 70% formic 
acid (FA) in water. SDS-soluble fractions were loaded directly onto ELISA plates, 
whereas FA-soluble fractions were diluted 1:20 in a neutralization buffer (1 mol/L Tris 
base, 0.5 mol/L NaH2PO4) before loading. Levels of Aβ40 and Aβ42 were analyzed 
using an ELISA kit (Biosource, Camarillo, CA, USA) according to the manufacturer’s 
instructions. The plates were read at 450 nm using a plate reader (Molecular Dynamics, 
Sunnyvale, CA). All values were calculated as pmol per g based on the wet weight of 
brain cortical tissues. 
 
12. Thiobarbituric acid reactive substances (TBARS) assay 
ThioBarbituric Acid Reactive Substances (TBARS) are naturally present in 
biological specimens and include lipid hydroperoxides and aldehydes which increase in 
concentration as a response to oxidative stress (Armstrong and Browne, 1994). TBARS 
assay values are usually reported in malonaldehyde (malondialdehyde, MDA) 
equivalents, a compound that results from the decomposition of polyunsaturated fatty 
acid lipid peroxides.  The TBARS assay is a well-recognized, established method for 
quantifying these lipid peroxides (Ohkawa et al., 1979). 
This assay is based on the reaction of a chromogenic reagent, 2-thiobarbituric acid, 
with MDA at 100°C. One molecule of MDA reacts with 2 molecules of 2-thiobarbituric 
acid via a Knoevenagel-type condensation to yield a chromophore with absorbance 
maximum at 532 nm, as shown below in figure 18. 
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Figure 18. Reaction between 2-thiobarbituric acid and MDA under acidic conditions ends up 
with a product which adsorbance is 531 nm 
 
The mouse cerebral cortex was homogenized in RIPA buffer (10% w/v) containing the 
chelating agent diethylenetriamine pentaacetic acid (500 µM); 0.2 mL of suspension 
were added to 4.0 mL of 36 mM TBA (thiobarbituric acid) solubilised in 10% 
CH3COOH, pH 4 (LaMotta et al., 2007). After heating for 60 min at 100 °C, the 
reaction was stopped by cooling the test tubes in ice for at least 2 h. 1.5 ml of n-butanol 
was added and each test tube was vigorously mixed for 30 s and centrifuged at 250 ×g 
for 10 min. The organic layer was taken and the resulting pink colour was determined in 
a spectrophotometer at 532 nm. The acid did not produce colour when tested without 
the addition of the homogenate, demonstrating the absence of a direct reaction with 
TBA. Calibration curve was performed using 1,1,3,3-tetramethoxypropane and each 
curve point was subjected to the same treatment as that of the homogenate. The results 
were reported as nmol of malondialdehyde per mg protein. All samples were run in 
twice.
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ZEBRAFISH EXPERIMENT 
 
1. Zebrafish  
All zebrafish husbandry and experiments were performed in accordance with UK 
legislation under a license granted by the Home Office and with local ethical approval. 
Zebrafish (Danio rerio) were reared under standard conditions on a 14 h light:10 h dark 
cycle in the fish facility (Department of Physiology, Development and Neuroscience, 
University of Cambridge, UK). 
Embryos were collected from natural spawning, staged according to established 
criteria (Kimmel, 1995) and reared in embryo medium (5 mM NaCl, 0.17 mM KCl, 
0.33 mM CaCl2, 5 mM HEPES) at 28.5°C. Tupfel long fin (TL) wildtype strain were 
used. 
Zebrafish are commonly used as in vivo model of development: they have several 
advantages like transparency, external development with large number of embryos, the 
development of zebrafish is very fast and all stages are well described (Fig. 19) . 
Homologs of many autophagy related genes are found in zebrafish, so it is  an excellent 
model for studying autophagy. 
Autophagy can be studied in zebrafish by knocking down, knocking out or 
overexpressing autophagy related genes in different ways, and the most advanced 
technologies thus far to knock out genes in zebrafish are TALENs and CRISPR. 
        
 
 
Figure 19. Stages of the embryonic development of the zebrafish. Zebrafish develop from one 
cell to the entire organism in 72 hours. All the stages are well described and recognizable 
(source:http://www.uoneuro.uoregon.edu/k12/zfk12.html) 
 
 
2. TALENs technology 
TALEN (Transcription Activator-Like Effector Nucleases) is an innovative 
technique to editing the genome with engineered nucleases. This technique enables 
researchers to target the genome exactly where they want with high precision. TALEs 
are transcriptional activators that specifically bind and regulate plant genes during 
pathogenesis. TALENs are made of two parts: one part, TALE domain, binds the DNA: 
within the TALE structure, a central repeat domain mediates DNA recognition, and 
each repeat unit of 33-35 amino acids can bind a specific base. The base preference of 
each units is determined by two critical adjacent amino acid referred to as the “repeat 
variable di-residues” (RVD); this DNA binding part consist of 18-24 repeat modules 
that are not thought to interfere each other. To the DNA binding part, a nuclease domain 
is fused so TALENs are used to generate double-stranded breaks by using two TAL 
effectors to each cleave a single strand of DNA (Fig. 20).  
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Figure 20. Transcription Activator-Like Effector Nucleases (TALEN) bind target DNA 
sequences to direct a FokI nuclease domain to cut the DNA. TALENs have multiple DNA 
binding domains linked in series to create an array. The arrays each bind a separate sequence 
and a dimeric FokI nuclease domain cleaves the DNA within what is referred to as a space 
region. These engineered nucleases frequently induce breaks that are repaired via Non 
Homologous End Joining (NHEJ), which is error-prone and can result in insertion or deletion 
of a few bases, creating an indel (Moore et al., 2012). 
 
The space between the two individual TALENs DNA binding site is an important 
parameter for effective cleavage, usually a spacer of about 15 bp works well. 
The DNA ends formed by the cleavage are repaired by the cell, often leaving deletion or 
small insertions. So most of the repair events would alter the reading frame of a gene 
and create a knock-out. 
 
3. TALEN plasmids 
The TALENs plasmids were made by an academic consortium (Sander et al., 2011), 
purchased from Addgene and supplied as bacterial stabs.  The bacteria was streaked on 
agar plates (with ampicillin) and grown overnight at 37°C.  A single colony was picked 
and grown in LB (Lysogeny Broth) medium containing ampicillin overnight, in shaking 
incubator at 37°C. Then the DNA was purified using Macherey Nagel plasmid midi 
prep kit according to manufactures instructions. 
The plasmids were then linearized through a restriction enzyme and TALEN Atg5 
encoding RNA was transcribed in vitro from TALEN expression vectors using the 
mMESSAGE mMACHINE® T7 Ultra (Ambion, Life techonologies) and then 
introduced into early zebrafish embryos by microinjection 
 4. Microinjection 
Approximately 2nl of TALEN Atg5-encoding RNA (300 pg/nl) was injected in one-
cell stage wild type embryos using pulled glass capillaries; the embryos were lined up 
on a glass slide and injected through the yolk into the cell using a microinjector. 
Injection volume was calibrated by measuring the size of injection volume in mineral 
oil using a microscope with eyepiece reticule. For every injection a portion of wt 
uninjected embryos were saved and examined to ensure that those were a good quality 
embryos, otherwise the batch was discarded and not analysed further. 
After injection, embryos were stored at 28.5°C in the dark in an incubator, at 6 hours 
post fertilization (h.p.f.) they were cleared of dead and unfertilized eggs, at 24 h.p.f. and 
48 h.p.f. they were cleared of the dead and the abnormal ones; 10 single embryos from 
each batch of injection were collected in order to check the effectiveness of injection 
and once successful mutation was confirmed, all the remaining injected embryos were 
raised to adulthood. 
 
5. PCR and enzymatic digestion 
DNA extraction from single embryos was performed using the Extract-N-Amp 
Tissue PCR kit (Sigma), and genomic DNA was used to perform standard PCR. The 
primers directed against atg5 used the following program: lid heating to 110°C, 5 min at 
95°C followed by 40 cycles: each cycle involved 30 sec at 95°C, 30 sec at 60.3°C-
60.8°C and 40 sec at 72°C. After cycles were completed, samples were held at 72°C for 
an additional 10 min and then were stored at 8°C. 
In order to check the presence of the amplificated gene, a portion of the PCR product 
was  run in a gel electrophoresis using 0.5X Tris/borate /EDTA buffer and 0.8% agarose 
gel with SafeView DNA staining agent. DNA was visualized on a UV lightbox imaged 
with a camera and then printed. 
Then the remaining PCR product was added to a mix with the restriction enzyme 
BspHI (10000 units/ml, BioLabs), 1µl of enzyme was used to digest 1µg of DNA, 
incubated at 37°C overnight with no star activity. The digestion products were run on a 
0.8% agarose gel with Gel Green Nucleic Acid Gel Stain (Biotium) to check the 
products after restriction enzyme digestion. In wild type DNA the BspHI-mediated 
digestion produces two fragments: 500 bp and 200 bp, in mutated DNA an additional 
undigested product band, 700bp, is shown. 
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The undigested band was cut out of the gel and DNA and extracted and sequenced to 
check the mutation site. 
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RAT STUDY 
 
In this study we investigated the tissue toxicity of Aβ42 aggregated in vitro in the 
presence or in the absence of OLE by injecting the NBM of adult male Wistar rats with 
a solution containing OLE or Aβ42 aggregated in the absence (oligomers) or in the 
presence of OLE.  
 
1. Results and discussion 
1.1. Aβ aggregation 
The structural features of the amyloid aggregates grown in the presence or in the 
absence of OLE were analyzed by TEM prior to injection. The Aβ42 sample aggregated 
in the absence of OLE consisted of oligomeric species and short protofibrils (see arrows 
and arrow-heads respectively, figure 21), while in the Aβ42 sample aggregated with 
OLE essentially amorphous material was present (Fig. 21), as previously reported 
(Rigacci et al., 2011). The use of a mixture of variously aggregated material resembles 
the condition that develops in the brain during the disease, since the aggregation of the 
Aβ peptide is not a synchronous process. Moreover, in the presence of OLE the Aβ42 
aggregation path did not exhibit a clear sequence of steps with well defined 
conformationally and morphologically distinct species; rather, at the Aβ:OLE ratio used 
in our experiments, the aggregating material displayed a delay time of over 5 h, and 
subsequently poor Thioflavin T positivity and no toxicity. At 24 h amorphous 
aggregates were present that do not change remarkably upon further aging and only at 
long incubation times beaded curvy fibrillar assemblies emerge from the amorphous 
material (Rigacci et al., 2011). 
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Figure 21. TEM analysis of Aβ aggregates. 50 µM. Aβ  was incubated in aggregation 
conditions for 24 h in the absence (left) or in the presence (right) of 450 µM OLE. Aggregates 
were loaded onto a formvar- and carbon-coated nickel grid, negatively stained with 1.0% (w/v) 
uranyl acetate and examined using a JEM 1010 transmission electron microscope at 80 kV 
excitation voltage. Oligomers (arrows) and short protofibrils (arrowheads) are indicated on the 
left panel  
 
1.2. ChAT 
Thirty days after injection into the NBM of variously aggregated Aβ, the number of 
ChAT-positive magnocellular neurons detected in the injected area was significantly 
reduced (≈−33%) as compared with those found in all other groups (Fig. 22 A and B). 
Notably, the number of ChAT-positive neurons was substantially unchanged in the 
NBM injected with Aβ aggregated for 24 h with OLE, respect to control rats. Beside 
confirming Aβ aggregate toxicity to cholinergic neurons in the NBM, these data 
indicated that OLE is, by itself, innocuous to the neuronal cells and, more interestingly, 
that Aβ aggregation in the presence of OLE results in the growth of aggregates 
completely non-toxic not only to cultured cells, as previously reported (Rigacci et al., 
2011), but also in tissue. 
 
R e s u l t s  a n d  D i s c u s s i o n  | 115 
Rat 
 
 
Figure 22. ChAT positive neurons in the injected NBM of rats. 
(A) Representative photomicrographs of ChAT positive magnocellular neurons in the NBM 
injected with PBS, OLE, Aβ and Aβ-OLE. 
(B) Quantitative analysis of ChAT-positive neurons revealed a statistically significant reduction 
of ≈33% (*P < 0.05) in the number of ChAT-positive cells in the Aβ-injected NBM respect to all 
other groups. (One-way ANOVA plus Bonferroni post-comparison test). Scale bar 100 µm 
applies to all images . 
 
1.3. Aβ peptide 
To confirm that the different toxicity to the cholinergic neurons of the injected 
material resulted from the presence, in the injected area, of the differently aggregated 
peptide (Aβ or Aβ-OLE) we performed an immunohistochemical analysis with two 
different antibodies: 6E10, which recognizes Aβ in its non-aggregated and aggregated 
form, or A11, which is specific for Aβ oligomers (Kayed et al., 2003). Aβ detection was 
carried out in double labeling immunofluorescence with GFAP which recognizes 
astrocytes and the so-revealed astrogliosis drove us to the site of injection, a reference 
that is useful to detect the small amount of injected Aβ. We found an intense astrocyte 
reaction, revealed as GFAP-positive hypertrophic astrocytes with long and thick 
branches, in a large area of the Aβ-injected NBM (Fig. 23 A) . Astrocyte reaction was 
also detected in the Aβ-OLE injected NBM, however it was confined to the needle 
trace, as expected, such that the area displaying astrogliosis was reduced as compared to 
that imaged in the Aβ-injected NBM (Fig. 23 b). Double labeling 
immunohistochemistry with the 6E10 antibody and the GFAP antibody plus DAPI 
showed a roughly equal amount of 6E10-positive Aβ peptide in the NBM injected with 
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Aβ or Aβ-OLE (Fig. 23 c and d). By contrast, double labeling immunohistochemistry 
with the A11 antibody, which recognizes Aβ soluble amyloid oligomers, and GFAP 
antibody plus DAPI, showed that the amount of A11-positive oligomers, entangled by 
astrocytes, was much higher in the Aβ-injected NBM than in the Aβ-OLE-injected one 
(Fig. 23 e and f). 
 
Figure 23. Fluorescent staining for astrocytes, Aβ peptide and soluble amyloid oligomers in 
the Aβ and Aβ-OLE injected NBM of rats. 
(a–b) Single fluorescent immunohistochemistry for GFAP (green) antibody in the NBM injected 
with Aβ and Aβ-OLE. 
(c–f) Double labeling immunohistochemistry with GFAP (green) and the anti-Aβ 6E10 (red) 
antibodies (c–d) and with GFAP (green) and the anti-amyloid oligomers A11 (red) antibodies  
(e–f) plus DAPI (blue). Scale bars: 50 µm applies to a–b images; 25 µm applies to c–f images).  
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Taken together, the reported data confirm those obtained by in vitro aggregation 
experiments showing that the different structural features of Aβ aggregates grown in the 
presence of OLE respect to those grown in the absence of OLE (Rigacci et al., 2011) 
persist even in the complex environment found in tissue, with a significantly reduced 
toxic impact to cholinergic neurons. Our findings also suggest that the apparently 
amorphous Aβ aggregates grown in the presence of OLE do not display any tendency to 
undergo disassembly with leakage of toxic oligomers or monomeric Aβ subsequently 
undergoing oligomerization in tissue, a behavior that has been shown for aggregates of 
other peptides/proteins (Giorgetti et al., 2011). Moreover, it appears that the injected 
aggregates persist in tissue without any major modification over the investigated time 
period skipping the action of proteases or other tools aimed at clearing the material. 
Finally, the Aβ-OLE injected NBM displayed a reduced area of microglia activation. 
In fact, in this case activated microglial cells with swollen cell body and short processes 
were detected along the needle trace, as expected, but not elsewhere (Fig. 24 A and B). 
By contrast, in the Aβ-injected NBM many activated microglial cells were detected both 
in the injected area and in the internal capsula/lateral globus pallidus and deep layers of 
the cortex (Fig. 24 A and B). In the NBM injected with PBS or OLE none, or only a few 
activated microglial cells were detected, respectively (Fig. 24 A and B), confirming the 
substantial lack of neurotoxicity of the phenol.  
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Figure 24. Microglia reactivity in the injected NBM of rats. 
(A) Representative photomicrographs of Iba 1 immunopositive glial cells in the NBM and along 
the needle trace of PBS, Aβ, OLE and Aβ-OLE injected rats. Note in the Aβ-injected rats the 
presence of activated microglial cells in the NBM as well as along the needle trace. 
(B) Representative high magnification images of each treatment. Ctx, cortex; LV, lateral 
ventricle; Str, striatum; NBM, nucleus basalis magnocellularis.  
 
These data suggest that the aggregates grown in the absence of OLE possess 
conformational features (possibly increased hydrophobic exposure) that promote glia 
involvement in the attempt to clear them from tissue, at variance, the aggregates grown 
in the presence of the phenol can be considered much more inert and unable to activate 
glia, further explaining the lack of any evident impairment of tissue/cell viability and/or 
functionality of the NBM injected with this material respect to that injected with Aβ 
aggregated in the presence of OLE.  
The path of Aβ aggregation is quite different from that occurring in the absence of 
the phenol. In the presence of OLE, the exposure of hydrophobic regions of the peptide 
(possibly favoring the interaction with lipid membranes) is hindered and the appearance 
of toxic oligomers is skipped; at short incubation times the peptide already precipitates 
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into a disordered mesh of apparently amorphous and harmless aggregated material from 
which at later times some ordered fibrillar organization arises, yet lacking the 
morphological features of typical mature fibrils. 
 
2. Conclusion 
The present study demonstrates that Aβ aggregated in the presence of OLE, the main 
phenolic component of extra virgin olive oil, is not toxic to cholinergic neurons in the 
rat NBM and unable to raise an evident inflammatory reaction as it is the case of Aβ 
aggregates grown under the same conditions but in the absence of OLE. The amount of 
soluble A11-positive oligomers was much lower in the NBM-injected with Aβ-OLE 
than in the NBM injected with Aβ alone, confirming that OLE stably hinders the 
formation of toxic species. 
A marked reduction of astrocytes and microglia reaction was revealed thirty days 
after injection of Aβ-OLE into the NBM respect to the NBM injected with Aβ 
aggregates. In conclusion, these findings indicate that OLE interferes with Aβ 
aggregation, reduces aggregate cytotoxicity and counteracts the associated 
neuroinflammation. 
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MOUSE STUDY 
Recently has been reported that OLE hinders amyloid aggregation of Aβ42 and its 
cytotoxicity in vitro (Rigacci et al., 2011). In this study we investigated the in vivo 
consequences of dietary supplementation of OLE on transgenic mouse model of AD by 
detecting the effects of the treatment on memory functions, brain amyloid deposition 
and autophagic machinery.  
 
1. Results 
1.1 Behavior 
TgCRND8 mice are cognitively impaired since the age of 3 months (Chishti et al., 
2001) and, as already reported, no behavioral differences between 3- and 7-month-old 
TgCRND8 mice have been observed (Fiorentini et al., 2010). 
Therefore, transgenic mice of 3.5 and 6 months of age were grouped to increase the 
number of animals evaluated for cognitive function after 8 weeks of administration of 
food supplemented or not with OLE (n= 12/group for all groups). 
OLE treatment was well tolerated and no treated animals died. 
During the last week of treatment, memory performance was investigated by two 
widely used tests, the step down inhibitory avoidance (SD) and the object recognition 
tests (ORT). No significant differences were observed between wt and OLE-fed or 
untreated Tg mice during the training test of the SD test. However, in the retention test 
step-down latencies recorded for Tg mice were significantly reduced compared to wt 
mice and not significantly different from training latency, indicating that Tg mice were 
unable to memorize the punishment and to perform the inhibitory avoidance. OLE 
administration to Tg mice significantly improved their performance, that reached the 
level displayed by wt mice (Fig. 25).  
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Figure 25. Step down inhibitory avoidance test. One-way ANOVA plus Bonferroni’s post 
comparison test shows a statistically significant increase in the mean retention latencies in 
untreated and OLE-treated wt and in OLE-treated Tg mice, as compared to their respective 
training latencies (§P<0.001). Untreated Tg mice do not show significant differences between 
training and retention latencies. The retention latencies of untreated Tg mice significantly differ 
from the retention latencies of all the other groups (#P<0.001); data are reported as mean 
values ± S.E.M. Number of animals: n = 12/group. 
 
Then the same mice were tested for ORT with a retention interval of 60 min. In the 
T1 trial the exploration time of the familiar object was comparable in the four groups, 
where OLE-fed and untreated animals showed no deficiencies in exploratory activity, 
directional movement towards the objects and locomotor activity. In the T2 trial, 
untreated Tg mice exhibited impairments in novel object preference compared to wt 
mice, as shown by the significant reduction in the discrimination score (untreated Tg: 
0.3767±0.051; untreated wt: 0.5909±0.037) (Fig. 26). The ability of OLE-fed Tg mice 
to discriminate between the familiar and novel object was significantly improved 
(0.60±0.073) compared to that of untreated Tg mice and undistinguishable from that of 
wt mice (OLE-fed: 0.6525±0.044; untreated: 0.5909±0.037). Altogether, the results of 
the memory performance tests indicate that in our mouse model cognitive impairment is 
completely prevented/rescued by OLE administration to young/middle-aged Tg mice.  
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Figure 26. Object recognition test. The discrimination score recorded in the T2 trial during 
untreated Tg mice performance significantly differs from the discrimination index of all other 
groups (*P<0.05). The dotted line indicates the chance level performance; data are reported as 
mean values ± S.E.M. Number of animals: n = 12/group . 
 
1.2. Neurogenesis 
In the attempt to examine the neuronal progenitor cell proliferation, wild type control 
and Tg mice were administered BrdU during the last 3 days of treatment and were then 
sacrificed 24 h after the final BrdU injection. 
Mice of both genotypes displayed newly generated cells mostly in the sub granular 
zone of dentate gyrus of the hippocampus, as shown by the fluorescent BrdU 
immunoreactivity which labels the nuclei of replicating cells irrespective of cell lineage 
(Fig. 27 A). Notably, quantitative analysis of BrdU+ cells revealed a significant 
reduction in the number of proliferating cells in the untreated Tg compared to untreated 
wt mice, thus indicating that the neurodegenerative process associated with the 
transgene expression dramatically dampens the proliferation,  as previously described 
(Fiorentini et al., 2010). Following OLE treatment, the proliferation of neural progenitor 
cells in the sub granular zone of dentate gyrus appeared to be increased in Tg mice (Fig. 
27 A). Quantitative analysis of the fluorescent BrdU+ cells demonstrated a significantly 
higher number of proliferating cells in the OLE-treated Tg than in untreated Tg mice 
(Fig. 27 B).  Altogether these findings indicate  that OLE administration increases the 
proliferation of newborn cells in the subgranular zone of the hippocampus in 3.5-month-
old Tg mice. 
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Figure 27. Cell proliferation in the subgranular zone and effect of OLE diet. 
(A) BrdU-positive cells of the neurogenic dentate gyrus area in 3.5-month-old OLE-fed and 
untreated tg and wt mice. 
(B) The number of BrdU+ cells is significantly lower in the untreated tg than in the OLE-fed tg 
mice ( * p < 0.01, one-way ANOVA plus Newman-Keuls post hoc test; n = 5/group), which 
showed a number of new born cells similar to wild type mice . 
 
1.3. Aβ deposition 
Next, we checked whether the improved cognitive performance of OLE-fed 
young/middle-aged Tg mice resulted from any altered amyloid load respect to untreated 
Tg mice. Few, round-shaped, small to medium size plaques were detected by an anti-
Aβ42 antibody in the cortex and hippocampus of untreated 3.5-month-old Tg mice (Fig. 
28 A). In 6-month-old Tg mice the Aβ load became heavier with a calculated total 
plaque area in the cortex and hippocampus of about 1600 µm2 and 1400 µm2, 
respectively (Fig. 28 B), which was markedly reduced in the brains of age-matched Tg 
mice fed with OLE (Fig. 28 A). Quantitative analysis of total Aβ plaque area and 
number in the cortex and the hippocampus revealed that the effect of OLE treatment 
was significant both in 3.5- and 6-month-old Tg mice, supporting a remarkable 
protective effect of OLE against early and middle stage of Aβ deposition. 
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Figure 28. Analysis of Aβ plaque burden in the cortex and hippocampus of TgCRND8 mice. 
(A) Representative photomicrographs of Aβ42 immunopositive deposits. (n = 5/group, six 
sections from each mouse). Insets: high magnification images of representative plaques. Scale 
bars = 500 µm applies to all reconstructed images and 20 µm to all magnified images. 
(B) Quantitative analysis of total plaque area and plaque number in untreated and OLE-fed Tg 
mice (n = 6 for 3.5 and 6 months Tg mice). *P<0.05, **P<0.01 and ***P<0.001. Data are 
reported as mean values  ± S.E.M.) 
 
ELISA assay results showed that Aβ40 and Aβ42 SDS and formic-acid soluble 
fractions measured in the cortex of OLE-fed Tg mice of both ages were significantly 
reduced as compared to those measured in age-matched untreated Tg mice (Fig. 29). 
This data confirmed the one obtained by quantitative analysis of Aβ42 previously 
described and showed an effect of OLE also in Aβ40 peptide formation . 
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Figure 29. ELISA assay for Aβ40 and Aβ42 in the cortex of TgCRND8 mice. Cortical levels 
of SDS- and formic acid-soluble Aβ40 and Aβ42 peptides in OLE-fed and untreated Tg mice 
were compared. Both Aβ40 and Aβ42 levels were significantly decreased in OLE-fed Tg versus 
age-matched untreated Tg (n = 5/group) mice. *P<0.05, **P<0.01 and ***P<0.001. Data are 
reported as mean values ± S.E.M. mo= month-old 
 
Plaque morphology was investigated through Thioflavin S staining, which detects β-
sheet structures, and immunofluorescence with OC antibody, which specifically 
recognizes fibrillar oligomers and amyloid fibrils (Kayed et al., 2007). These reactions 
showed that in both the cortex (Fig. 30) and hippocampus of OLE-fed Tg mice of both 
ages the radiating plaques displayed a less dense core surrounded by fewer and smaller 
round-shaped deposits than in untreated Tg mice. Moreover, in the brain of 6-month-old 
Tg mice, displaying an intermediate stage of plaque deposition, feeding with OLE 
resulted in the presence of several radiating plaques with ribbon-like/diffuse core and in 
a remarkable presence of fluffy deposits (arrow in figure 30), whereas the plaques found 
in untreated Tg mice typically displayed a very dense core (arrowhead in figure 30). 
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Figure 30. Plaque morphology: Thioflavin S and OC immunofluorescence. Representative 
photomicrographs of Thioflavin S histochemistry (green) (n = 4/group) and OC 
immunolabeling (red) (n = 5/group) of amyloid plaques in the cortex of untreated and OLE-fed 
Tg mice. In the brains of 6-month-old OLE-fed Tg mice several radiating plaques with ribbon-
like/diffuse core and fluffy deposits (arrow) are present. Arrowhead indicates dense core 
amyloid plaques. Scale bars = 25µm  
 
Altogether, these findings suggest that OLE, besides interfering with de novo amyloid 
deposition, favours preformed plaque disassembly. 
 
1.4. Autophagy 
It is widely recognized that autophagy protects neurons from Aβ-induced 
cytotoxicity, thus we investigated whether autophagy was involved in the interference 
of OLE with the de novo deposition and disassembly of Aβ. Actually, an intense bright 
and punctate immunoreactivity for Beclin 1, one of the proteins involved in the 
initiation and execution of autophagy, was detected in the soma, perikarya and dendrites 
of neurons in different layers of somatosensory/parietal and entorhinal/piriform cortices 
of Tg mice fed with OLE as compared to age-matched untreated Tg mice with no 
apparent age-related differences (Fig. 31 A). Although to a lesser extent than in OLE-
fed Tg mice, Beclin 1 immunoreactivity was stronger also in OLE-fed wt mice than in 
untreated animals,as exemplified for 3.5-month-old mice in figure 31 A, suggesting a 
general effect of OLE as inducer of Beclin 1 expression. In the cortex of OLE-fed 
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animals of both ages, Beclin 1 levels showed a trend towards an increase in wt mice and 
a significant increase in the Tg mice compared to the respective age-matched untreated 
animals, as exemplified in figure 31 B for 3.5-month-old mice. 
 
 
 
Figure 31. Autophagic protein Beclin 1 expression in the cortex of wt and TgCRND8 mice. 
(A) Representative images of Beclin 1 immunoreactivity showed an intense bright and punctuate 
Beclin 1 staining in the soma, perikarya and dendrites of neurons in the somatosensory/ parietal 
cortex of Tg mice and, to a lesser extent, in the wt mice fed with OLE, as compared to age-
matched untreated Tg and wt mice (n=5/group). Scale bars=50µm for the low magnification 
images and 20 µm for the high magnification images of untreated and OLE-fed 6-month-old Tg 
mice. 
(B) Western blotting analysis of Beclin 1 levels in cortical tissue, exemplified for 3.5 month-old 
mice, normalized for β-actin (n=6-7/group). In the cortex of OLE-fed animals Beclin 1 levels 
show a trend towards an increase in the wt mice and in the OLE-fed Tg mice Beclin 1 levels 
were significantly increased respect to age-matched untreated wt and Tg mice (**p<0.01)  
 
OLE-induced autophagy was further confirmed by immunohistochemical analysis of 
LC3-II, the membrane-associated lipidated LC3 form that appears in newly formed 
autophagosomes (Hansen and Johansen, 2011). Stronger and brighter LC3 puncta were 
detected in the neuronal cell bodies and processes in the somatosensory/parietal (Fig. 32 
A) and entorhinal/piriform cortices of Tg mice fed with OLE, as compared to age-
matched untreated Tg mice. As for Beclin 1, LC3 immunoreactivity was stronger also in 
all OLE-fed than in untreated (Fig. 32 A) wt mice. As for Beclin 1, in the cortex of 
OLE-fed Tg and wt mice of both ages LC3-II levels showed a trend towards an increase 
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in the wt mice and a significant increase in the Tg mice respect to age-matched 
untreated wt and Tg mice, as exemplified for 3.5-month-old mice (Fig. 32 B). 
 
 
 
 
Figure 32. Autophagic protein LC3 expression in the cortex of wt and TgCRND8 mice. 
(A) Representative images f LC3 immunoreactivity showed a strong and bright LC3 puncta in 
the neuronal cell bodies and processes of neurons in the somatosensory/parietal cortex of Tg 
mice and to a lesser extent, in the wt mice fed with OLE, as compared to age-matched untreated 
Tg and wt mice (n=5/group). Scale bars=50µm for the low magnification images and 20 µm for 
the high magnification images of untreated and OLE-fed 6-month-old Tg mice. 
(B)Western blotting analysis of LC3 levels in cortical tissue, exemplified for 3.5 month-old 
mice, normalized for β-acton (n=6-7/group). LC3 levels are expressed as LC3-II/LC3-I levels. 
In the cortex of OLE-fed animals LC3 levels were significantly increased respect to age-
matched untreated wt and Tg mice (**p<0.01). 
 
Overall, our data indicate that OLE triggers autophagy not only in Tg but also in wt 
mice suggesting a possible beneficial effect of this polyphenol also against age-related 
neurodegeneration such as that occurring in sporadic AD, with an effect similar, at the 
molecular level, to that elicited by caloric restriction (Pallauf and Rimbach 2012). In 
general in the hippocampus autophagy was less evident, some Beclin 1 and LC3 puncta 
were detected in the CA1, CA3 and dentate gyrus of OLE-fed Tg mice only. 
To better assess the protective role of the increased autophagy in OLE-fed mice we 
checked whether it results in autophagosome-lysosome fusion. An intense cathepsin B 
immunoreactivity was detected as bright puncta in small-sized lysosomes within 
neurons in the superficial and deep layers of the somatosensory/parietal and 
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entorhinal/piriform cortices of 3.5 month-old Tg mice fed with OLE (Fig. 33 A). 
Significant co-localization was found in these animals by double staining with Abs 
against cathepsin B and p62, a cargo receptor targeting many cellular substrates for 
autophagic degradation (Salminen et al., 2012) (Fig. 33 A). A similar staining was 
found in the wt mice treated or untreated with OLE, independently of animal age, as 
exemplified for 3.5- month-old mice (Fig. 33 A), and the quantitative analysis 
confirmed that cathepsin B reached similar levels in all these mice (Fig. 33 B).  
Altogether, these findings suggest that the autophagosome-lysosome fusion needed 
for cargo degradation is under way in OLE-fed Tg and wt mice whereas a marked 
reduction of the cathepsin B expression is present in the same cortical areas of untreated 
3.5-month-old Tg mice (Fig. 33 B), with no co-localization between cathepsin B and 
p62, indicating a transgene-associated dysfunction of the autophagic pathway. In the 
cortex of untreated 6-month-old Tg mice (Fig. 33 C), bright cathepsin B 
immunoreactivity occurred mostly in enlarged lysosomal compartments within neuronal 
soma (arrows) as already reported for cathepsin D staining in the affected brain regions 
of 6- month-old Tg mice (Yang et al., 2011). As in young Tg mice fed with OLE, also 
in 6-month-old Tg mice fed with OLE a bright cathepsin B immunoreactivity appeared 
in small-sized lysosomes, whereas cathepsin B-positive giant lysosomes were almost 
absent (Fig. 33 C). Moreover, in wt mice, either untreated or treated with OLE (Fig. 33 
A), and in OLE-fed Tg mice of both ages, p62 immunoreactivity was markedly greater 
than in age-matched untreated Tg mice (Fig. 33 A and C), as confirmed by Western 
blotting of brain extracts, here shown for 3.5-month-old mice (Fig. 33 B). A substantial 
lack of co-localization between cathepsin B and p62 was found in 6-month-old 
untreated Tg mice (Fig. 33 C). As shown for younger mice, also in this case OLE 
feeding was associated with a recover of p62-cathepsin B co-localization (Fig. 33 C, 
yellow staining), indicating that OLE administration rescues autophagosome-lysosome 
function also in advanced stages of amyloid deposition.  
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Figure 33. Autophagosome-lysosome fusion in the cortex of untreated and OLE-fed wt and 
Tg mice. 
(A) Merge of cathepsin B (green) and p62 (red) immunoreactivity in 3.5-month-old wt and Tg 
mice. Co-localization between cathepsin B and p62 staining was detected as bright yellow 
puncta in small-sized lysosomes in the cortex of untreated wt mice and OLE-fed Tg and wt mice 
(n = 6/group). Scale bar = 25 µm. Inset: high magnification of a p62 and cathepsin B positive 
neuron. Scale bar = 14 µm. 
(B) Western blotting analysis of cathepsin B and p62 levels in the cortex of 3.5-month-old wt 
and Tg mice; wt = pool of untreated and OLE-fed wt mice (n = 10); Tg = untreated, and OLE-
fed Tg mice (n = 6/group). Both cathepsin B and p62 levels were significantly increased in 
OLE-fed Tg mice, as compared to untreated Tg mice. Data are representative of four 
experiments and are normalized for β-actin and reported as mean values ±S.E.M. *p<0.05, 
**p<0.01. 
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(C) Single and double fluorescent immunohistochemistry with cathepsin B (green) and p62 
(red) antibodies in the cortex of untreated and OLE-fed Tg mice. In the untreated Tg mice, 
bright cathepsin B immunoreactivity occurred in enlarged lysosomal compartments (arrows), 
p62 immunoreactivity was light and no co-localization between cathepsin B and p62 was found. 
Inset: high magnification of a cell with cathepsin B-positive giant lysosomes. In the OLE-fed Tg 
mice, a bright cathepsin B immunoreactivity appeared in small-sized lysosomes, p62 
immunoreactivity was greater than in untreated Tg mice and a significant co-localization 
between cathepsin B and p62 was evident. (n = 6). Scale bars = 25 µm applies for single 
cathepsin B staining and 10 µm applies to the inset and high magnification images. 
 
1.5. Neuroinflammation 
Amyloid deposits in the brain activate an inflammatory response that contributes to 
cell sufferance and functional decline (Fuhrmann et al., 2010). Accordingly, we 
investigated whether OLE-treatment reduced the inflammatory response in our Tg mice. 
We detected hypertrophic astrocytes with long and thick branches in the cortex and in 
all the subregions of the hippocampus of untreated Tg mice (Fig. 34). By contrast, in the 
OLE-fed animals the astrocyte reaction was considerably milder (Fig. 34), indicating 
reduction of inflammation. 
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Figure 34. Astrocyte reaction in the brain of untreated and OLE-fed TgCRND8 mice. 
Reconstruction of representative photomicrographs of GFAP immunoreactivity in the cortex 
and hippocampus. Hypertrophic astrocytes with long and thick branches were detected in the 
brain of untreated Tg mice. In the OLE-fed animals the astrocyte reaction was considerably 
milder. Insets: high magnification of GFAP-positive astrocytes (n = 4–5/group). Scale bars: 
500 µm for all reconstructed images and 25 µm for all insets. 
 
Then we investigated whether the latter was the result of the antioxidant power of 
OLE; TBARS assay showed that the lipid peroxidation in the cortex of 3.5-month-old 
Tg mice was not significantly reduced by OLE treatment (Fig. 35). 
 
 
Figure 35. Lipid peroxidation in the cortex of wt, untreated and OLE-fed TgCRND8 mice. 
TBARS assay results in cortical homogenates of 3.5-month-old mice showed that lipid 
peroxidation in transgenic mice was not significantly reduced by OLE treatment. *P<0.05. 
Data are reported as mean values ± S.E.M. (n = 3–4 mice/group). Each sample was analyzed in 
two replicates. 
 
Next, we investigated the effect of OLE administration on microglia morphology. 
Surprisingly, activated microglia with enlarged cell bodies, thickened and retracted 
processes or losses of branches were detected in the hippocampus (not shown) and 
cortex of OLE-fed 6-month-old Tg mice (Fig. 36). Such a scenario coincided and 
agreed with the presence of the less dense ‘‘fluffy’’ amyloid plaques described above, 
suggesting activated microglia involvement in plaque remodelling and phagocytosis. In 
untreated Tg mice some morphologically activated microglia were detected only in 6-
month-old animals while in 3.5-month-old mice resting microglia with thin cell bodies 
and elongated branches were mostly detected (Fig. 36). These data support protection 
by OLE against the inflammatory response to amyloid deposits mainly at the astrocyte 
level, while microglia activation by OLE can mainly contribute to plaque clearance. 
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Figure 36. Microglia reaction in the brain of untreated and OLE-fed TgCRND8 mice. 
Iba1 immunopositive microglial cells in the cortex. Note the presence of microglia with 
enlarged cell bodies, thickened and retracted processes (n = 4–5/group) in the cortex of OLE-
fed 6-month-old Tg mice. Scale bar: 25 µm applies to all images . 
 
2. Discussion 
The present research provides a compelling evidence that, in young/middle-aged 
TgCRND8 mice, diet supplementation for 8 weeks with OLE remarkably improves 
animal behavior in two memory tests respect to normally fed littermates, with scores 
reaching those displayed by age-matched wt mice. Improved behavior is accompanied 
by a significant reduction in Aβ40 and Aβ42 levels as well as in size and compactness 
of Aβ plaques and by the presence of fluffy deposits in the older Tg mice. Altogether, 
our data suggest that OLE treatment reduces de novo Aβ deposition and favors 
preformed plaque disassembly. These results agree with findings on a recombinant C. 
elegans strain expressing human Aβ42 in the cytoplasm of muscle cells, showing that 
worms grown on an OLE-supplemented medium displayed remarkably improved 
motility and reduced plaque deposition (Diomede et al., 2013). It has been already 
reported that the inability to acquire the step down-inhibitory response and to explore a 
novel object over a familiar one in this mouse model reflects dysfunction of cortical 
areas (Francis et al., 2012). Functional disruption in the neuronal network has 
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repeatedly been reported in AD mouse models (Rudinskiy et al., 2012). Aberrant 
neuronal activity and significant reduction of the number of active neurons is 
particularly present near amyloid plaques, whose presence causes disturbances resulting 
in abnormalities of whole neuronal networks both in animal models (Grienberger et al., 
2012) and in asymptomatic patients with amyloid deposits (Sperling et al., 2009). Our 
data demonstrated that OLE treatment of young/middle-aged Tg mice results in a 
concomitant improvement of non-spatial episodic memory and working memory 
together with an increased hippocampal neurogenesis, amelioration of cortical 
neuropathological aspects and a remarkable induction of autophagy underscores a tight 
link between these effects. 
TgCRND8 mice develop a pattern of Aβ deposition recalling several aspects of 
human AD. Small size Aβ42 immunopositive plaques appear in various brain areas, 
including the cortex and the hippocampus. As a function of age, they become small-
medium to big in size and acquire a compact core, becoming numerous and reaching the 
maximum roughly by 7-8 months of age (Chishti et al., 2001). OLE administration with 
diet to pre-plaque TgCRND8 mice for 8 weeks results in a remarkable reduction of the 
Aβ load, with a significant decrease of levels, plaque number and area, in agreement 
with the in vitro anti-aggregation effect of OLE already reported (Rigacci et al., 2011). 
In the OLE-treated older Tg mice, the Aβ cortical levels are reduced and the plaques 
appear less compact displaying ribbon-like and fluffy morphologies in both the cortex 
and the hippocampus, indicating the occurrence of dual concomitant effects of OLE, 
prevention of amyloid deposition and disaggregation of preformed plaques. It is 
increasingly recognized that autophagy protects neurons from Aβ-induced cytotoxicity 
and that autophagy dysfunction is a molecular link between brain ageing, Aß 
accumulation in the brain parenchyma and cognitive impairment (Rubinsztein et al., 
2011; Yang et al., 2011). Recently, brain inflammation and Aβ deposition following 
some triggering insult have been proposed to establish a self-reinforcing cycle 
integrating the amyloid cascade hypothesis presently considered at the basis of cerebral 
impairment in AD (Herrup 2010). Deletion of Beclin 1 in mice has been reported to 
increase Aβ deposits, to decrease neuronal autophagy and to promote neuronal 
degeneration, while gene therapy using lentivirus expressing Beclin 1 reduces amyloid 
pathology in APP transgenic mice (Pickford et al., 2008). Accordingly, we associate the 
amelioration of cognitive function of young/middle-aged animals and of 
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neuropathology with a remarkable induction of the autophagic pathway in the cortex of 
OLE-treated Tg mice. A strong punctuate immunoreactivity and higher levels of 
autophagosome-lysosome markers, from Beclin-1 to LC3 and cathepsin B, are detected 
in the cortex and, to a lesser extent, in hippocampal areas of OLE-fed Tg mice at both 
stages of amyloid deposition, as compared to untreated age-matched Tg mice. In the Tg 
mice, OLE administration triggers the autophagic machinery to the level detected in 
control wt mice and leads to the delivery of autophagosome substrates to lysosomes for 
degradation. By contrast, in the untreated Tg mice autophagosome-lysosome markers 
analysis reveals a clear dysfunction of the autophagic pathway. The cortical and 
hippocampal astrocyte reaction detected in untreated Tg mice is strongly ameliorated by 
OLE administration. This anti-inflammatory activity of OLE treatment is not associated 
with the known OLE anti-oxidant activity, which plays a minor role, if any, in all the 
effects we have found. In fact, the OLE-induced migration of microglia to the amyloid 
plaques favoring phagocytosis of amyloid deposits could maintain/produce an oxidant 
environment thus underlying the absence of significant antioxidant effects of OLE 
administration. In addition, since OLE is highly prone to oxidation, it probably loses its 
anti-oxidant power before reaching mice brain. These data strongly support the idea that 
OLE treatment combats Aβ neurotoxicity and Aβ-induced cognitive impairment in our 
mouse model through reduction of plaque load and consistency resulting from a strong 
induction of autophagy, concomitantly with a recovery of the lysosomal system (whose 
dysfunction is one of the earliest disturbances that occur in AD and from microglia 
activation (Ginsberg et al., 2010). The two responses could co-operate to the final 
protective effect; in fact, the migration of the activated microglia to the Aβ deposits 
would result in plaque disassembly and fragmentation; the activated autophagy would 
complete the protective response explaining reduced plaque burden, dimensions and 
compactness. The beneficial effects of the MD on attenuating cognitive impairment, 
AD-like pathology and neurodegenerative diseases has been repeatedly reported 
(Scarmeas et al., 2006; Féart et al., 2009). 
Overall, the behavioral and histological data presented in our study support the 
notion that the beneficial effects of the MD can, at least in part, be traced back to the 
intake of extra virgin olive oil and its main polyphenol, OLE. We also provide a 
molecular explanation of the protective effects elicited by OLE against age-related and 
AD-type neurodegeneration. Our findings are strengthened by previous data indicating 
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that in rat and humans, orally administered olive oil phenols, including OLE, its 
glycoside and/or one of its derivatives arising from tissue metabolism, are intestinally 
absorbed skipping degradation by microorganisms in the colon, cross the blood-brain 
barrier and are found inside brain parenchyma (Serra et al., 2012; Vissers et al., 2002). 
In conclusion, our results support the possibility that dietary supplementation of OLE 
may prevent or delay the occurrence of AD and may reduce the severity of its 
symptoms. 
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ZEBRAFISH EXPERIMENTS 
 
The implication of autophagy-related genes in serious neural diseases have been well 
documented. Recently has been reported the important role of atg5 gene in zebrafish 
neurogenesis and organogenesis: knockdown studies demonstrated that zebrafish atg5 is 
required for normal morphogenesis of brain regionalization and body plan (Hu et al., 
2011). 
In order to study the role of the autophagy in the embryonic zebrafish development, 
we aim to generate of Atg5-knockout zebrafish using TALEN technology. 
 
1. Experimental design 
First, we designed the TALEN to target the gene to mutate all the known splice 
variants. We chose a pair of TALENs (www.talendesign.org/mojohand) targeting the 3rd 
exon of atg5 gene: this exon showed the same sequence in both the splice 
transcriptional variants, it is upstream to protein family domains (Fig. 37) and the region 
between the two TALENs designed for this exon could be targeted by the specific 
restriction enzyme BspHI. 
          
 
 
Figure 37. Atg5 splice variants transcripts. This image show both the spliced transcripts for 
Atg5 gene,including Expressed Sequence Tag (EST) transcripts and non-coding RNAs 
(ncRNAs). Transcripts are drawn as boxes (exons) and lines connecting the boxes (introns); 
filled boxed represent coding sequence and unfilled boxes represent UnTranslated Region 
(UTR). For coding transcript (gold and red transcripts), protein motif and domains are shown 
in purple.  
 
DNA fragments encoding engineered TALENs arrays were cloned into plasmid to 
create the TALEN expression vectors; TALEN Atg5 encoding RNA was transcribed in 
vitro from TALEN expression vectors using the mMESSAGE mMACHINE® T7 Ultra 
(ambion, by life technologies) and then introduced into early zebrafish embryos by 
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microinjection. Subsequently, genomic DNA was isolated from a small number of the 
injected embryos and the somatic mutation efficiencies of the TALEN was assessed by 
sequencing or through restriction-enzyme digestion analysis: the genomic DNA 
sequence surrounding the TALEN-cut site was analysed to determine whether an indel 
mutation had destroyed the recognition site of a restriction enzyme. If such a site was 
identified, PCR product encompassing the TALEN-target site was digested with the 
BspHI restriction enzyme and analysed using gel electrophoresis. 
If TALEN-induced somatic mutations were detected with high frequency, the 
remaining injected embryos were raised to adulthood and screened as potential 
founders. Then we can detect the TALEN-induced indels mutations in the progeny of 
potential founders through restriction-enzyme digestion analysis to check if the 
TALEN-induced mutations are in the germ cells, and so the mutation could be 
hereditary. 
The offspring of the positive founders were raised to adulthood and then crossed with 
wt in order to establish a stable mutated fish line. The injected fish will show a mosaic 
pattern of mutation, and the following generations will be heterozygous: heterozygous 
fish can be then incrossed to obtain the homozygous, that will show the full knock out 
of the atg5 gene (Fig. 38). 
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Figure 38. Overview of the project. First TALEN mRNA was injected in one-cell stage wt 
embryos that were raised. Each spot of different colour indicates a different mutation in the 
target gene: since TALEN can just cut, the repair system can introduce different mutations in 
each cut (a stop codon, a frameshift, etc). So the injected fish showed a mosaic pattern of 
mutation: several cells had different genome. When the fish are 3-months-old, were crossed 
with wild type and the offspring was analysed: if it shows no mutation, it means that TALEN 
hasn’t worked or at least it had not mutated cells of the germ line; if the offspring is mutated, 
the babies were raised, and each embryos was heterozygous and showed just one kind of 
mutation. 
When the first generation grew up, the fish were crossed with a wt in order to establish a stable 
expressing fish line. The second generation will be heterozygous, and then they can be 
incrossed to obtain the homs. 
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2. Results 
Restriction enzyme digestion of the Atg5 PCR products showed a variety of digested 
product in the different samples, indicating that TALEN could be more or less effective. 
 
Figure 39. PCR for Atg5 gene and digestion with BspII restriction enzyme. Once the PCR 
reaction for Atg5 gene was performed,, the PCR products were digested; in wild type embryos 
the digestion produces two fragments (500 bp and 200 bp), in mutated embryos an undigested 
band (700 bp) is shown. 
 
Comparing the brightness of the undigested and digested products, it is possible to 
roughly estimate how effective is the TALEN:  
- very strong: the product is almost undigested (34% of the samples) 
- strong: more than 50% of the product is undigested (48%) 
- moderate: about 50% of the product is undigested (32%)  
- mild: less than 50% of the product is digested (1%) 
These results show that the effect of TALEN Atg5 is quite strong: 82% of the examined 
samples showed more than the 50% of undigested product, so TALEN had mutated the 
Atg5 gene in a high percentage of injected embryos. 
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3. Discussion 
These preliminary data show a high percentage of mutation fish in TALEN Atg5 
injected fish and provide promising prospects for the production of two more 
generations of atg5 +/-  fish in order to obtain the homozygous animals by incrossing 
heterozygoses. 
Studying the full knockout of Atg5, one of the most important genes involved in 
starting autophagic process, will provide to clear the role of autophagy in the 
development of central nervous system and zebrafish body plan. 
Autophagy has been suggested as potential therapeutic target in pathologies 
characterized by aggregates, and further studies on this process will provide an insight 
of the role of this process in the brain. 
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